Investigations of Potential Modifier Genes in Hereditary Haemochromatosis by Brew, Jennifer Mary
i 
 
 
 
Investigations of Potential Modifier Genes in 
Hereditary Haemochromatosis 
 
 
 
by 
Jennifer Mary Brew, B Med Sci (Hons) 
 
 
 
 
A thesis submitted for the degree of  
Doctor of Philosophy  
of The Australian National University. 
 
 
 
 
December, 2010 
ii 
 
Declaration 
All results and analysis presented in the following thesis are my own original 
work. The Canberra Region haemochromatosis Database (CRHD), set up by Prof 
Mark Bassett, was well established at the commencement of this study. 
Extraction of DNA from many of the patient samples was performed prior to this 
study by Erin Walker, and many of the control DNAs had also previously been 
extracted. Collection of patient details and arrangement for collection of patient 
samples for the database was performed by Helen Rodgers. All lymphoblastoid 
cell lines (LCLs) generated from the patient samples were prepared by the 
candidate, LCLs from most control samples were generated by fellow MGRU lab 
members. The Statistical Consulting Unit at the ANU, in particular Terry 
Neeman, provided advice on the statistical analyses performed in each chapter.  
The original work in this thesis has not previously been submitted for a degree 
at this or any other university.  
 
 
 
 
Jennifer Brew 
  
iii 
 
Acknowledgements 
First and foremost I have to thank my primary supervisor, Juleen, for her 
constant encouragement, support and belief in me when I needed it most. I 
could not have done it without you! Also to Phil and Bronya for their 
unwavering support and for their thoughtful comments and suggestions along 
the way. 
 
I would also like to thank all the members of MGRU and Molecular Genetics 
who were there for me throughout my studies and who would listen to my rants 
and cheer me up when I was overwhelmed by it all.  
 
Thank you to Mark Bassett whose patients form the basis of the Canberra 
Region Haemochromatosis database. I am also grateful to the 
haemochromatosis families for their cooperation and participation, without 
which this project would not have been possible.  
 
Finally I would like to thank my family, for their love and support and for always 
being there for me no matter what. A very special thank you to Robbie who 
bore the brunt of my madness particularly over the last few months.  
 
  
  
iv 
 
Abstract 
Hereditary haemochromatosis (OMIM #235200) is a late onset disorder 
resulting from excess iron absorption. It causes symptoms such as bronze 
pigmentation of the skin, joint pain, abdominal pain, weight loss, impotence, 
cardiomyopathy, diabetes and may lead to cirrhosis of the liver. The most 
common cause of this disease in Caucasians is homozygosity for the C282Y 
mutation in the HFE gene on chromosome 6p21.3. The penetrance of the C282Y 
mutation is not complete with many environmental and genetic factors 
influencing the phenotypic expression of the disease.  
 
A number of SNPs in genes in the iron metabolic pathway previously associated 
with altered serum iron indices were tested in the current study. The results 
suggested that two of the SNPs, namely rs1799852 in Transferrin and rs884409 
in CYBRD1 may contribute to altered SF levels in HFE-associated 
haemochromatosis.  
 
The first major finding of this study was a significantly higher serum ferritin (SF) 
level observed in iron-loaded male C282Y homozygotes who were symptomatic 
compared to those that were asymptomatic. This was not associated with age 
and suggests there is a threshold level of SF above which symptoms occur. This 
discordance between the symptomatic and asymptomatic C282Y homozygotes 
formed the basis of subsequent analyses.  
 
A second major finding was the association of the TNFα 21112 promoter 
haplotype with increased SF levels in symptomatic male C282Y homozygotes. To 
explore the mechanism underlying this association, luciferase assays were 
performed in the presence and absence of extracellular iron. The results 
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revealed there was no definitive change in TNFα expression associated with the 
21112 haplotype compared to the other haplotypes. 
 
The expression levels of a number of genes in the iron pathway (HFE, HAMP, 
TFRC, TFR2 and TNFα) were measured in lymphoblastoid cell lines derived from 
males of different TNFα haplotypes and HFE genotypes. The C282Y 
homozygotes analysed in this study included both symptomatic and 
asymptomatic samples. The major finding of the expression studies was that the 
TNFα 21112 haplotype was associated with altered TFRC expression levels 
specifically in the symptomatic C282Y homozygotes. This provides an 
explanation of the increased SF levels seen in these patients. While a 
mechanism for the modulation of TFRC expression by the TNFα haplotype 
remains unclear, this study has confirmed TNFα as a significant modifier gene in 
HFE-associated haemochromatosis.  
  
The discovery of modifier genes in both conventional and unconventional 
pathways of iron metabolism may allow for the development of novel 
preventative and treatment strategies in a new era for hereditary 
haemochromatosis. 
 
 
 
 
 
 
 
vi 
 
Conference Abstracts and Presentations 
Brew JM, Rodgers H, Azmanov DN, Walker EJ, Wilson SR, Cavanaugh JA (2007). 
A novel association between a TNFα haplotype & serum ferritin in hereditary 
haemochromatosis. 29th-31st August 2007, Brisbane, Queensland, Australia, PO. 
 
Brew JM, Rodgers H, Azmanov DN, Walker EJ, Bassett ML, Wilson SR, 
Cavanaugh JA (2008). A novel association between a TNFα haplotype and serum 
ferritin in symptomatic hereditary haemochromatosis. 58th Annual meeting of 
the American Society of Human Genetics, November 11-15 2008, Philadelphia, 
Pennsylvania, USA, PO1456/W 
 
Brew JM, Cavanaugh JA. Mapping the causal variants in an interesting family 
with iron overload (2009). 7th GeneMappers Conference, April 14-17 2009, 
Katoomba, NSW, Australia, SO63 
 
Brew JM, Cavanaugh JA, Bassett ML (2009) A Novel Approach to Mapping 
Causal Variants in a Family with Extreme Iron Overload. 59th Annual meeting of 
the American Society of Human Genetics, October 20-24 2009, Honolulu, 
Hawaii, USA, PO370W  
 
 
  
vii 
 
Abbreviations 
ARCBS   Australian Red Cross Blood Service 
bp   Base pairs  
BMP   Bone morphogenetic protein 
CEPH Centre d’Etude du Polymorphisme Humain (Human 
Polymorphism Study Centre) 
CYBRD1  Cytochrome b reductase 1, also known as DYCTB 
CRHD   Canberra Region Haemochromatosis Database 
DMT1/NRAMP2 Divalent Metal Transporter 1 
EBV   Epstein Barr Virus 
FAC   Ferric Ammonium Citrate 
FTH1   Ferritin Heavy chain 
FTL   Ferritin light chain 
FPN1/SLC40A1 Ferroportin  
GOI   Gene of interest 
HAMP   Hepcidin antimicrobial peptide  
Hb   Hemoglobin 
HCP1   Heme carrier protein 1 
HH   Hereditary haemochromatosis 
HFE/HLA-H  Hereditary haemochromatosis gene 
HJV/HFE2  Hemojuvelin (encoded by HFE2 gene) 
HLA   Human Leukocyte antigen 
HMOX   Heme oxygenase 
HWE   Hardy Weinberg Equilibrium 
IL-6   Interleukin 6 
IRE   Iron responsive element 
IRP   Iron responsive protein  
KO   Knockout 
LCL   Lymphoblastoid cell line 
LD   Linkage Disequilibrium 
MAF   Minor allele freqeuncy 
Mb   Megabases 
MHC   Major Histocompatiblilty Complex 
PBS   Phosphate buffered saline 
RT°C   Room temperature 
SDM   Site Directed Mutagenesis  
SEM   Standard Error of the Mean 
SF   Serum Ferritin 
SNP   Single Nucleotide Polymorphism 
TF   Transferrin  
TFBS   Transcription factor binding site 
TFRC   Transferrin Receptor (1) 
TFR2   Transferrin Receptor 2 
TNFα   Tumour Necrosis Factor alpha 
TSS   Transcription start site 
UTR   Untranslated region 
viii 
 
Table of contents 
Declaration ............................................................................................................... ii 
Acknowledgements ................................................................................................. iii 
Abstract ................................................................................................................... iv 
Conference Abstracts and Presentations ................................................................ vi 
Abbreviations ......................................................................................................... vii 
Table of contents ................................................................................................... viii 
List of Figures ......................................................................................................... xvi 
List of Tables ......................................................................................................... xviii 
Chapter 1. Introduction ..................................................................................................... 1 
1.1. Bodily iron uptake ............................................................................................ 1 
1.1.1. Iron absorption from the diet ................................................................. 2 
1.1.1.1. Heme iron ............................................................................................ 2 
1.1.1.2. Non-heme iron .................................................................................... 3 
1.1.2. Iron uptake .............................................................................................. 4 
1.1.3. Iron recycling by the reticuloendothelial system (RES) .......................... 5 
1.1.4. Maintaining iron homeostasis ................................................................ 7 
1.1.4.1. Iron responsive elements .................................................................... 9 
1.2. Inherited iron overload .................................................................................. 10 
1.2.1. Definition and types .............................................................................. 10 
1.3. Haemochromatosis due to HFE mutations .................................................... 11 
1.3.1. Clinical presentation ............................................................................. 11 
1.3.2. Diagnosis and treatment ....................................................................... 12 
1.3.3. Prognosis ............................................................................................... 13 
1.4. Genetics of hereditary haemochromatosis (HH) ........................................... 13 
1.4.1. Most common mutations – C282Y and H63D ....................................... 13 
1.4.2. Prevalence of C282Y and H63D ............................................................. 14 
1.4.3. Racial Origins of C282Y and H63D ......................................................... 15 
1.4.4. Other HFE mutations ............................................................................. 17 
1.5. HFE protein structure and function ............................................................... 17 
1.5.1. Tissue expression patterns of HFE ........................................................ 17 
1.5.2. Protein structure and normal function ................................................. 17 
1.5.3. Protein structure disruption by C282Y and H63D ................................. 18 
1.5.4. Immune function of HFE? ..................................................................... 19 
1.6. Regulation of HFE Expression ........................................................................ 20 
1.6.1.1. Transcriptional control – HFE promoter studies ............................... 20 
1.6.1.2. Alternate transcripts of HFE .............................................................. 21 
1.7. Penetrance of the HFE mutations .................................................................. 21 
1.7.1. Biochemical versus clinical disease penetrance ................................... 21 
1.7.2. Estimations of disease prevalence - population studies ....................... 22 
1.7.3. Environmental modifiers of penetrance ............................................... 23 
1.7.4. Modifier genes in HH ............................................................................ 24 
1.7.4.1. Modifier genes in mice ...................................................................... 24 
1.7.4.2. Human studies of modifier genes in HH ........................................... 24 
1.7.4.2.1. HFE gene region ......................................................................... 25 
1.7.4.2.2. Sequencing iron metabolic pathway genes ............................... 25 
ix 
 
1.7.4.2.3. Large scale SNP studies .............................................................. 27 
1.7.4.2.4. Haptoglobin (HP) ....................................................................... 27 
1.7.4.2.5. Tumour Necrosis Factor alpha (TNFα) ....................................... 27 
1.7.4.2.6. Genes in other pathways ........................................................... 28 
1.7.4.3. Frequency of modifier gene variants ................................................ 28 
1.8. Aims and hypothesis ...................................................................................... 28 
Chapter 2. Materials and Methods ................................................................................. 30 
2.1. Samples .......................................................................................................... 30 
2.1.1. The Canberra Region Haemochromatosis Database ............................ 30 
2.1.2. Controls ................................................................................................. 31 
2.1.3. Commercial Cell lines ............................................................................ 31 
2.1.3.1. Mammalian cells ............................................................................... 31 
2.1.3.2. Bacterial cell lines .............................................................................. 31 
2.2. Sample processing ......................................................................................... 32 
2.2.1. Crude cell separation ............................................................................ 32 
2.2.2. Serum ferritin levels .............................................................................. 32 
2.2.3. Ficoll-Paque isolation of mononuclear cells from whole blood ........... 33 
2.2.4. EBV transformation of lymphocytes (establishment of lymphoblastoid 
cell lines) 34 
2.2.4.1. EBV transformation of fresh lymphocytes ........................................ 34 
2.2.4.2. EBV transformation from frozen lymphocytes ................................. 34 
2.2.5. Cell line maintenance ............................................................................ 35 
2.2.5.1. Lymphoblastoid cell lines .................................................................. 35 
2.2.5.2. HepG2, Caco-2 and HEK293H cell lines ............................................. 36 
2.2.5.3. B95-8 cells – production of supernatant containing EBV particles ... 36 
2.2.5.4. Freezing cells for long term storage in liquid nitrogen ..................... 36 
2.2.5.4.1. LCLs ............................................................................................ 36 
2.2.5.4.2. Commercial cell lines ................................................................. 37 
2.2.5.5. Reviving cells from liquid nitrogen .................................................... 37 
2.2.6. Mycoplasma testing of cell lines ........................................................... 37 
2.2.7. DNA extraction ...................................................................................... 38 
2.2.7.1. DNA extraction from whole blood .................................................... 38 
2.2.7.2. DNA extraction from cell lines .......................................................... 39 
2.2.7.3. DNA extraction from saliva ............................................................... 39 
2.2.7.4. Quality control DNA .......................................................................... 40 
2.2.8. RNA extraction ...................................................................................... 40 
2.2.8.1. DNaseI treatment of total RNA ......................................................... 41 
2.2.8.2. First strand Reverse Transcription PCR (RT-PCR) – generation of 
cDNA 42 
2.2.9. Genotyping ............................................................................................ 42 
2.2.9.1. Polymerase Chain Reaction (PCR) ..................................................... 42 
2.2.9.2. PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis
 43 
2.2.9.3. Real-time allelic discrimination ......................................................... 43 
2.2.9.4. Sequencing ........................................................................................ 44 
2.2.9.5. Quality control PCR testing of samples ............................................. 44 
2.2.10. Gel electrophoresis ............................................................................... 45 
x 
 
2.2.10.1. Agarose gel electrophoresis ............................................................ 45 
2.2.10.2. Polyacrylamide Gel Electrophoresis (PAGE) ................................... 45 
2.2.11. Gel extraction of DNA ........................................................................... 46 
2.2.12. Expression studies – Real time PCR ...................................................... 46 
2.2.13. Cloning ................................................................................................... 47 
2.2.13.1. Vectors ............................................................................................ 47 
2.2.13.2. Generation of inserts and site-directed mutagenesis .................... 47 
2.2.13.3. Cloning into pGEM-T ....................................................................... 48 
2.2.13.4. Colony screening PCRs .................................................................... 49 
2.2.13.5. Isolation of constructs from bacterial culture ................................ 50 
2.2.13.6. Removing inserts from pGEM-T ...................................................... 50 
2.2.13.7. Preparing pGL4.10 for cloning ........................................................ 50 
2.2.13.8. Cloning into pGL4.10 ....................................................................... 51 
2.2.13.9. Screening pGL4.10 constructs ......................................................... 52 
2.2.14. Transfecting human cell lines................................................................ 52 
2.2.15. Optimising luciferase vector ratios ....................................................... 53 
2.2.16. Performing Luciferase assays ................................................................ 53 
2.3. General statistical methods ........................................................................... 54 
2.3.1. Allele frequencies .................................................................................. 54 
2.3.2. Hardy Weinberg Equilibrium (HWE) ..................................................... 54 
Chapter 3. Study of SNPs in iron metabolic pathway genes previously associated with 
serum iron indices ........................................................................................................... 55 
3.1. Introduction ................................................................................................... 55 
3.2. Materials and Methods ................................................................................. 56 
3.2.1. Samples from the Canberra Region Haemochromatosis Database 
(CRHD) 56 
3.2.2. Control Samples .................................................................................... 57 
3.2.3. Genotyping ............................................................................................ 58 
3.2.4. Analysis and statistics............................................................................ 58 
3.3. Results ............................................................................................................ 58 
3.3.1. SF levels in HH patients and blood donor controls ............................... 58 
3.3.2. Allele frequencies in patients and controls .......................................... 59 
3.3.3. Single SNP analysis in a heterogeneous population ............................. 60 
3.3.3.1. TMPRSS6 (rs4820268), TF (rs2280673) and CYBRD1 (rs884409) SNPs 
are not associated with SF levels ....................................................................... 60 
3.3.3.2. rs3811647 in TF is associated with decreased SF levels ................... 62 
3.3.3.3. rs1799852 in TF is associated with increased SF levels .................... 63 
3.3.4. Single SNP analysis in C282Y homozygotes .......................................... 64 
3.3.4.1. rs4820268 in TMPRSS6, and rs2280673 and rs3811647 in TF are not 
associated with SF in the C282Y homozygotes .................................................. 64 
3.3.4.2. rs1799852 in TF is not associated with SF levels .............................. 64 
3.3.4.3. rs884409 in CYBRD1 is associated with decreased SF levels ............ 66 
3.4. Discussion ...................................................................................................... 67 
3.4.1. Serum ferritin levels in patients and controls ....................................... 67 
3.4.2. Allele frequencies of the SNPs in patients and controls ....................... 68 
3.4.2.1. rs1799852 (TF) in C282Y homozygotes ............................................. 68 
xi 
 
3.4.3. No association of TMPRSS6 rs4820268 or TF rs2280673 with SF levels
 69 
3.4.4. TF rs3811647 and SF levels ................................................................... 70 
3.4.5. CYBRD1 rs884409 as a modifier of SF levels in C282Y homozygotes ... 70 
3.4.6. Alternate function for rs2280673? ....................................................... 71 
3.5. Conclusions .................................................................................................... 72 
Chapter 4. TNFα as a modifier gene of hereditary HFE-associated haemochromatosis 73 
4.1. Introduction ................................................................................................... 73 
4.2. Materials and Methods ................................................................................. 74 
4.2.1. Samples ................................................................................................. 74 
4.2.2. TNFα SNPs and microsatellite markers ................................................. 75 
4.2.3. Haplotype construction ......................................................................... 76 
4.2.4. Linkage Disequilibrium .......................................................................... 77 
4.2.5. Statistical analyses ................................................................................ 77 
4.3. Results ............................................................................................................ 78 
4.3.1. TNFα promoter SNP analysis ................................................................. 78 
4.3.1.1. Single SNP analysis ............................................................................ 78 
4.3.1.2. TNFα promoter SNPs haplotype ....................................................... 80 
4.3.1.2.1. Linkage disequilibrium and number of haplotypes ................... 80 
4.3.1.2.2. TNFα Haplotypes and log10SF in male C282Y homozygotes ...... 81 
4.3.2. Microsatellite markers .......................................................................... 83 
4.3.2.1. Microsatellite allele frequencies ....................................................... 83 
4.3.2.2. A primer mutation – D6S265............................................................. 86 
4.3.2.3. Microsatellite haplotype analysis...................................................... 86 
4.4. Discussion ...................................................................................................... 88 
4.4.1. TNFα and SF levels ................................................................................ 88 
4.4.2. Microsatellite analysis ........................................................................... 89 
4.4.3. TNFα and iron metabolism ................................................................... 91 
4.5. Conclusion ...................................................................................................... 92 
Chapter 5. Expression of the TNFα promoter haplotypes in a luciferase system .......... 93 
5.1. Introduction ............................................................................................... 93 
5.2. Materials and methods ............................................................................. 94 
5.2.1. Luciferase constructs ............................................................................ 94 
5.2.2. Cell lines ................................................................................................ 94 
5.2.3. Iron challenge of the cell lines .............................................................. 95 
5.2.4. Transfections ......................................................................................... 95 
5.2.5. Luciferase Assays ................................................................................... 96 
5.2.6. Analysis and Statistics ........................................................................... 97 
5.2.7. TFBS prediction ..................................................................................... 98 
5.3. Results ............................................................................................................ 98 
5.3.1. Allele specific effects on expression ..................................................... 99 
5.3.2. Caco-2 haplotype results ..................................................................... 102 
5.3.3. HEK293H haplotype results................................................................. 104 
5.3.4. HepG2 haplotype results..................................................................... 104 
5.3.5. TFBS predictions and potential function in TNFα regulation .............. 105 
5.4. Discussion .................................................................................................... 107 
5.4.1. Cell line differences in TNFα expression ............................................. 107 
xii 
 
5.4.2. TFBS prediction programs ................................................................... 108 
5.4.3. Factors influencing the observed changes in expression ................... 109 
5.4.3.1. The increased expression of haplotypes with the rare allele at -1031
 110 
5.4.3.2. Differential expression driven by -863? .......................................... 111 
5.4.3.3. Decreased expression with the rare allele at -308 ......................... 112 
5.4.3.4. The 21112 haplotype and the influence on expression .................. 113 
5.4.4. TNFα and iron homeostasis ................................................................ 114 
5.4.4.1. Overview of iron absorption and homeostasis ............................... 114 
5.4.4.2. TNFα influence on iron homeostasis .............................................. 114 
5.4.4.3. TNFα and haemochromatosis ......................................................... 115 
5.4.5. Future directions ................................................................................. 117 
5.5. Conclusions .................................................................................................. 119 
Chapter 6. Expression studies on selected genes in the iron metabolic pathway ....... 120 
6.1. Introduction ................................................................................................. 120 
6.2. Materials and Methods ............................................................................... 121 
6.2.1. Samples ............................................................................................... 121 
6.2.2. Determination of the iron dosage range for the LCLs ........................ 122 
6.2.3. Growth and iron treatment ................................................................ 123 
6.2.4. RNA extraction and cDNA synthesis ................................................... 124 
6.2.5. Real time PCR ...................................................................................... 124 
6.2.5.1. Performing the assays ..................................................................... 124 
6.2.5.2. Calculating ∆CT values ..................................................................... 125 
6.2.5.3. Calculation of the relative expression (2-ΔΔCT) ................................. 126 
6.2.6. Analysis and statistics.......................................................................... 127 
6.3. Results .......................................................................................................... 128 
6.3.1. Variable expression of the genes ........................................................ 128 
6.3.2. Expression of HFE in LCLS .................................................................... 130 
6.3.2.1. Expression of HFE under basal conditions ...................................... 130 
6.3.2.2. Expression of HFE in response to iron ............................................. 132 
6.3.3. Expression of TFRC in LCLs .................................................................. 134 
6.3.3.1. Expression of TFRC under basal conditions..................................... 136 
6.3.3.2. Expression of TFRC in response to iron ........................................... 136 
6.3.4. Expression of HAMP in LCLs ................................................................ 141 
6.3.4.1. Expression of HAMP under basal conditions .................................. 143 
6.3.4.2. Expression of HAMP in response to iron ......................................... 144 
6.3.5. Expression of TFR2 in LCLs .................................................................. 147 
6.3.6. Expression of TNFα in LCLs .................................................................. 147 
6.3.7. Results summary ................................................................................. 148 
6.4. Discussion .................................................................................................... 149 
6.4.1. The LCL model – relevance to iron homoeostasis? ............................ 150 
6.4.2. Expression results in the C282Y heterozygotes .................................. 151 
6.4.2.1. Expression under basal conditions .................................................. 151 
6.4.2.2. Expression in response to iron ........................................................ 152 
6.4.3. Basal expression of genes in the iron metabolic pathway in C282Y 
homozygotes and controls ................................................................................... 153 
xiii 
 
6.4.4. Gene expression in response to iron in C282Y homozygotes and 
controls 153 
6.4.4.1. TFR2 expression is unresponsive to iron ......................................... 153 
6.4.4.2. Reduced HAMP response in C282Y homozygotes .......................... 154 
6.4.4.3. Expression of TFRC in response to iron and in relation to the TNFα 
21112 haplotype in C282Y homozygotes ......................................................... 154 
6.4.5. Future directions ................................................................................. 155 
6.5. Conclusions .................................................................................................. 157 
Chapter 7. General Discussion and Conclusions ........................................................... 158 
7.1. Increased SF in symptomatic C282Y homozygotes compared to 
asymptomatic C282Y homozygotes.......................................................................... 158 
7.2. Replication of previous association studies between SNPs in candidate 
modifier genes and iron indices ............................................................................... 159 
7.3. TNFα as a modifier gene in HH .................................................................... 161 
7.3.1. Genetic association of the promoter haplotype with SF levels .......... 161 
7.3.2. Functional evidence – the TNFα 21112 haplotype is associated with the 
expression of TFRC in LCLs.................................................................................... 161 
7.3.3. How does the TNFα 21112 promoter haplotype influence the 
expression of TFRC?.............................................................................................. 162 
7.3.3.1. Variable expression of TNFα ........................................................... 162 
7.3.3.2. Altered TNFα protein function ........................................................ 162 
7.3.3.3. Epigenetic modifications ................................................................. 165 
7.3.3.4. Linkage disequilibrium with another loci on 6p21.3 ....................... 166 
7.3.4. Significance of the TNFα 21112 promoter haplotype to the phenotypic 
variability in HH .................................................................................................... 166 
7.4. Personalised medicine and modifier genes in HH ....................................... 167 
7.5. Future directions in the identification of additional modifier genes in HH 168 
7.6. Conclusions .................................................................................................. 170 
Appendices .................................................................................................................... 172 
Appendix A. Electronic links ................................................................................. 172 
Appendix B. Gene names and symbols ................................................................ 173 
Appendix C. Mutations in HFE, HFE2, HAMP, TFR2, FPN1 and other genes that 
cause iron loading in humans ................................................................................... 175 
Appendix D. Buffers and Chemicals ..................................................................... 179 
Appendix D.1 5X TBE buffer ................................................................................. 179 
Appendix D.2 50X TAE buffer ............................................................................... 179 
Appendix D.3 1XPBS ............................................................................................. 179 
Appendix D.4 Cell lysis buffer for DNA extractions (buffer A) ............................. 179 
Appendix D.5 Blood buffer B ................................................................................ 179 
Appendix D.6 Phenol: chloroform ........................................................................ 180 
Appendix D.7 Ladders ........................................................................................... 180 
Appendix D.8 Loading dyes .................................................................................. 180 
Appendix E. Bacterial cultures ............................................................................. 180 
Appendix E.1 Luria broth ...................................................................................... 180 
Appendix E.2 Luria broth/Amp agar plates .......................................................... 181 
Appendix F. Tissue culture reagents and media .................................................. 181 
Appendix F.1 200mM (100x) L-glutamine ............................................................ 181 
xiv 
 
Appendix F.2 100X Pen/Strep ............................................................................... 181 
Appendix F.3 Heat-inactivated FCS (HI-FCS) ........................................................ 181 
Appendix F.4 Transforming media (TFM) ............................................................. 181 
Appendix F.5 Culture Media (CM) for LCLs and B95-8 cells ................................. 182 
Appendix F.6 Culture Media 2 (CM2) for HepG2, Caco-2 and HEK293H cells ..... 182 
Appendix F.7 Freezing media (FM) ....................................................................... 182 
Appendix F.8 Wash media .................................................................................... 182 
Appendix F.9 Trypsin ............................................................................................ 182 
Appendix G. PCR primers and conditions ............................................................. 183 
Appendix G.1 Microsatellite alleles and sizes ...................................................... 186 
Appendix G.2 Real time PCR  Allelic Discrimination conditions, Taqman assays . 186 
Appendix G.3 Expression assays real time PCR .................................................... 187 
Appendix H. Restriction Digest conditions ........................................................... 187 
Appendix H.1 HFE C282Y (rs1800562).................................................................. 187 
Appendix H.2 HFE H63D (rs1799945) ................................................................... 187 
Appendix H.3 TNFα -863 (rs1800630) .................................................................. 187 
Appendix I. Site-directed mutagenesis ............................................................... 188 
Appendix I.1 Primers ............................................................................................ 188 
Appendix I.2 PCR conditions ................................................................................. 188 
Appendix J. Non-significant associations of SNPs in TF and TMPRSS6 with SF 
levels 189 
Appendix J.1 TMPRSS6 – rs4820268 .................................................................... 189 
Appendix J.2 Transferrin – rs2280673 .................................................................. 189 
Appendix J.3 Transferrin – rs3811647 .................................................................. 190 
Appendix K. Expected TNFα haplotype frequencies based on SNP frequencies . 191 
Appendix L. Luciferase results – HEK293H and HepG2 cells ............................... 192 
Appendix L.1 Luciferase results for HEK293H cells .............................................. 192 
Appendix L.2 Luciferase results for HepG2 cells .................................................. 193 
Appendix M. Table of predicted TFBS changes due to the SNPs -1031, -863, -857, -
308 and -238 in the TNFα promoter ......................................................................... 194 
Appendix N. Expression results from LCLs – HFE ................................................. 196 
Appendix N.1 Expression of HFE under basal conditions ..................................... 196 
Appendix N.2 The relative expression of HFE, 0.2mM FAC ................................. 197 
Appendix N.3 The relative expression of HFE, 5mM FAC .................................... 198 
Appendix O. Expression results from LCLs – TFRC ............................................... 199 
Appendix O.1 Expression of TFRC under basal conditions ................................... 199 
Appendix O.2 The relative expression of TFRC, 0.2mM FAC ................................ 200 
Appendix O.3 The relative expression of TFRC, 5mM FAC ................................... 201 
Appendix P. Expression results from LCLs – HAMP ............................................. 202 
Appendix P.1 HAMP expression under basal conditions ..................................... 202 
Appendix P.2 The relative expression of HAMP, 0.2mM FAC .............................. 203 
Appendix P.3 The relative expression of HAMP, 5mM FAC ................................. 204 
Appendix Q. Expression results from LCLs – TFR2 ............................................... 205 
Appendix Q.1 Expression distribution pattern of TFR2 in LCLs ............................ 205 
Appendix Q.2 The expression of TFR2 under basal conditions ............................ 206 
Appendix Q.3 The relative expression of TFR2, 0.2mM FAC ................................ 207 
Appendix Q.4 The relative expression of TFR2,  5mM FAC .................................. 208 
xv 
 
Appendix R. Expression results from LCLs – TNFα ............................................... 209 
Appendix R.1 Expression distribution pattern of TNFα in LCLs ............................ 209 
Appendix R.2 The basal expression of TNFα ........................................................ 210 
Appendix R.3 The relative expression of TNFα, 0.2mM FAC................................ 211 
Appendix R.4 The relative expression of TNFα, 5mM FAC ................................... 212 
References ..................................................................................................................... 213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
List of Figures 
Figure 1.1. A brief representation of bodily iron uptake and losses under normal 
conditions (A) and in haemochromatosis (B).................................................................... 2 
Figure 1.2. Basic overview of iron uptake in the enterocyte for heme and non-heme 
iron.. .................................................................................................................................. 4 
Figure 1.3. Overview of the uptake of transferrin-bound iron (TF-Fe) by macrophages  5 
Figure 1.4. Recycling of iron within macrophages. ........................................................... 6 
Figure 1.5. Regulation of HAMP expression in the hepatocyte. ....................................... 8 
Figure 1.6. The typical structure of an IRE ...................................................................... 10 
Figure 2.1. An example of the Mycoplasma PCR. ........................................................... 38 
Figure 2.2. Site directed mutagenesis of the region to be cloned. ................................ 48 
Figure 2.3. The pGEM-T vector ....................................................................................... 49 
Figure 2.4. The pGL4.10 luciferase expression vector. ................................................... 51 
Figure 3.1. The average log10SF results by genotype at the SNPs rs4820268 (A), 
rs2280673 (B), and rs884409 (C)..................................................................................... 61 
Figure 3.2. The average log10SF values for the heterogeneous population based on 
their genotype at rs3811647........................................................................................... 62 
Figure 3.3. The average log10SF values for the heterogeneous population based on 
their genotype at rs1799852........................................................................................... 63 
Figure 3.4. The average log10SF levels for male C282Y (YY) homozygotes who were 
asymptomatic or symptomatic based on their genotype at rs1799852 in TF. ............... 65 
Figure 3.5. The average log10SF levels for male C282Y (YY) homozygotes who were 
asymptomatic or symptomatic based on their genotype at rs884409 in CYBRD1. ........ 66 
Figure 4.1. Position of the TNFα promoter SNPs and the microsatellites studied relative 
to the HFE and TNFα genes. ............................................................................................ 75 
Figure 4.2. Average log10SF levels in symptomatic C282Y homozygotes with and 
without the rare allele at the TNFα -1031 (blue) and -238 (purple) promoter SNPs. .... 79 
Figure 4.3. The frequencies of the different TNFα promoter haplotypes in the control 
(blue) and C282Y homozygote (purple) chromosomes.. ................................................ 81 
Figure 4.4. The average log10SF levels associated with TNFα promoter haplotypes 
containing the rare allele at -1031 in symptomatic C282Y homozygotes. ..................... 82 
Figure 4.5. Allele frequencies for the microsatellites on C282Y homozygotes (purple) 
and control chromosomes (blue). ................................................................................... 85 
Figure 5.1. The effects of the different TNFα promoter SNPs on the expression of the 
luciferase reporter gene in each of the cell lines under normal transfection conditions 
(A) and under iron (5mM FAC) challenge (B). ............................................................... 100 
Figure 5.2. Relative expression of the TNFα promoter constructs in Caco-2 cell line. 103 
Figure 5.3. A consensus of predicted TFBS changes as a result of each of the five SNPs 
in the TNFα promoter used in this study. ..................................................................... 106 
Figure 6.1. The distribution of the ∆CT values for each of the genes, under basal 
conditions (A), with 0.2mM FAC (B), and with 5mM FAC (C).. ..................................... 129 
Figure 6.2. The distribution of the ∆CTs for HFE expression in LCLs. ........................... 131 
Figure 6.3. The expression of HFE in LCLs treated with 0.2mM FAC relative to the 
untreated cells. ............................................................................................................. 132 
Figure 6.4. The average relative expression of HFE in response to 0.2mM FAC with 
respect to the TNFα 21112 promoter haplotype. ......................................................... 133 
xvii 
 
Figure 6.5. The distribution of the ∆CTs for TFRC expression in LCLs. ......................... 135 
Figure 6.6. The basal expression levels of TFRC in LCLs of different HFE genotypes.. . 136 
Figure 6.7. The relative expression of TFRC in response to 0.2mM FAC in LCLs. ......... 138 
Figure 6.8. The relative expression changes of TFRC due to the different FAC 
concentrations .............................................................................................................. 140 
Figure 6.9. The distribution of the ∆CTs for HAMP expression in LCLs. ....................... 142 
Figure 6.10. The expression of HAMP under basal conditions, analysed by HFE 
genotype. ...................................................................................................................... 143 
Figure 6.11. The average basal expression of HAMP in C282Y homozygotes that 
possess the TNFα 21112 promoter haplotype, with and without the presence of 
symptoms ...................................................................................................................... 144 
Figure 6.12. The difference in HAMP expression response to iron in LCLs of differing 
HFE genotypes. .............................................................................................................. 145 
Figure 6.13. The relative expression changes of HAMP in response to iron in samples 
with and without the TNFα 21112 promoter haplotype .............................................. 146 
Figure 6.14. The changes in the relative expression of HAMP for the C282Y 
heterozygotes at 0.2mM and 5mM FAC ....................................................................... 147 
Figure 6.15. The basal expression level of TNFα analysed by HFE genotype. . ............ 148 
Figure 7.1. The structure of the predicted IRE in the 3’UTR of TNFα. . ........................ 164 
Figure J.1. The average log10SF levels for all samples (A) and male C282Y homozygotes 
(B) based on their genotype at rs4820268 in TMPRSS6..........................................189 
Figure J.2. The average log10SF levels for all samples (A) and male C282Y homozygotes 
(B) based on their genotype at rs2280673 in TF.....................................................189 
Figure J.3. The average log10SF levels for all samples (A) and male C282Y homozygotes 
(B) based on their genotype at rs3811647 in TF.....................................................190 
Figure L.1. Relative expression of the TNFα promoter constructs in the HEK293H cell 
line ........................................................................................................................192 
Figure L.2. Relative expression of the TNFα promoter constructs in the HepG2 cell 
line........................................................................................................................193 
Figure N.1. Basal expression of HFE in LCLs............................................................196 
Figure N.2. Relative HFE expression results from LCLs treated with 0.2mM FAC......197 
Figure N.3. Relative HFE expression results from LCLs treated with 5mM FAC.........198 
Figure O.1. Basal expression of TFRC in LCLs...........................................................199 
Figure O.2. Relative TFRC expression results from LCLs treated with 5mM FAC........200 
Figure O.3. Relative TFRC expression results from LCLs treated with 5mM FAC........201 
Figure P.1. Basal expression of HAMP in LCLs.........................................................202 
Figure P.2. Relative HAMP expression results from LCLs treated with 0.2mM FAC....203 
Figure P.3. Relative HAMP expression results from LCLs treated with 5mM FAC.......204 
Figure Q.1. The distribution of the ∆CTs for TFR2 expression in LCLs......................205 
Figure Q.2. Basal TFR2 expression results from LCLs...............................................206 
Figure Q.3. Relative TFR2 expression results from LCLs treated with 0.2mM FAC.....207 
Figure Q.4. Relative TFR2 expression results from LCLs treated with 5mM FAC.......208 
Figure R.1. The distribution of the ∆CTs for TNFα expression in LCLs......................209 
Figure R.2. Basal TFR2 expression results from LCLs................................................210 
Figure R.3. Relative TNFα expression results from LCLs treated with 0.2mM FAC....211 
Figure R.4. Relative TNFα expression results from LCLs treated with 5mM FAC.......212 
xviii 
 
List of Tables 
Table 1.1. The different types of inherited iron overload in terms of the typical age of 
clinical presentation and the causal genes that have been identified. .......................... 11 
Table 1.2. Genes/gene regions identified modifying the penetrance of HFE-associated 
haemochromatosis in either mouse and/or human studies. ......................................... 26 
Table 3.1. The average log10SF and age of the control group (blood donors with no 
C282Y mutations) and the haemochromatotic C282Y homozygotes subdivided into 
symptomatic and asymptomatic groups. ....................................................................... 59 
Table 3.2. Allele frequencies for the SNPs in controls, samples from the CRHD and 
C282Y homozygotes (YY).. ............................................................................................... 60 
Table 4.1. The positions of the microsatellite and SNP markers used in this study in 
relation to the primary reference assembly on NCBI (GRCh37 NT_007592.15). ........... 76 
Table 4.2. Allele frequencies for the TNFα SNPs in controls and C282Y homozygotes 
(YY).. ................................................................................................................................ 78 
Table 5.1. Transfection parameters of the cell lines used for the luciferase assays. ..... 96 
Table 5.2. The total number of useable replicates for each construct under normal and 
high iron (5mM FAC) conditions in each of the cell lines.. ............................................. 99 
Table 5.3. The outcomes of pairwise significance testing between the alleles at each 
SNP in the cell lines in untreated and treated (5mM) conditions.. .............................. 101 
Table 5.4. The pairwise p values associated with haplotype expression levels in the 
Caco-2 cell line. ............................................................................................................. 103 
Table 6.1. The properties of the LCLs used in the current study including HFE genotype, 
TNFα haplotype and the presence of symptoms in the C282Y homozygotes.. ............ 122 
Table 6.2. An example of the calculation used to generate the standard deviation (s.d.) 
for the ∆CT values. ........................................................................................................ 126 
Table 6.3. The steps involved in the calculation of the relative expression (2-∆∆CT) of 
genes in response to iron using an example from the results.. .................................... 127 
Table 6.4. A summary of the significant expression results (p<0.05) under both basal 
and iron treated (0.2mM FAC unless stated otherwise) conditions in LCLs for all the 
genes tested.. ................................................................................................................ 149 
Table B.1. Gene names and symbols used commonly throughout this thesis. ............ 173 
Table B.2. A list of genes which contain an IRE in the 5’UTR or 3’UTR and a brief 
description of the gene function.............................................................................174 
Table C.1. Atypical mutations in HFE that cause iron overload................................175 
Table C.2. Mutations in HFE2 (hemojuvelin) that cause iron overload......................176 
Table C.3. Mutations in HAMP that cause iron overload in humans.........................177 
Table C.4. Mutations in TFR2 that cause iron overload in humans..........................177 
Table C.5. Mutations in FPN1 that cause iron overload in humans..........................178 
Table C.6. Mutations in other genes that cause iron overload................................178 
Table D.1. Commonly used loading dyes for electrophoresis of PCR products..........180 
Table G.1. The primer sets used in the current study..............................................183 
Table G.2. PCR conditions for the primer sets.........................................................184 
Table G.3. The microsatellite alleles and sizes used in this study...............................186 
Table G.4. The Taqman SNP assays used in this study. ............................................186 
Table G.5. The expression assays used in this study including threshold and 
background values used in the analysis...................................................................187 
xix 
 
Table I.1. Primers used for cloning and SDM.............................................................188 
Table I.2. Amplification conditions and expected product sizes for the SDM primer 
pairs.........................................................................................................................188 
Table K.1. TNFα haplotype frequencies in the population compared to the expected 
frequencies..............................................................................................................191 
Table L.1. The pairwise p values associated with haplotype expression levels in the 
HEK293H cell line. .................................................................................................192 
Table L.2. The pairwise p values associated with haplotype expression levels in the 
HepG2 cell line.......................................................................................................193 
Table M.1. The predicted TFBS that are altered as a consequence of one of the five 
TNFα promoter SNPs studied...................................................................................194 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
 
 
1 
 
1. Chapter 1. Introduction 
Hereditary haemochromatosis (OMIM #235200) is an inherited condition 
whereby excess iron is absorbed from the diet and accumulates within the 
body. The clinical presentation of haemochromatosis was first described by von 
Recklinghausen in 1865 with debate surrounding the inheritance patterns of the 
disease emerging almost a century later. The autosomal recessive inheritance of 
haemochromatosis was confirmed in 1977 (Simon, Bourel et al. 1977) but the 
causal gene, HFE, was not identified until 1996 (Feder, Gnirke et al. 1996). Since 
that time the reduced penetrance of the described mutations has led to the 
search for modifier genes.  
 
Gene names referenced throughout this thesis are based on nomenclature as 
defined by the Human Genome Organisation (HUGO, http://www.hugo-
international.org/) unless otherwise stated. A full list of gene names and 
acronyms is presented in Appendix B.  
 
1.1. Bodily iron uptake 
Iron is an essential element in the normal functioning of human cells and is 
required for the synthesis of DNA, cellular respiration and oxygen transport 
(Yen, Fancher et al. 2006). The amount of iron in the body is tightly regulated as 
both deficiency and excess of iron are associated with pathological conditions. 
Around 10% of dietary iron is absorbed by the body each day (Parkkila, Niemela 
et al. 2001) corresponding to 1-2mg of iron and the same amount is lost through 
bleeding, exfoliation of the skin and intestinal epithelial cells, and through 
biliary and urinary secretions (Latunde-Dada, McKie et al. 2006). The balance of 
iron uptake with iron losses needs to be maintained as there is no pathway for 
the excretion of iron once it has been absorbed. In haemochromatosis, the 
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amount of iron absorbed is in excess of that which is excreted resulting in a net 
gain in the amount of iron in the body, with excess iron primarily stored in the 
liver. A brief outline of iron homeostasis is presented in figure 1.1. 
 
 
Figure 1.1. A brief representation of bodily iron uptake and losses under normal 
conditions (A) and in haemochromatosis (B). Much of the iron absorbed in the body is 
required for erythropoeisis. Iron is recycled in back to the plasma iron pool through the 
phagocytosis of erythrocytes by macrophages. A small amount of iron is absorbed daily 
to replace any iron losses (through bleeding and the sloughing of epithelial cells) with 
any excess iron stored in the liver. In haemochromatosis, the amount of iron absorbed 
is in excess of the amount lost thus leading to accumulation of iron, primarily in the 
liver. Figure reprinted from (Pietrangelo 2006). 
 
1.1.1. Iron absorption from the diet 
1.1.1.1. Heme iron 
There are two forms of iron absorbed in the duodenum, heme iron from animal 
sources and non-heme iron from vegetables and grains. Heme iron is more 
bioavailable than non-heme iron in that it is more efficiently absorbed by 
enterocytes, but it does not account for the majority of the iron absorbed. Only 
one transporter has been identified that is able to traffic heme into the cell, 
namely Heme carrier protein 1 (HCP1) (Shayeghi, Latunde-Dada et al. 2005). 
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Within the cell, heme is broken down to Fe2+ by the heme oxygenase enzymes 
(HMOXs). Little else is known about the heme absorption pathway. Much of the 
research has focussed on the non-heme pathway as heme iron absorption 
remains relatively unchanged in response to environmental signals (Hunt and 
Roughead 2000) and the amount absorbed is saturable (Pizarro, Olivares et al. 
2003) compared to non-heme iron which is not saturable.  
 
1.1.1.2. Non-heme iron 
The absorption of non-heme iron from the diet is a complex process that is still 
not fully understood. Non-heme iron is present in the intestinal lumen in the 
ferric state (Fe3+) and must be reduced to the ferrous form (Fe2+) in order to 
cross the apical membrane. Cytochrome b reductase 1 (CYBRD1) performs this 
vital function and the Fe2+ is transported across the membrane via divalent 
metal transporter 1 (DMT1, HUGO: SLC11A2) (Trinder, Fox et al. 2002). Iron can 
be stored within the enterocyte as ferritin (encoded by the heavy (FTH1) or light 
chains (FTL)), utilised by the cell (e.g. in protein or energy production) or it can 
be transported across the basolateral membrane through the only known 
transporter that traffics iron into the circulation, the ferroportin transporter 
(FPN1, HUGO: SLC40A1) (Fleming, Britton et al. 2004). The Fe2+ ion must then be 
converted back to Fe3+ once in the plasma, a function which is performed by 
hephaestin (HEPH). The ferric ion is then able to bind to transferrin (TF) to 
become Fe-TF. Each TF molecule can bind up to two Fe3+ ions, with Fe-TF also 
known as holo-transferrin or holo-TF. TF with no iron bound it is called apo-
transferrin (apo-TF) (Aisen 2004). A brief overview of the uptake of iron in the 
enterocyte is outlined in figure 1.2. 
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Figure 1.2. Basic overview of iron uptake in the enterocyte for heme and non-heme 
iron. Heme iron traffics through HCP1 into the cytosol where it is broken down to Fe2+ 
by HMOXs and enters the transit iron pool. Non-heme iron (in the form of Fe3+) is 
reduced to Fe2+ by CYBRD1 before it enters the cell through DMT1. The Fe2+ can be 
converted to ferritin (FTH1/FTL) for storage, utilised by the cell or extruded from the 
cell through FPN1. Once across the membrane the Fe2+ is oxidised to Fe3+ and it binds 
TF to allow delivery to the tissues. Image modified from (Chua, Graham et al. 2007).  
 
1.1.2. Iron uptake 
Once iron has entered the blood stream, it must be taken up by cells in order to 
be utilised. This occurs primarily through receptor mediated endocytosis of TF-
Fe bound to the transferrin receptor (TFRC) (Knutson and Wessling-Resnick 
2003). HFE (the haemochromatosis gene protein) associates with TFRC on the 
cell surface but is dislodged when the TFRC binds TF-Fe. The low pH in the 
resulting endosome is believed to disrupt the TF-Fe conjugate and Fe3+ is 
released. The Fe3+ is reduced to Fe2+ by STEAP3 and exported out of the 
endosome by DMT1. Once in the cytoplasm the Fe2+ is stored as ferritin, utilised 
by the cell or transported out of the cell via the FPN1 pathway. This process is 
outlined in figure 1.3. 
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Figure 1.3. Overview of the uptake of transferrin-bound iron (TF-Fe) by macrophages. 
TF-Fe binds to TFRC on the cell surface and an endosome is formed within the cell. The 
acidic nature of the endosome results in iron (Fe3+) release from TF. This iron is 
reduced by STEAP3 to Fe2+ and transported out of the endosome via DMT1. The TFRC 
and TF are recycled back to the cell surface. In the cytoplasm, the Fe2+ can be utilised 
by the cellular processes, stored as ferritin (FTL or FTH1) or transported out of the cell 
via FPN1. Once extruded from the cell, the Fe2+ is oxidised by HEPH back to Fe3+ so it 
can bind TF and traffic to an area of need. Figure modified from (Chua, Graham et al. 
2007).  
 
1.1.3. Iron recycling by the reticuloendothelial system 
(RES) 
Macrophages play an important role in iron homeostasis by recycling the iron 
from senescent erythrocytes for incorporation into new erythrocytes (Latunde-
Dada, McKie et al. 2006). After the erythrocytes are phagocytosed by a 
macrophage, they are broken down into heme, which in turn is broken down by 
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the heme oxygenases (HMOXs) to Fe2+, which is then available for the cell to 
utilise. Haptoglobin (HP) is a soluble protein that binds free haemoglobin (Hb) to 
prevent toxicity associated with the breakdown Hb. The HP-Hb complex is 
endocytosed via binding to the CD163 receptor on macrophages (Nielsen, 
Moller et al. 2010). The globin moieties are broken down in the lysosome 
releasing heme which is trafficked via HCP1 into the cytosol where the HMOXs 
further degrade it to Fe2+. The Fe2+ can then be utilised or exported via FPN1 as 
required. This is outlined in figure 1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Recycling of iron within macrophages. HP binds free Hb and the HP-Hb 
complex is endocytosed by the macrophage through interaction with the CD163 
receptor. The Hb is broken down to heme which is exported out of the endosome into 
the cytosol via HCP1. Cytosolic heme is also produced from the breakdown of 
senescent erythrocytes phagocytosed by the macrophage. The heme is broken down 
by HMOX to Fe2+ where it can be stored, utilised or exported out of the cell through 
FPN1. The Fe2+ is then oxidised to Fe3+ and binds to TF for delivery to the appropriate 
tissues.  
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1.1.4. Maintaining iron homeostasis 
The understanding of iron homeostasis regulation increased with the 
identification of the purported master regulator of iron absorption, hepcidin 
(encoded by the HAMP gene). Hepcidin was originally recognised as an anti-
microbial peptide in human urine (Krause, Neitz et al. 2000) and blood (Park, 
Valore et al. 2001) studies. In the iron pathway, hepcidin binds to FPN1 (on the 
baso-lateral membrane of enterocytes and on macrophages) causing it to 
become internalised and resulting in iron retention within the cell and 
prevention of iron from entering the plasma (Nemeth, Tuttle et al. 2004). 
Hepcidin is produced predominantly by the liver, the main storage site for 
excess iron and thus the hepatocytes are believed to be the major site of iron 
homeostasis (Gehrke, Herrmann et al. 2005).  
 
The regulation of hepcidin is complex with a number of transmembrane 
proteins associated with the initiation of HAMP transcription via a number of 
different pathways. In an inflammation mediated response, interleukin-6 (IL6) 
induces the expression of HAMP through the JAK-STAT pathway (Wrighting and 
Andrews 2006). Recently members of the bone-morphogenetic protein (BMP) 
pathway have been implicated as key regulatory molecules in modulating HAMP 
expression (Corradini, Schmidt et al. 2010). Signalling through the BMP receptor 
(BMPR), by BMP6 in particular, induces the expression of HAMP through the 
SMAD signalling pathway (Babitt, Huang et al. 2006). Hemojuvelin (HJV) is 
present on the hepatocyte membrane. In conditions of low iron, HJV may be 
cleaved to its soluble form (sHJV) by another membrane protein, serine 
protease matriptase-2 (TMPRSS6). The sHJV inhibits HAMP induction by binding 
BMPs and preventing them from binding the BMPR (Silvestri, Pagani et al. 
2008). The pathways involved in HAMP regulation are outlined in figure 1.5. 
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Figure 1.5. Regulation of HAMP expression in the hepatocyte. IL6 binds to the IL6R, 
activating the JAK/STAT pathway to enhance HAMP expression. When iron is abundant 
(TFR2 is thought to detect iron levels but the mechanism is unknown), BMPs bind to 
the BMPR and HAMP expression is activated through the SMAD pathway. When iron is 
low, TMPRSS6 cleaves HJV which then binds to the BMPs so they cannot bind BMPR 
and HAMP expression is not up-regulated.  
 
Whilst hepcidin controls the efflux of iron from cells, the uptake of iron is also 
regulated, although the two pathways are not mutually exclusive. The 
mechanisms of iron regulation are not fully understood and the precise 
functions of some of the proteins involved in this pathway remain unknown. 
TFRC is the main receptor for iron uptake on the cell membrane. HFE and holo-
TF compete for binding sites on TFRC (Giannetti and Bjorkman 2004), and as the 
holo-TF has a greater affinity, it causes the dissociation of HFE and iron is 
absorbed into the cell. Transferrin receptor 2 (TFR2) is thought to play a role in 
HAMP 
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the regulation of iron absorption by sensing iron saturation levels of transferrin 
(Wallace, Summerville et al. 2005). 
 
1.1.4.1. Iron responsive elements 
Iron responsive elements (IREs) are sequences of around 30 bp that form 
hairpin structures in the untranslated region (UTR) of the mRNA of certain genes 
in the iron metabolic pathway. The IRE forms a six nucleotide loop, typically 5’-
CAGUGN-3’ and a stem of variable length but which has a small asymmetrical 
bulge on the 5’ strand, five nucleotide pairs down from the loop (Pantopoulos 
2004; Campillos, Cases et al. 2010). The basic structure of an IRE is outlined in 
figure 1.6. The two iron responsive proteins (IRPs), namely aconitase (ACO1 or 
IRP1) and iron responsive element binding protein 2 (IREB2 or IRP2) bind to IREs 
with high affinity when iron levels are low and either stabilise the mRNA to 
enhance expression (when the IRE is in the 3`UTR), or block translation of the 
mRNA (when the IRE is in the 5`UTR) (Eisenstein and Blemings 1998). Genes that 
have IREs in their 3`UTR include TFRC and DMT1 and those with IREs in the 
5`UTR include FTL, FTH1, and FPN1. Other genes that contain IREs include those 
encoding proteins involved in heme synthesis and the citric acid cycle; a full list 
is presented in table B.2 (appendix). TFRC has the only known mRNA to contain 
multiple IREs, with five IREs in the 3`UTR (Pantopoulos 2004).  
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Figure 1.6. The typical structure of an IRE showing the six nucleotide apical loop (n14-
n19) and a stem structure which an asymmetrical bulge at C8. This bulge is thought to 
be required for interaction with the IRPs. Figure reprinted from (Campillos, Cases et al. 
2010).  
 
1.2. Inherited iron overload 
1.2.1. Definition and types 
Haemochromatosis is a disease of excess iron storage and there are four main 
types of disease. The major differential between the types is the age of disease 
presentation which is primarily the consequence of mutations in different genes 
(table 1.1). Type I haemochromatosis is the most common form and this late 
onset disease is caused by mutations in the HFE gene. This form of the disease is 
the focus of this thesis. Type II haemochromatosis (or juvenile 
haemochromatosis) has very similar symptoms to type 1 but occurs at a 
younger age as a result of mutations in either the hemojuvelin (encoded by 
HFE2) or hepcidin (HAMP) genes. Type III haemochromatosis results from 
mutations in the TFR2 gene and type IV is caused by mutations in FPN1. Type 4 
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(also known as ferroportin disease) is caused by autosomal dominant mutations 
whereas the other three types of disease are inherited in an autosomal 
recessive pattern. A full list of mutations for each of these genes is presented in 
Appendix C.  
 
Table 1.1. The different types of inherited iron overload in terms of the typical age of 
clinical presentation and the causal genes that have been identified. 
Haemochromatosis Clinical Presentation Causal Gene/s 
Type I Late onset HFE 
Type II Juvenile HFE2, HAMP 
Type III Late onset TFR2 
Type IV Juvenile FPN1 
 
1.3. Haemochromatosis due to HFE mutations 
1.3.1. Clinical presentation 
Hereditary haemochromatosis (HH) is most commonly caused by the C282Y 
mutation in HFE, resulting in an excess of 1-2mg of iron being absorbed per day.  
During childhood, male adolescence and menstruating women there is no 
accumulation of iron due to high growth demands and iron losses (Pietrangelo 
2003). The excess iron eventually begins accumulating within the parenchymal 
tissues of the liver, heart and endocrine tissues (Siah, Ombiga et al. 2006) 
leading to symptoms such as bronze pigmentation of the skin, joint pain, 
abdominal pain, weight loss, impotence, cardiomyopathy, and diabetes. This 
overload may eventually lead to severe organ damage such as cirrhosis and 
cancer. Organ damage results from the highly reactive iron producing free 
radicals via the Fenton reaction and these free radicals attack and damage DNA, 
membranes and proteins (Yen, Fancher et al. 2006). As the liver is the main 
storage site for iron in the body it receives the most damage from the excess 
iron, and this presents as fibrosis and cirrhosis.  Haemochromatosis patients 
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also have a much higher incidence of primary hepatocellular carcinoma 
(Hanson, Imperatore et al. 2001). 
 
1.3.2. Diagnosis and treatment 
The diagnosis of HH usually occurs when patients are in their 5th-6th decade of 
life due to the length of time it takes for the iron to accumulate within the body 
and for the development of symptoms (Robson, Merryweather-Clarke et al. 
2004; Yen, Fancher et al. 2006). The age of onset is generally later in females as 
they are protected from the effects of iron accumulation through menstruation 
and pregnancy and so symptoms do not usually appear until after menopause 
(Pietrangelo 2004). Diagnosis of HFE-determined HH occurs primarily via 
measuring iron stores by serum ferritin (SF) and transferrin saturation (TfSat) 
levels and usually only secondarily by genetic testing. Generally iron overload is 
defined as having blood serum levels greater than 300µg/L and 50% for males 
and over 200µg/L and 45% for females for SF and TfSat respectively. Liver 
biopsies may be performed to measure the extent of iron accumulation and 
damage in this tissue, however this practice is decreasing due to the availability 
of less invasive techniques such as MRI (Tziomalos and Perifanis 2010).  
 
There are two accepted treatment options for HH. The most common treatment 
is simply phlebotomy, which involves giving blood regularly (e.g. one unit 
weekly or fortnightly) until SF and TfSat levels have decreased to normal levels. 
The phlebotomy treatment stimulates erythropoiesis which uses up the body 
iron stores, thereby decreasing SF and TfSat (Beutler, Hoffbrand et al. 2003). 
Very rarely, chelation therapy may be administered as treatment to increase 
iron excretion but it is less efficient and more expensive than phlebotomy 
(Hanson, Imperatore et al. 2001).  
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1.3.3. Prognosis 
The prognosis of HH is excellent with a normal lifespan expected if diagnosed 
before serious organ damage, such as cirrhosis, has occurred. Phlebotomy 
treatment carries little risk and should be performed on all patients with 
elevated iron stores (SF and TfSat) as it can reduce the severity of symptoms 
(Powell, Dixon et al. 2006).  
 
1.4. Genetics of hereditary haemochromatosis (HH) 
1.4.1. Most common mutations – C282Y and H63D 
HH was known to have a genetic component that was linked to HLA-A3 on 
chromosome 6 (Simon, Bourel et al. 1976; Powell, Ferluga et al. 1987) long 
before the discovery of the causal HFE gene at 6p21.3 in 1996 (Feder, Gnirke et 
al. 1996). More than 80% of patients in the Feder et al study were found to be 
homozygous for a G>A missense mutation at nucleotide 845 of HFE resulting in 
a cysteine being replaced by a tyrosine at amino acid 282 (C282Y mutation). A 
second mutation at nucleotide 187 (C>G) that caused a histidine to change to an 
aspartic acid at residue 63 (H63D) was also identified as affecting iron loading, 
although to a lesser extent than C282Y (Feder, Gnirke et al. 1996). Later a third 
mutation, S65C (A>T at nucleotide 193 changing a serine to a cysteine at residue 
65) that may also cause disease was identified (Simonsen, Dissing et al. 1999); 
however, the effect of this mutation on HH is not widely accepted. Linkage 
disequilibrium (LD) in the interval containing these three mutations is very tight 
and they virtually never occur simultaneously on a chromosome (Rochette, 
Pointon et al. 1999; Merryweather-Clarke, Pointon et al. 2000; Beutler, Felitti et 
al. 2001) except in very rare cases (Thorstensen, Asberg et al. 2000; Best, Harris 
et al. 2001; Lucotte, Champenois et al. 2001) 
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1.4.2. Prevalence of C282Y and H63D 
HH is the most common disease with an autosomal recessive inheritance 
pattern in Caucasians with the prevalence of the C282Y mutation approximately 
ten times that of cystic fibrosis causing alleles (Pietrangelo 2004). Within 
Caucasian populations in Australia, the frequency of the C282Y allele has been 
calculated as between 0.077 (Rossi, Bulsara et al. 2001) and 0.072 (Cavanaugh, 
Wilson et al. 2002) with a corresponding prevalence for C282Y homozygosity of 
0.53% and 0.50%, respectively. These values are consistent with the worldwide 
average C282Y homozygosity in people of northern European descent that has 
been calculated to be approximately 0.5% (Papanikolaou, Politou et al. 2000; 
Jackson, Carter et al. 2001; Powell, Dixon et al. 2005). The prevalence of these 
mutations in non-white populations is much lower with a large population study 
in the US providing estimates for C282Y homozygosity in Native Americans, 
Hispanics, African Americans, Pacific Islanders and Asians that were at least one 
quarter of the frequency in the non-Hispanic whites (Adams, Reboussin et al. 
2005).  
 
The distribution of C282Y matches the distribution of haemochromatosis 
disease; however, the H63D mutation has been found in populations where no 
HH has been found (Merryweather-Clarke, Pointon et al. 2000). The frequency 
of H63D in the Caucasian Australian population has been estimated at between 
0.141 (Cavanaugh, Wilson et al. 2002) and 0.162 (Gochee, Powell et al. 2002). 
The allele frequencies for the H63D mutation are similar in haemochromatosis 
patients and the general population, but when LD and the extremely rare 
occurrence of the C282Y/H63D haplotype are taken into account, H63D is 
actually more prevalent in haemochromatosis than in the general population 
(Beutler 1997; Beutler, Felitti et al. 2001). The presence of either C282Y or H63D 
alleles even in the heterozygous state is able to influence iron overload 
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(Whitfield, Cullen et al. 2000). Population studies have shown that compound 
heterozygosity for C282Y and H63D presents a higher risk for the development 
of HH than either mutation alone, and the extent of iron loading generally 
follows the trend C282Y homozygotes > C282Y/H63D compound heterozygotes 
> H63D homozygotes > C282Y heterozygotes > H63D heterozygotes > wildtype 
(Cardoso, Porto et al. 2001; Beutler, Felitti et al. 2002).  
 
1.4.3. Racial Origins of C282Y and H63D  
The C282Y mutation is found exclusively in individuals of European ancestry and 
it occurs on a prevalent Caucasian haplotype that is uncommon in Africans and 
Asians (Aguilar-Martinez, Thelcide et al. 1999). The rare occurrences of C282Y in 
non-Europeans are almost certainly the result of admixture (Merryweather-
Clarke, Pointon et al. 2000). In Europe the C282Y allele frequency declines from 
the North to the South (Lucotte 1998), and there is some debate as to whether 
this reflects a Celtic (i.e. Irish, Scottish, Welsh or Bretons) (Lucotte 1998) or 
Scandinavian (Viking) (Milman and Pedersen 2003) origin. Whichever ancestry is 
correct, most C282Y chromosomes carry an ancestral haplotype, although there 
is some evidence that C282Y has arisen independently in Sri Lanka (Rochette, 
Pointon et al. 1999) and also in Hispanics (Aguilar-Martinez, Thelcide et al. 1999) 
more recently than the European mutation.  
 
H63D is found throughout Europe, North Africa, Asia and the Middle East, but is 
rare in populations that resist admixture such as the Ashkenazi Jews 
(Merryweather-Clarke, Pointon et al. 2000). The H63D mutation is thought to be 
older than the C282Y mutation given the larger number of haplotypes on which 
H63D resides and the low recombination frequencies in the MHC region 
(Merryweather-Clarke, Pointon et al. 2000; Toomajian and Kreitman 2002).  
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Linkage disequilibrium (LD) in the HFE gene region suggests that C282Y could be 
older than 6000 generations (Cardoso and de Sousa 2003). However, because 
this region is subject to reduced recombination and the region of LD is larger on 
C282Y chromosomes than on normal chromosomes, it has been suggested that 
the mutation may have arisen much later (Ajioka, Jorde et al. 1997). The C282Y 
mutation has been estimated to have arisen 60-70 generations ago and the high 
frequency of the mutation seen today may be the result of a founder effect 
(Lucotte 1998; Milman and Pedersen 2003), decreased recombination rates 
(Pratiwi, Fletcher et al. 1999), genetic drift (Merryweather-Clarke, Pointon et al. 
2000), selection, rapid population expansion or a combination of any of these 
factors (Thomas, Fullan et al. 1998). There is some suggestion that there has 
been positive selection for the C282Y mutation (Rochette, Pointon et al. 1999; 
Pietrangelo 2003) with estimates that a 20% increase in the frequency of this 
mutation per generation must have occurred if it arose from a single ancestor 
60-70 generations ago (Whitfield, Cullen et al. 2000; Pietrangelo 2003). There is 
some evidence that women with the C282Y mutation are less likely to become 
iron deficient as a consequence of diet, some types of infection, multiple 
pregnancies or a combination of these factors (Rochette, Pointon et al. 1999; 
Whitfield, Cullen et al. 2000) however it remains unclear if this may have 
resulted in selection for the C282Y allele. It has also been suggested that HFE 
may be a receptor for one or more pathogens and that the C282Y mutation 
renders cells unavailable to the alleged pathogen (Merryweather-Clarke, 
Pointon et al. 2000). While there are no specific candidates, HFE has recently 
been shown to be a target for the HIV-1 Nef protein (Drakesmith, Chen et al. 
2005) suggesting there may be some substance to this claim. There is also a 
possibility that the C282Y mutation may be associated with an allele at an as yet 
unidentified locus that has been subjected to selection (Merryweather-Clarke, 
Pointon et al. 2000; Toomajian and Kreitman 2002).  
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1.4.4. Other HFE mutations 
Several other mutations in the HFE gene have been identified in 
haemochromatotics, however many of these mutations are private (unique to 
the lineage in which each were identified) or specific to particular regions in 
which they may have increased in the population due to founder events. This is 
the case for certain mutations in Italy (Piperno, Arosio et al. 2000; Salvioni, 
Mariani et al. 2003), some of which contribute to iron overload only in the 
presence of the C282Y or H63D mutations (Menardi, Perotti et al. 2002). A full 
list of mutations in HFE that cause haemochromatosis are presented in table C.1 
(appendix). 
 
1.5. HFE protein structure and function 
1.5.1. Tissue expression patterns of HFE 
HFE is expressed in all cells to at least some degree in humans (Feder, 
Tsuchihashi et al. 1997). The strongest expression is present in intestinal crypt 
cells, hepatocytes, monocytes and tissue macrophages including the Kupffer 
cells in the liver (Menardi, Perotti et al. 2002; Knutson and Wessling-Resnick 
2003). This wide distribution of expression reflects the requirement of every cell 
for iron. 
 
1.5.2. Protein structure and normal function 
HFE is a non-classical MHC class I molecule encoded by seven exons, with the 
seventh not translated (Pietrangelo and Camaschella 1998; Bahram, Gilfillan et 
al. 1999). The 343 amino acid protein is 49kDa and consists of a signal peptide 
(which is cleaved), three extracellular loops (α domains), a transmembrane 
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domain and a short cytoplasmic tail (Feder, Penny et al. 1998). Like all MHC 
class I molecules, HFE associates non-covalently with beta-2-microglobulin 
(β2M) (Feder, Tsuchihashi et al. 1997; Feder, Penny et al. 1998). This interaction 
is necessary for the accurate export of HFE from the endoplasmic reticulum 
(ER), insertion of HFE into the cell membrane (Riedel and Stremmel 1997) and 
the maintenance of the correct orientation in the membrane (Bomford 2002). In 
classical MHC class I molecules, the α1 and α2 domains form the peptide 
binding groove but crystal structures have shown that in HFE, the distance 
between the α1 and α2 domains is reduced compared to classical MHC class I 
molecules, which abolishes the peptide binding function (Lebron, Bennett et al. 
1998; Drakesmith and Townsend 2000). The crystal structure of HFE suggests 
that the extracellular α1 domain interacts with TFRC (Lebron, Bennett et al. 
1998) on the cell surface. 
 
1.5.3. Protein structure disruption by C282Y and H63D 
The C282Y mutation occurs in exon four of HFE and disrupts a critical disulfide 
bridge in the α3 domain. This subsequently disrupts the interaction with β2M 
resulting in protein retention in the ER and Golgi (Feder, Tsuchihashi et al. 1997) 
with no protein present on the cell membrane (Feder, Penny et al. 1998). It has 
been demonstrated that the tissues with the strongest HFE expression in 
unaffected individuals (intestinal crypt cells and macrophages) are actually iron 
deficient in HH patients. It is thought that the absence of HFE on the cell 
membrane due to the C282Y mutation disrupts normal signalling and as a result, 
these cells cannot detect increases in bodily iron and so they release all their 
iron stores (Pietrangelo 2003). This lack of iron within the cells also means less 
iron is lost through the shedding of these cells (Pietrangelo 2004). 
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The H63D mutation occurs in exon two which corresponds to the α1 domain. No 
detectable changes in β2M interaction or intracellular processing have been 
reported for the H63D mutation (Feder, Tsuchihashi et al. 1997) however, the 
disruption of a salt bridge may lead to a local rearrangement of the α1 loop and 
possibly interfere with either correct functioning (Feder, Penny et al. 1998; 
Lebron, Bennett et al. 1998) and/or stability of the protein (Roy, Carlson et al. 
2000).  
 
1.5.4. Immune function of HFE?  
Given that HFE is an MHC like molecule, investigations of a possible functional 
role for HFE in the immune system have been explored. The sequestration of 
iron by cells to reduce the availability of iron to invading pathogens is well 
established but the specific part played by HFE is not clearly defined. In terms of 
other immune functions, some studies have reported perturbations in T cell 
numbers in C282Y homozygotes (generally CD8+ T cells) (Porto, Cardoso et al. 
2001; Fabio, Zarantonello et al. 2002; Barton, Wiener et al. 2005; Cruz, Melo et 
al. 2006). Mouse studies have also suggested that HFE is involved in the 
selection of part of the CD8+ T cell repertoire (Rohrlich, Fazilleau et al. 2005; 
Yewdell and Hickman-Miller 2005) and may affect the selection of particular 
chains in the T cell receptor (TCR) (Cardoso, Porto et al. 2001). It has also been 
proposed that the iron-poor phenotype of macrophages in HH leads to 
resistance to certain pathogens that rely on macrophage iron, such as 
Mycobacterium tuberculosis (Moalem, Weinberg et al. 2004) (see also 
discussion above of a possible selective advantage for HH). While there is 
potential for an immune function for HFE, it is not likely to be vital to normal 
immune functioning given the high frequency of the C282Y mutation and the 
lack of evidence of any detrimental immune system functions in C282Y 
homozygotes.  
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1.6. Regulation of HFE Expression 
1.6.1.1. Transcriptional control – HFE promoter studies 
Soon after the identification of HFE, a report identifying the rat promoter of HFE 
and putative human and mouse promoters was published (Sanchez, Queralt et 
al. 1998). Both TATA and a CAAT boxes were recognized in the putative human 
promoter and several transcription factor binding sites (TFBS) that appeared to 
be conserved between the three species were also identified. A more recent 
paper partially characterised the structure of the human HFE promoter using a 
luciferase reporter gene system in different cell lines and showed tissue specific 
factors were involved in the expression of HFE (Mura, Le Gac et al. 2004). It was 
also suggested that the promoter contains regions for low basal expression (as 
for housekeeping genes) in addition to elements for the transient up-regulation 
of expression when required (Mura, Le Gac et al. 2004). Little attention has 
been paid to the precise definition of the HFE promoter and this is likely to be a 
consequence of the major disruption to protein function provided by the C282Y 
allele. 
 
Studies on the expression of HFE have found no differences in expression levels 
between C282Y homozygotes and controls in both enterocytes (Kelleher, Ryan 
et al. 2004) and liver biopsies (Gleeson, Ryan et al. 2006). Another study 
compared the allelic specific expression for both C282Y and H63D in peripheral 
blood mononuclear cells from heterozygotes and found that the mutant alleles 
at both C282Y and H63D were expressed at comparatively higher levels than the 
respective wildtype allele (Rosmorduc, Poupon et al. 2000). However the 
techniques used in this study have been extensively criticised (Bergamaschi, 
Rolandi et al. 2001; Bayley and Verweij 2002).  
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1.6.1.2. Alternate transcripts of HFE 
In the original paper identifying HFE as the causal HH gene, a 4.0kb transcript 
was identified via Northern blot analyses; however, as the isolated cDNA was 
only 2.7kb, the possibility of multiple transcripts was suggested (Feder, Gnirke 
et al. 1996). Subsequent studies found that the different sized transcripts are 
the result of both alternate splicing and alternate polyadenylation signals 
(Fleming, Britton et al. 2004) with different cell types showing different 
transcript profiles (Rhodes and Trowsdale 1999). An mRNA encoding a soluble 
form of the protein has also been described (Jeffrey, Basclain et al. 1999; 
Rosmorduc, Poupon et al. 2000) although it is uncertain whether this exists as a 
fully functional protein. The existence of an antisense RNA that covers the first 
two exons, part of the first intron and additional upstream material of HFE has 
been described (Thenie, Gicquel et al. 2001) and although the expression levels 
were low, it was observed in multiple tissues. HFE appeared to be negatively 
regulated by the presence of the reverse transcript (Thenie, Gicquel et al. 2001) 
but further experiments on the role of this transcript and the relevance to the 
regulation of HFE have not been reported.  
 
1.7. Penetrance of the HFE mutations 
Penetrance is a measure of how many individuals possessing a disease genotype 
actually develop the disease phenotype. In the case of HH it generally refers to 
the percentage of C282Y homozygotes that develop both biochemical signs and 
symptoms of haemochromatosis.  
 
1.7.1. Biochemical versus clinical disease penetrance 
Several studies have considered the penetrance of the main HFE mutations, but 
comparisons are problematic given the inconsistencies in the definition of both 
disease and non-disease (in terms of asymptomatic patients). Much of the 
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debate centres on whether penetrance calculations should be based upon the 
biochemical presentation of the disease (elevated TfSat and SF), or whether it 
should be based on the clinical signs of the disease (Ryan, Byrnes et al. 2002; 
Beutler 2003). Given that the presence of biochemical overload without 
symptoms still necessitates phlebotomy treatment, and most diagnoses of HH 
are based on biochemical evidence and non-specific symptoms such as joint 
pain and fatigue (Beutler, Hoffbrand et al. 2003), it seems appropriate to define 
penetrance on the basis of biochemical evidence for iron overload. Addressing 
the issue of when to define a C282Y homozygote as asymptomatic is more 
challenging given the variability in the age at which HH presents and is 
diagnosed. The main discrepancy between studies occurs when C282Y 
homozygotes are classified as asymptomatic when they are not yet of an age 
when the disease phenotype typically presents, biochemically or clinically. This 
is particularly true for females given the later age of onset compared to males.   
 
1.7.2. Estimations of disease prevalence - population 
studies 
Since the identification of HFE, the suggestion has been made that although the 
C282Y mutation is very common, the actual disease entity of haemochromatosis 
is relatively rare with penetrance estimated at a mere 1% or below (Beutler, 
Felitti et al. 2002; McCune, Al Jader et al. 2002; Beutler 2003). These studies are 
based on the clinical presentation of the disease and questions remain about 
the lack of consideration of the age of the subjects studied (Adams 2000; 
McCune, Al Jader et al. 2002), the assessment of symptoms, sample bias and 
exclusion of certain C282Y homozygotes (Bassett, Wilson et al. 2002; Beutler, 
Felitti et al. 2002). In one of the largest studies to date, clinical penetrance was 
estimated at less than 1% but biochemical indices of iron overload were present 
in around 75% of males and almost 40% of females homozygous for C282Y 
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(Beutler, Felitti et al. 2002). As patients with biochemical iron overload are 
treated irrespective of symptoms, it is impossible to determine the lifetime 
clinical penetrance of the C282Y mutation if patients are treated for elevated 
iron before symptoms develop. This is because biochemical measures of iron 
overload increase with time (Olynyk, Hagan et al. 2004; Powell, Dixon et al. 
2006) and if untreated, may lead to increased iron accumulation in the organs 
(Pietrangelo 2004). 
 
In Australia the penetrance of C282Y is estimated to be 75% for biochemical 
markers and 50% for clinical definition (Olynyk, Cullen et al. 1999; Cavanaugh, 
Wilson et al. 2002). The values for the penetrance of C282Y are similar across 
studies of people of similar ethnicity from different countries (Merryweather-
Clarke, Pointon et al. 2000; Ryan, Byrnes et al. 2002; Adams, Reboussin et al. 
2005; McCune, Ravine et al. 2006).  
 
1.7.3. Environmental modifiers of penetrance 
There are a number of external factors that may influence the extent of iron 
loading in HH. Both age and gender are important determinants of penetrance 
but lifestyle factors can also play a role. Dietary factors that can increase iron 
uptake include excessive consumption of both red meat and alcohol, and 
vitamin C and iron supplements can also increase iron absorption (Rossi, Bulsara 
et al. 2001). While perhaps less well known, dietary factors that may decrease 
iron absorption include tannates (such as those in tea), and both calcium and 
phosphates bind iron in the intestinal lumen and inhibit absorption (Beutler, 
Felitti et al. 2001; Hanson, Imperatore et al. 2001). Non-dietary influences on 
iron levels in the body include blood loss (such as regular blood donation or 
bleeding conditions/trauma) and the presence of infections such as hepatitis.  
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1.7.4. Modifier genes in HH 
The effect of modifier genes on the expression of a variety of diseases is well 
documented where they may influence penetrance, dominance modification, 
expressivity and pleiotropy (Nadeau 2001). It is now commonly accepted that 
there are genetic factors in addition to HFE that affect iron homeostasis in HH 
and the identification of modifier genes in HH may be important in elucidating 
gene interactions and also for novel treatment and preventative strategies 
(Nadeau 2003). 
 
1.7.4.1. Modifier genes in mice 
Hfe knockout (KO) mice on different background strains develop significant 
differences in iron loading both in terms of SF and hepatic iron concentration 
(Fleming, Holden et al. 2001). A further study of these animals has implicated 
chromosomal regions that house genes involved in the iron metabolic pathway 
(Bensaid, Fruchon et al. 2004). As mice do not develop the full range of 
symptoms associated with human haemochromatosis, it is unlikely that all 
modifiers of the human genotype will be identified in the mouse model of HH 
(Bensaid, Fruchon et al. 2004). Two candidate modifiers identified in mice have 
yet to be studied in humans, namely: ceruloplasmin, a cytosolic ferroxidase that 
functions primarily in copper metabolism (Gouya, Muzeau et al. 2006); and 
Mon1a that is involved in the vesicular traffic of proteins including FPN1 (Wang, 
Paradkar et al. 2007). Further studies are required to determine the effect, if 
any, of these genes in human HFE-determined HH penetrance.  
 
1.7.4.2. Human studies of modifier genes in HH 
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A twin study investigating the C282Y and H63D mutations and blood iron 
parameters found between 30-45% of the variation in the HH phenotype in 
humans can be explained by genes other than HFE (Whitfield, Cullen et al. 
2000). The identification of these genes has been problematic as of those 
identified, most have failed to replicate in subsequent studies, which may 
largely be attributed to a lack of a universally applied definition of the HH 
disease phenotype. A summary of the candidate modifier genes identified so far 
is presented in table 1.2 with more in depth descriptions below.  
 
1.7.4.2.1.  HFE gene region 
Given the strong linkage disequilibrium around the HFE locus and the likelihood 
that people with the ancestral haplotype have more severe disease (Jazwinska 
and Powell 1997), a modifier gene may be present in this region. Pratiwi et al 
(1999) found two distinct peaks of LD around the HFE locus with one of these 
peaks associated with iron loading in males suggesting a modifier gene/allele 
may be present in this area (Pratiwi, Fletcher et al. 1999). However, subsequent 
studies indicated there was no evidence for modifier genes in the vicinity of HFE 
(Barton, Wiener et al. 2005; McCune, Ravine et al. 2006).  
 
1.7.4.2.2.  Sequencing iron metabolic pathway genes 
A number of studies have addressed the question of other genes in the iron 
metabolic pathway being potential modifiers of HH by sequencing a selection of 
these genes. This approach has identified a number of polymorphisms that may  
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Table 1.2. Genes/gene regions identified modifying the penetrance of HFE-associated haemochromatosis in either mouse and/or human studies. 
Gene/SNP Human &/or 
mouse studies 
Effect Studies with positive association Studies with no association found 
Haptoglobin Both Increased iron loading with the 2-
2 genotype 
(Tolosano, Fagoonee et al. 2005) 
(Van Vlierberghe, Langlois et al. 
2001) (Delanghe and Langlois 
2002) (Le Gac, Ka et al. 2009) 
(Beutler, Gelbart et al. 2002) 
(Carter, Bowen et al. 2003) 
HFE gene region Human Increased iron loading with 
ancestral haplotype 
(Jazwinska and Powell 1997; 
Pratiwi, Fletcher et al. 1999) 
(Barton, Wiener et al. 2005; 
McCune, Ravine et al. 2006) 
TNFα Human Decreased levels in HH (Gordeuk, Ballou et al. 1992) 
(Fargion, Valenti et al. 2001) 
(Distante, Elmberg et al. 2003) 
TNFα -308 Human Rare allele increases iron loading (Krayenbuehl, Maly et al. 2006) (Beutler and Gelbart 2002) 
TGFβ1 codon 25 Human Increased risk of cirrhosis with 
rare allele 
(Osterreicher, Datz et al. 2005) n/a 
Ceruloplasmin Mouse Protective effect on iron loading (Gouya, Muzeau et al. 2006) n/a 
HAMP Human Increased iron loading (Jacolot, Le Gac et al. 2004), 5/784 
chromosomes with mutation 
(Biasiotto, Roetto et al. 2004) 
Mon1a Mouse Role in FPN1 trafficking (Wang, Paradkar et al. 2007)  
Mitochondrial 
variant 16189 
human Increased frequency in 
symptomatic C282Y homozygotes 
(Livesey, Wimhurst et al. 2004) (Beutler, Beutler et al. 2004) 
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impact disease phenotype but none were at a high enough frequency to be 
informative on a large scale (Biasiotto, Roetto et al. 2004; Jacolot, Le Gac et al. 
2004; Mendes, Ferro et al. 2008). Small sample sizes have contributed to the 
lack of findings in some studies (Lee, Gelbart et al. 2001; Lee, Gelbart et al. 
2002). 
 
1.7.4.2.3. Large scale SNP studies 
Recently a number of genome wide association studies have been performed to 
determine whether any SNPs associate with blood iron parameters. This has 
yielded some interesting results with the identification of SNPs in TF, TMPRSS6 
and CYBRD1 (Benyamin, McRae et al. 2009; Constantine, Anderson et al. 2009). 
An initial study also suggested a role for BMP2 SNPs in HH (Milet, D‚hais et al. 
2007) but subsequent studies failed to replicate these results (Milet, Le Gac et 
al. 2010).  
 
1.7.4.2.4.  Haptoglobin (HP) 
Haptoglobin functions to remove free Hb from the plasma (as outlined in 
section 1.1.3 above). It has two main alleles and exists as three forms, 1-1, 1-2 
and 2-2. Results from both mouse (Tolosano, Fagoonee et al. 2005) and human 
studies have suggested that the 2-2 genotype may be associated with increased 
iron stores (Van Vlierberghe, Langlois et al. 2001; Delanghe and Langlois 2002; 
Le Gac, Ka et al. 2009) however not all studies have been able to find a 
significant correlation (Beutler, Gelbart et al. 2002; Carter, Bowen et al. 2003) 
 
1.7.4.2.5.  Tumour Necrosis Factor alpha (TNFα) 
TNFα levels have been associated with HH in some (Gordeuk, Ballou et al. 1992; 
Fargion, Valenti et al. 2001) but not in all studies (Distante, Elmberg et al. 2003). 
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There are a number of SNPs in the promoter of TNFα and -308 in particular has 
been associated with iron loading in C282Y homozygotes in a recent study 
(Krayenbuehl, Maly et al. 2006) but again, has failed to be associated in others 
(Beutler and Gelbart 2002).  
 
1.7.4.2.6.  Genes in other pathways 
The 16189 mitochondrial variant had an increased frequency in C282Y 
homozygotes with iron overload compared to C282Y homozygotes without signs 
of iron overload (Livesey, Wimhurst et al. 2004). This was not replicated in a 
subsequent study (Beutler, Beutler et al. 2004). Mutations in the liver 
detoxifying enzyme UGT1A1 (Sikorska, Romanowski et al. 2010) and the 
mitochondrial enzyme ALAS2 (Lee, Barton et al. 2006) have also been associated 
with iron levels. 
 
1.7.4.3. Frequency of modifier gene variants 
For a modifier gene to significantly impact the overall penetrance of a disease, it 
must be at a high enough allele frequency to affect a clinically relevant 
proportion of patients. For example, the variant described in ALAS2 above (Lee, 
Barton et al. 2006) occurs at a frequency of 0.0013 and so the impact on HH 
penetrance would be minimal at best. 
 
1.8. Aims and hypothesis 
The central hypothesis underlying the present studies proposes that modifier 
genes impact on the penetrance of HFE mutations. These effects can be 
identified in subgroups of patients and controls of different genotypes with and 
without biochemical signs of iron overload. The main aims are:  
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- To confirm the modifying potential of recently identified polymorphisms in 
TMPRSS6, TF and CYBRD1  
- To investigate the validity of claims that TNFα is a modifier gene. 
- To determine if differences in the expression of a number of genes in the 
iron pathway correlates with genotypic and phenotypic data in a 
lymphoblastoid cell line model.  
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2. Chapter 2. Materials and Methods 
2.1. Samples 
2.1.1. The Canberra Region Haemochromatosis 
Database 
The Canberra Region Haemochromatosis database (CRHD) contains data on 
haemochromatosis patients who were referred to or diagnosed by Professor 
Mark Bassett at The Canberra Hospital. The database was created in 2000 as a 
clinical resource to allow detailed investigation of the haemochromatosis 
phenotype whilst also containing important family data. The majority of 
probands (i.e. those in the family first presenting with HH to Prof Bassett) in the 
database are from Canberra and the surrounding region, however family 
members do not necessarily reside in this area. Patients were recruited to the 
database as a result of a referral from their GP or specialist, or after contacting 
the research group after reading publicity material about the database. 
 
The information collected from patients includes details of gender, age, height, 
weight, any chronic blood loss and/or blood donations, pregnancy and 
menstrual history for females, dietary information (through a questionnaire), GP 
contact details and information on family members interested in participating. 
Nevertheless institutional ethics approval requires that patients are informed 
that they may choose not to provide complete information. As a consequence 
not all datasets on all participants are complete. 
 
At September 2010 there are 1760 individuals in the database from 411 
families. Blood has been collected and DNA has been extracted from 411 
individuals from 191 families.  
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2.1.2. Controls 
Two different types of control samples were used. The most widely used 
samples were from a pool of 196 Caucasian Australian Red Cross Blood Service 
(ARCBS) donors collected from 1998-2005. Because of ARCBS confidentiality, 
only gender and year of birth were available but the assumption of good health 
was made due to their completion of the ARCBS questionnaire regarding health 
status and subsequent acceptance as a donor. The other set of control samples 
were from self-described healthy co-workers. All control and patient samples 
were collected and studied in accordance with the Helsinki Declaration of 1975 
revision of 1996 (http://www.wma.net/e/humanrights/policy_meetings.htm) 
with appropriate institutional ethics review and approval (both Canberra 
Hospital and ANU Human Research Ethics Committees)  
 
2.1.3. Commercial Cell lines 
2.1.3.1. Mammalian cells 
Three commercial human cell lines were used in luciferase assays, namely 
human embryonic cell line HEK293H (Invitrogen, Carlsbad CA, USA, cat# 11631-
017), human Caucasian hepatocyte adenocarcinoma HepG2 (Sigma-Aldrich, 
Castle Hill, Australia, cat# 85011430) and human Caucasian colon 
adenocarcinoma Caco-2 (Sigma-Aldrich, cat# 86010202). The Epstein Bar Virus 
(EBV) producing B-lymphoblastoid marmoset cell line B95-8 (ATCC, Manassas, 
USA, cat# CRL-1612) was grown to harvest EBV.  
 
2.1.3.2. Bacterial cell lines 
The Escherichia coli DH5α strain (Invitrogen, cat#18265-017) was used in cloning 
protocols.  
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2.2. Sample processing 
Blood was collected at either a pathology collection centre, through a patients’ 
GP or by a registered nurse at the Medical Genetics Research Unit (MGRU) into 
9 ml ACD (acid-citrate-dextrose, Becton, Dickinson and Company, Sydney, 
Australia, cat# 364606) blood tubes, with a total collection of approximately 30 
ml per individual. Upon arrival in the laboratory, a 10 μl quality control sample 
was taken followed by crude cell separation, collection of mononuclear cells and 
storage of the sample for DNA extraction, details of which follow. 
 
2.2.1. Crude cell separation 
Samples were centrifuged (1800 RPM, 10 min, RT°C) to separate the phases and 
2 ml of plasma was collected into two sterile 1.5 ml screw top tubes. The tubes 
were first frozen at -20°C and then transferred to -70°C for long-term storage. 
The remaining blood was transferred to a sterile 50 ml tube and used in the 
Ficoll-Paque procedure outlined below (section 2.2.3).  
 
2.2.2. Serum ferritin levels 
Where possible, pre-treatment serum ferritin levels were obtained from patient 
records. Serum ferritin levels were determined in the biochemistry laboratory 
by ACT pathology for patients and controls, using the Immulite 2000 system. 
The normal range for males and females are <370μg/L and <200μg/L 
respectively.  
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2.2.3. Ficoll-Paque isolation of mononuclear cells from 
whole blood  
Mononuclear cells were isolated by Ficoll-Paque (GE, New York, USA, cat# 17-
1440-03) gradient as follows: after collection of plasma, remaining blood was 
transferred to a sterile 50 ml tube. Sterile 1XPBS (phosphate buffered saline, 
appendix D) was added to a final dilution of 1: 2 blood: PBS. A sterile glass 
Pasteur pipette was then gently placed in the mixture to facilitate the layering 
of 5-7 ml of Ficoll-Paque underneath the blood. The pipette was removed and 
after centrifugation of the blood (20 min, 10°C, 1800 RPM, low brake, Beckman 
Coulter Allegra R6 centrifuge), four visible layers were identified: from the 
bottom; packed erythrocytes with granulocytes on the top, Ficoll-Paque, 
mononuclear cells, and a plasma layer which also contained platelets. The 
mononuclear layer was collected into a sterile 15 ml tube with a sterile plastic 
transfer pipette and the remaining sample was stored at -20°C for later DNA 
extraction (section 2.2.7). Collected cells were then washed twice in 10 ml of 
1XPBS with centrifugation (1000 RPM, 10 min, 10°C) between washes. Washed 
cells were resuspended in 5-10 ml 1XPBS and the viable lymphocyte number 
estimated using a haemocytometer and Trypan Blue (Sigma-Aldrich, cat# T8154) 
exclusion. Depending on cell number, cells were then frozen and/or 
transformed. Cells were frozen at 1x107cells/ ml of freezing medium (FM, see 
appendix F) in the vapour phase of liquid nitrogen after first been frozen to -
70°C at a rate of -1°C/minute in a Mr Frosty (Nalgene, Rochester NY, USA, cat# 
5100) filled with isopropanol (Ajax Fine Chemicals, Taren Pt, Australia, cat# 
A425-2.5L-GL). At least 2x106 cells were utilised for the immediate 
transformation procedure as outlined below. The main priority was for 
successful transformation, followed by provision of a backup aliquot of cells for 
subsequent immortalisation should the first attempt be unsuccessful.  
 
34 
 
2.2.4.  EBV transformation of lymphocytes 
(establishment of lymphoblastoid cell lines) 
B lymphocytes were immortalized via EBV transformation to lymphoblastoid cell 
lines (LCLs) which served as a perpetual source of DNA and RNA and as an 
experimental tool for manipulation of environmental conditions. 
Transformations were performed either on freshly collected lymphocytes or on 
lymphocytes stored in liquid nitrogen for up to eight years. 
 
2.2.4.1. EBV transformation of fresh lymphocytes 
After Ficoll-Paque separation, at least 2x106 washed cells were pelleted (1000 
RPM, 10 min, 10°C) and resuspended in 500 µl of B95-8 cell line supernatant 
(containing EBV particles, see section 2.2.5.3) in a 15 ml tube. Cells were 
incubated at 37˚C in a closed-cap system for 90 min. After this time 1-1.5 ml of 
pre-warmed transforming media (TFM, appendix F) was added, the cell 
suspension was transferred into a prelabelled T25 flask (Nunc, Roskilde, 
Denmark, cat# 163371) and incubated at 37˚C with 10% CO2. The CO2 
percentage was higher than the standard 5% based on empirical evidence that 
the LCLs grow faster and more effectively at this elevated CO2 level. Depending 
on the initial number of cells and the proliferation response to a T cell mitogen 
(phytohemagglutinin (PHA), Gibco, Auckland, New Zealand, cat# 10576-015) in 
the TFM, cells began clumping together after 2-10 days. Media was 
supplemented with 0.5-1 ml of fresh TFM as required.  
 
2.2.4.2. EBV transformation from frozen lymphocytes 
Whilst most samples were transformed from freshly isolated lymphocytes, this 
was not always possible because of work flows or because transformation was 
not always successful the first time. Lymphocytes frozen in liquid nitrogen were 
retrieved and kept on ice before being rapidly defrosted in a 37°C water bath. 
35 
 
Cells were transferred to a 15 ml tube and gently washed with 6-7 ml wash 
media (appendix F) that was added one drop at a time. Each drop was fully 
incorporated into the suspension before the next drop was added. Cells were 
centrifuged (1000 RPM, RT°C, 10 min, low brake) and resuspended in 500 μl 
B95-8 cell line supernatant (section 2.2.5.3). 1 ml of warm TFM was added and 
cells were transferred to a prelabelled T25 flask or alternatively to a 24 well plate 
(MP Biomedicals, Solon USA, cat# 76-063-05) if the cell count was lower than 
5x106 cells. Cells were subsequently treated as per the fresh transformation 
except that once cells had reached confluence in a single well of the 24 well 
plate, they were transferred to a T25 flask.  
 
2.2.5. Cell line maintenance 
2.2.5.1. Lymphoblastoid cell lines 
All cell lines required long-term cultivation at 37˚C, 10% CO2 (in ventilated or 
filtered flasks). Incubators were sterilised regularly. After initial transformation, 
media replenishment (0.5-1 ml of TFM) was performed at least once every 10 
days, more commonly every 4-7 days. After ca. three weeks from the initial 
transformation, cultivation medium (CM-appendix F) replaced TFM and cells 
were fed twice weekly. When the culture volume reached 5 ml, media was 
replaced in ratios of 1:2 or 1:3 with new media in order to remove waste 
products and cellular debris whilst continuing to increase the total culture 
volume. At 10 ml of culture, cells were fed as normal but then ca. 10 ml was 
transferred to a T75 flask (Nunc, cat# 156499) and incubated as before with the 
flask lying down. Both the T25 and T75 cultures were maintained through the 
continual addition of media (2-3 ml and 10-13 ml CM every 3-4 days 
respectively) until there were at least 4x107 cells in the T75 to permit long term 
storage of cells and the harvesting of cells for DNA and RNA.  
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2.2.5.2. HepG2, Caco-2 and HEK293H cell lines 
The HepG2, Caco-2 and HEK293H cell lines were maintained in cultivation media 
2 (CM2, appendix F). Media was replaced every 2-4 days. Confluent cells were 
sub-cultivated at 1:5 splits. Media was removed; cells were washed with 1XPBS 
and incubated with trypsin (appendix F) for 5 min at 37°C to detach adherent 
cells for resuspension and subsequent sub-cultivation.  
 
2.2.5.3. B95-8 cells – production of supernatant containing 
EBV particles 
The semi-adherent B95-8 cells were revived from liquid nitrogen as described in 
section 2.2.5.5. and were cultured in CM under standard conditions (37°C, 10% 
CO2) with media replacement every 2-4 days. Cells were grown until confluent 
in a T175 flask (Nunc, cat# 159910) and were then disregarded for ten days to 
induce EBV production. After ten days, the supernatant was collected and 
centrifuged (10 min, 1200 rpm, RT°C, Beckman Coulter Allegra R6 centrifuge) to 
remove any large cellular debris. The supernatant was then filtered through a 
0.2µm filter (Nalgene, Rochester, USA, cat# 295-4520) and stored at -20°C for 
immediate use or in the vapour phase of liquid nitrogen for longer term storage.  
 
2.2.5.4. Freezing cells for long term storage in liquid nitrogen 
2.2.5.4.1.  LCLs 
LCLs were frozen in liquid nitrogen so that they could be revived and cultivated 
in the future, thus providing a perpetual source of the cell line. To do this, cells 
were grown to at least 4x107 cells in a T75 flask (ca. 25-40 ml) before thorough 
mixing and collection in a 50 ml tube. Cells were vortexed briefly to break any 
remaining cell clumps and two aliquots of 10 μl were each transferred to 1.5 ml 
tubes. One of these aliquots was used for DNA extraction and subsequent 
quality control (see section 2.2.9.5), whilst the other aliquot was used to 
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estimate total cell number using a haemocytometer and trypan blue exclusion. 
A minimum of three vials with at least 6x106 cells each were frozen in liquid 
nitrogen at a concentration of 1x107cells/ml FM. Aliquots of cells for subsequent 
RNA extraction at 6x106 – 1x107 cells in 1 ml RNAlater (Ambion, Austin, USA cat# 
AM7021) and DNA extraction (6x106 – 1x107 cells in 1XPBS) were also stored as 
indicated. For RNA and DNA extraction procedures, see sections 2.2.7 and 2.2.8 
respectively.  
 
2.2.5.4.2.  Commercial cell lines 
HEK293H, Caco-2, HepG2 and B95-8 cells were treated as per the LCLs, except 
that they were frozen at densities of 1x106 cells/ml in FM.  
 
2.2.5.5. Reviving cells from liquid nitrogen 
The procedure of reviving LCLs from liquid nitrogen was almost identical to 
bringing up lymphocytes from liquid nitrogen (section 2.2.4.2) but rather than 
resuspending the cells in TFM with B95 supernatant after washing the cells, they 
were resuspended in 5 ml CM in a T25 flask. Cells reached confluence within a 
few days and were transferred to a T75 to increase cell number for utilisation as 
required. 
 
2.2.6. Mycoplasma testing of cell lines 
Mycoplasma contamination can affect virtually every parameter within the cell 
culture system. Mycoplasma lack a cell wall thus are resistant to many 
antibiotics. Their small size (<1µm) means they can fit through most filters and 
also makes them difficult to detect under normal inverted light microscopy 
(Young, Sung et al. 2010). In order to test the cell lines for Mycoplasma 
infection, a direct PCR was performed (as this is one of the most sensitive 
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methods (Young, Sung et al. 2010)) on the quality control sample taken when 
the cell lines were frozen. Primers that detected multiple Mycoplasma species 
were multiplexed with a set of control primers to check for amplification. PCR 
and electrophoresis conditions are listed in appendix G. A positive control 
sample of Mycoplasma hominis (ATCC, Manassas, USA, cat# 23114) was used in 
all PCRs. An example result is outlined in figure 2.1. 
 
 
Figure 2.1. An example of the Mycoplasma PCR showing the control PCR band (red 
arrow) and a positive control for the Mycoplasma band (green arrow). The marker is 
indicated with the letter M. None of the samples tested positive for Mycoplasma.  
 
2.2.7. DNA extraction 
Genomic DNA from blood was extracted for a large proportion of samples prior 
to the commencement of this work, however there were new samples, 
recollections and also some samples that required re-extraction due to the 
sample depletion. 
 
2.2.7.1. DNA extraction from whole blood 
Extraction of DNA involved the addition of 20-40 ml of cold buffer A (appendix 
D) to the remaining blood from the lymphoprep procedure (section 2.2.3) to a 
final volume of 45-50 ml. Samples were shaken vigorously, centrifuged (1800 
RPM, 10 min, RT°C, Beckman Coulter Allegra R6 centrifuge), the supernatant 
was discarded and the pellet resuspended in 15 ml cold buffer A, shaken and 
centrifuged as previously. The pellet was resuspended in 2.5 ml buffer B 
M 
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(appendix D). 1/50th volume of 10% SDS (Amresco, Solon, USA, cat# 0227-100g) 
and 1.0 mg proteinase K (50 μl of 20 mg/ml, Amresco, cat# K525) were added 
before incubation at 50°C for at least 6 hrs. Standard organic phenol/chloroform 
extraction with slight modification was used for purification of the DNA 
(Sambrook, Fritsch et al. 1989). Gel plugged tubes (Becton Dickinson and 
Company, cat# 366510) assisted with separation of the aqueous and organic 
phases. Two purification steps with half-volume 1:1 phenol: chloroform 
(appendix D) and a final purification step with one volume chloroform, involved 
vigorous shaking of the phases and separation at 1,300 RPM for 10 min at 25˚C. 
After the last separation, the aqueous phase was transferred into a 10 ml tube 
and precipitated with 2-2.5 volumes of cold absolute ethanol (Ajax Fine 
Chemicals, cat# A214-2.5L PL) overnight at -20˚C. The DNA was recovered by 
centrifugation (1800 RPM, 30 min, 4°C) then washed twice with cold 70% 
ethanol, dried and resuspended in TE buffer (appendix D). DNA was quantified 
via spectrophotometry at 260nm and 280nm. An aliquot of each DNA was then 
diluted in sterile distilled water to a working PCR concentration of 5-10 ng/µl.  
 
2.2.7.2. DNA extraction from cell lines 
The procedure for extracting DNA from cell lines was identical to the protocol 
for blood DNA extraction, except the cells (stored in 1XPBS) in a 10 ml tube 
were washed only once with 7 ml buffer A and spun as above. Samples were 
then resuspended in buffer B, Proteinase K and 10% SDS were added and they 
were subjected to further purification as described. 
 
2.2.7.3. DNA extraction from saliva 
For some patients, blood collection was not viable and so saliva was collected 
for extraction of DNA. The recommended protocol for OrageneTM saliva DNA 
extraction kit (Genotek, Ottawa, Canada, cat# OG-250) was followed. In brief, 
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after collection of the samples in the OrageneTM vial, they were incubated 
overnight at 50˚C. To extract the DNA, 500 µl of the sample was transferred into 
a sterile 1.5 ml tube and mixed with OrageneTM Purifier (20 µl or 1/25 volume) 
followed by incubation on ice for 10 min. After centrifugation (13,000 RPM, 3 
min, RT°C), the supernatant was removed into a fresh tube, and DNA was 
precipitated with an equal volume of 95% ethanol for 10 min at RT˚C. To collect 
the DNA, the tube was centrifuged (13,000 RPM, 1 min, RT˚C), the supernatant 
discarded, and the pellet dried out. Finally, 50 µl of TE buffer was added to 
resuspend the DNA. Samples were diluted to a working concentration of 1/20 
with sterile distilled water.  
 
2.2.7.4. Quality control DNA 
For quality control purposes, a small aliquot of each blood sample and cell line 
processed was subjected to a rapid extraction process. The processing of bloods 
involved the collection of a 10 µl sample of whole blood into a 1.5 ml tube, 
addition of 20X volume of blood buffer A (appendix D) followed by vigorous 
shaking and centrifugation (13200 RPM, 2 min, RT°C). The supernatant was 
removed and the pellet was resuspended in 5X volume of QuickExtract solution 
(Epicentre, Madison, USA, cat# QE09050), vortexed, incubated at 65°C for 30 
min followed by a 15 min incubation at 98°C. The resulting DNA was then used 
in PCR following standard procedures. For LCLs, a 10 μl aliquot of the cell 
suspension was collected in a 1.5 ml tube, 50 μl Quick Extract Solution was 
added and the samples was processed as for the blood. 
 
2.2.8. RNA extraction 
Cells at 2x106 – 1x107 per ml were stored in RNAlater and frozen at -70°C prior 
to extraction of RNA. Total RNA was isolated following the recommended 
protocol, using TRIreagent (Ambion, cat# AM9738). Briefly, samples were 
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thawed on ice, washed once with 1XPBS before one volume of TRIreagent was 
added. Disruption of the cellular components was achieved by homogenization 
through a 25G needle at least 10 times. Incubation for 5 min at RT˚C was 
followed by vigorous mixing with 1/5 volume chloroform for 15 sec and a 
second incubation for 10 min at RT˚C. The proteins, polysaccharides, fatty acids 
and cellular debris were separated in an organic phase from the phase 
containing RNA via centrifugation (13200 RPM, 15 min, 4˚C). The aqueous phase 
was transferred into a fresh 1.5 ml tube and mixed with 1/2 volume 
isopropanol. RNA was precipitated for 10 min at RT˚C and collected by 
centrifugation (13200 RPM, 8 min, 4˚C). The pellet was washed with 75% 
ethanol, air dried and resuspended in 100 μl RNA storage solution (Ambion cat# 
7001).  
 
2.2.8.1. DNaseI treatment of total RNA 
For purification of the RNA samples from possible DNA contamination, samples 
were treated with DNaseI (2 U/μl, Ambion cat# AM2222) in 1X DNaseI buffer 
(supplied with the enzyme) at 37˚C for 30 min. After heat inactivation of the 
enzyme at 75˚C for 10 min, the RNA samples were purified by phenol-
chloroform extraction. One volume phenol: chloroform 1:1 was added to the 
samples, followed by centrifugation (13200 RPM, 15 min, 4˚C). The upper 
aqueous phase was transferred into a fresh tube and the RNA was precipitated 
with one volume of ice-cold isopropanol and 5 μl glycogen (Ambion, cat# 
AM9510) with incubation on ice for 30 min. RNA was collected by centrifugation 
(13200 RPM, 15 min, 4˚C), washed in 75% ethanol, air dried and resuspended in 
40 μl RNA storage solution. RNA was quantified via spectrophotometry at 
260nm and 280nm and frozen at -70°C for long-term storage.  
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2.2.8.2. First strand Reverse Transcription PCR (RT-PCR) – 
generation of cDNA 
Total RNA was transcribed to cDNA using MMLV reverse transcriptase according 
to the manufacturer’s instructions. 200ng of total RNA was used for first-strand 
cDNA synthesis. The RNA was mixed with 0.25 μl oligodT (50μM, Ambion cat# 
5730G), 0.25 μl random decamers (Ambion, cat# 5722G) and made up to 15.5 μl 
with DEPC-water (Ambion, cat# AM9906). Samples were incubated at 70°C for 5 
min then put on ice for 1 min. A mix of 25U of MMLV reverse transcriptase 
(Ambion, cat# AM2044), 1X first strand buffer (supplied with enzyme), 1 μl of 
10mM dNTPs (Bioline, cat# BIO-39036, 39037, 39038, 39039), 1 μl of 0.1M DTT 
(Invitrogen, cat# Y00147), and 10U of RNAse out (Ambion, cat# 2684) in a total 
volume of 4.5 μl was then mixed in with the RNA/oligodT/decamers mix and 
incubated at 42°C for 2 hrs followed by heat inactivation of the enzymes at 70°C 
for 15 min. Samples were stored at 4°C until required. cDNA was used in real 
time PCR at a working concentration of 1/10 (diluted in DEPC water).  
 
2.2.9. Genotyping 
DNA extracted from patient and control samples was genotyped at a number of 
microsatellite markers and single nucleotide polymorphisms (SNPs) using a 
number of methods including polymerase chain reaction (PCR), restriction 
fragment length polymorphism (RFLP) analysis and real time PCR allelic 
discrimination. Two investigators called genotypes independently and conflicts 
were either resolved or repeated.  
 
2.2.9.1. Polymerase Chain Reaction (PCR) 
PCR reactions were performed on either Eppendorf, MJ or Corbett Research 
machines. The standard three-step cycle included denaturing at 94˚C, annealing 
at various temperatures and extension at 72˚C for various times depending on 
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size of the amplified segment. Where possible, a two-step PCR was used, 
omitting the extension temperature (Smith, Carpten et al. 1995). In a 12 μl PCR 
reaction, 0.5U Biotaq polymerase (Bioline, Alexandria, NSW, Australia, cat# BIO-
21040), 1X Biotaq buffer, 1:1:1:1 mixture of dNTPs at 0.1mM each, primers at 
0.125 – 0.5µM, and 1.5 – 3.0mM MgCl2 (Bioline, cat# MG204F) were used with 
the volume the volume made up to 10 μl with sterile distilled water. Typically 2 
μl of DNA at a concentration of 5 ng/μl or 10 ng/μl was added as the template in 
the PCR experiments. All primers and PCR conditions are listed in appendix G.  
 
2.2.9.2. PCR-Restriction Fragment Length Polymorphism (PCR-
RFLP) analysis 
PCR-RFLP analysis utilizes an elimination or creation of a recognition sequence 
of a restriction enzyme as a result of a single nucleotide polymorphism (SNP). 
Differentiation of the alleles is achieved by performing PCR and digesting the 
resulting fragment with the appropriate enzyme. Inclusion of a control 
restriction site within the PCR fragment is important as a control site for 
digestion; however, this is not always possible because additional sites may not 
be available in the surrounding sequence. PCR, digest and electrophoresis 
conditions are listed in appendices G and H.  
 
2.2.9.3. Real-time allelic discrimination 
At loci where the SNP did not result in a change in a restriction enzyme site or 
where the restriction digest was unreliable, samples were genotyped via real-
time allelic discrimination. The allelic discrimination was performed on the 
Applied Biosystems 7300 Real Time PCR System in 5 μl or 6 µl reactions with full 
conditions listed in appendix G. Reaction mixes for the 5 µl volume consisted of 
2.5 µl of TaqMan(R) Universal PCR master mix (Applied Biosystems, Foster City, 
USA, cat# 4364340), 0.25 µl of 20X assay (diluted in sterile water as appropriate) 
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and 2.25 µl of DNA (5-10 ng/µl). Reaction mixes for the 6 µl volume included 3.0 
µl of master mix, 0.3 µl of assay, 0.45 µl of sterile water and 2.25 µl of DNA (5-
10 ng/µl). Cycling conditions were as follows: initial denaturing at 95°C for 10 
min, and 40 cycles (50 cycles for rs1799852 and rs2280673) of 92°C for 15 sec, 
and 60°C for 1 min each.  
 
2.2.9.4. Sequencing 
Sequencing reactions were based on BigDye Terminator v3.1 chemistry (Applied 
Biosystems, cat# 4337457). A 1/4X sequencing reaction was performed with 2.0 
µl BigDye version 3.1, 3.0 µl of 5X sequencing buffer (Applied Biosystems), 3.2 
pmol of the specific primer, 150-300ng of construct DNA and sterile water up to 
20 µl. The cycling program was 94°C for 5 min, 30 cycles of 96°C for 10 sec, 50°C 
for 5 sec and 60°C for 4 min, and then the samples were maintained at 10°C in a 
Corbett capillary PCR machine. Sequencing reactions were precipitated with 5 µl 
of 125mM EDTA (Ajax, cat#180) and 60 µl of absolute ethanol mixed with the 20 
µl sequencing PCR product. Samples were incubated at RT°C for 15 min, before 
centrifugation at 13200 RPM for 30 min at RT°C. The pellet was washed in 70% 
ethanol and dried. Dried pellets were submitted to the Biomolecular Resource 
Facility at JCSMR for sequencing. 
 
2.2.9.5. Quality control PCR testing of samples 
Before cell lines were utilised in any of the experiments, a quality control PCR 
was performed to ensure the identity of the cell line. Four microsatellite 
markers on different chromosomes were genotyped (appendix G) on the DNA 
extracted from whole blood, cell line and the quality control samples (blood and 
cell line). There were no mismatches for any of the cell lines tested.  
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2.2.10. Gel electrophoresis 
Depending on the size of the fragments and the level of discrimination required 
between alleles, samples were either run on agarose or acrylamide gels. Full 
details are presented in appendix G.  
 
2.2.10.1. Agarose gel electrophoresis 
Agarose gels were made up to 1.5% (Amresco cat# 0710) in TAE buffer 
(appendix D). The addition of loading dyes (6X, appendix D) increased the 
density of samples and enabled monitoring of the fragments through the gel. 
Fragment size was assessed by comparison with appropriate molecular weight 
markers, in particular HaeIII digest of pBR322 (appendix D). Electrophoresis was 
performed at 100-150 mA for 30-90 min depending on the resolution required 
for the fragment identification. Fragments were visualised by staining gels after 
electrophoresis for 5-30 min in SybrSafe (Invitrogen cat# S33102) and UV 
transillumination. A digital image of the gel was captured using the Kodak 
GelDoc 100 Imaging system.  
 
2.2.10.2. Polyacrylamide Gel Electrophoresis (PAGE) 
High-resolution separation and identification of small fragments 30-300bp in 
length was achieved by polyacrylamide gel electrophoresis (PAGE). Eight, 10, 12 
or 15% acrylamide: bis-acrylamide 19:1 (Amresco cat# 0496) was set in 1XTBE 
buffer (appendix D) with polymerization occurring after the addition of 0.0875% 
ammonium persulphate (Ajax chemicals, cat# D3247) and 30 μl TEMED 
(Amresco, cat# 0761). Depending on the gel size, fragment size and desired 
separation, the gels were run at 10-40 mA for 3-16 hr at 14°C. Silver staining 
was used for visualization, where the gels were soaked in 0.1% silver nitrate 
(Amresco cat# 0377) for 5-20 min, rinsed in tap water and developed in a 
solution of 1.5% NaOH (Merck, Whitehouse Station, USA, cat# 1.06498.0500), 
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0.01% NaBH4 (Fluka, Castle Hill, Australia, cat# 71320), and 0.16% formaldehyde 
(Merck, cat# 10113.6C). A digital image of the gel was captured using the Kodak 
GelDoc 100 Imaging system. 
 
2.2.11. Gel extraction of DNA 
Samples were extracted from agarose gels using the Wizard® SV Gel and PCR 
Clean-Up System (Promega, cat# 9281) with 1mM guanosine (Fluka, cat# 51050) 
in the running buffer to reduce the damage to the DNA from using a UV light to 
visualise the bands (Grundemann and Schomig 1996). Samples were eluted in 
sterile water and quantified by spectrophotometry at 260nm and 280nm.   
 
2.2.12. Expression studies – Real time PCR  
The expression of a number of genes was quantified from cDNA generated from 
RNA extracted from LCLs. The relative quantification was performed on AB 7300 
Real Time PCR System in 10 µl or 20 µl reactions. All assays were inventoried 
assays from Applied Biosystems and were labelled with FAM. The internal 
control gene used in each case was 18S RNA (VIC-labelled). For every 
experiment, the assay for the gene of interest (GOI) and the 18S assay were 
duplexed. Reaction mixes for the 10 µl volume consisted of 5.0 µl of TaqMan(R) 
Universal PCR master mix, 0.5 µl of 20X assay, 2.5 µl of sterile water and 2 µl of 
cDNA (diluted 1:10 from concentrate). Reaction mixes for the 20 µl volumes 
included 10.0 µl of master mix, 1.0 µl of assay, 1.0 µl of sterile water and 8 µl of 
cDNA (diluted 1:10 from concentrate). Cycling conditions were as follows: initial 
denaturing at 95°C for 10 min, and 40 cycles (50 cycles for HAMP and HFE) each 
of 92°C for 15 sec followed by 60°C for 1 min. Full details of the experimental 
protocol and the analysis are listed in Chapter 6 and appendix G.  
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2.2.13. Cloning 
2.2.13.1. Vectors 
To ensure complete digestion of the insert for ligation to pGL4.10, inserts were 
firstly cloned into the pGEM-T vector.  
 
2.2.13.2. Generation of inserts and site-directed mutagenesis 
The region of interest was amplified via PCR with restriction sites in the primers 
to allow for directional cloning into the pGL4.10 vector. PCRs were performed in 
individuals homozygous for the particular sequence of interest. Site-directed 
mutagenesis was performed via PCR extension of overlapping gene segments 
(Heckman and Pease 2007) (Figure 2.2). Briefly, overlapping primers containing 
the relevant base change were used to amplify two smaller fragments with 
overlapping ends. These products were gel-purified (section 2.2.11), quantified 
via spectrophotometry, mixed 1:1 (20 ng of each) and used as a template for a 
PCR covering the whole region. All full length products were gel-purified and 
subsequently used in the cloning protocols. Primers, PCR conditions and the 
cloned sequence are presented in appendix I. 
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Figure 2.2. Site directed mutagenesis of the region to be cloned. Two overlapping PCR 
products (AD and CB) containing the introduced mutation, represented by a star, were 
amplified, gel purified, quantified, mixed 1:1 and used as a template for a PCR covering 
the entire region using primers A and B. Figure modified from (Heckman and Pease 
2007). 
 
2.2.13.3. Cloning into pGEM-T 
The pGEM-T vector allows easy insertion of purified PCR products and is 
presented in figure 2.3. Gel purified PCR products of the region of interest were 
A-tailed using up to 180 ng of purified PCR product, 1X Taq buffer (Promega, 
cat# M188A), 5U Taq polymerase (Promega, cat# M186E), 1.6 mM dATP 
(Invitrogen, cat# 55082) made up to 10 µl with sterile water. Reactions were 
incubated at 70°C for 30 min. 3 µl of the A-tailed products were then ligated to 
50 ng of pGEM-T (Promega, cat# A362A, figure 2.3) with 1x rapid ligase buffer 
(Promega, cat# C671A) and 3U of T4 DNA ligase (Promega, cat# M180A) and 
incubated at 4°C overnight. 90 µl of Escherichia coli DH5α competent cells were 
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mixed with the 10 µl ligation mix, incubated on ice for 20 min, before the cells 
were spread on pre-warmed 37°C Luria Broth agar plates supplemented with 1 
mM ampicillin (LB/Amp plates, see appendix E), and incubated at 37°C 
overnight. Subsequent colonies were screened for insert via PCR using the 
vector specific primers T7 and Sp6 (appendix G). 
 
 
Figure 2.3. The pGEM-T vector used as the initial cloning vector. It contains an 
ampicillin resistance gene (Ampr) to allow selection of colonies transformed with the 
vector when cultivated on media containing ampicillin. Screening of vectors for insert 
was performed via PCR using the SP6 and T7 primers. Image from Promega 
(http://www.promega.com).  
 
2.2.13.4. Colony screening PCRs 
Colonies were screened for presence of the insert using the primers Sp6 and T7 
by using a pipette tip to pick a colony and streaking it onto a pre-labelled sterile 
LB/amp plate. The end of the tip that had contacted the colony was then mixed 
directly into the PCR mix to dislodge any bacteria, before the tip was discarded. 
PCR and electrophoresis conditions are listed in appendix G.  
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2.2.13.5. Isolation of constructs from bacterial culture 
Colonies that screened positive for the insert via PCR were grown in 5-10 ml LB 
supplemented with 0.1 mM Ampicillin at 37°C overnight with agitation. Isolation 
of plasmid DNA from bacterial cultures was performed using a Qiagen Miniprep 
kit (Qiagen, Madison, USA, cat# 27106) as per the manufacturer’s instructions. 
Samples were eluted in 50 µl sterile water and quantified via 
spectrophotometry.  
 
2.2.13.6. Removing inserts from pGEM-T 
As mentioned above, directional cloning of the amplified segments was 
achieved by incorporating restriction sites for different enzymes into the 
primers, namely KpnI in the forward primer and XhoI in the reverse primer. 
Inserts were removed from pGEM-T for ligation to the luciferase expression 
vector, p-GL4.10. 150 ng of the pGEM-T constructs were digested with 5U KpnI 
(NEB cat# R0142L) and 20U XhoI (NEB cat# R0146L), 1XNEB buffer 2 (NEB cat# 
B7002S), 1XBSA (NEB cat# B9001S) made up to 20-40 µl with sterile water and 
incubated at 37°C for at least 3 hrs. Digests were run on a 1.5% TAE agarose gel 
and gel purified as per section 2.2.11. 
 
2.2.13.7. Preparing pGL4.10 for cloning 
The pGL4.10 luciferase vector (Promega, cat# E6651, figure 2.4) was digested 
for ligation to the inserts cut out of pGEM-T. 500 ng of pGL4.10 was digested 
with KpnI and XhoI as per the pGEM-T constructs. Before gel purification, the 
digested pGL4.10 was treated with alkaline phosphatase to prevent the possible 
religation of the sticky ends. 1.25U of Antarctic alkaline phosphatase (NEB cat# 
M0289S), 3 µl of supplied buffer and 6.75 µl of sterile water were added to the 
digested pGL4.10, incubated at 37°C for 20 min followed by inactivation of the 
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enzyme by heating to 65°C for 10 min The digested vector was then run on 1.5% 
TAE agarose at 100 mA for 45 min and gel purified as above.  
 
 
Figure 2.4. The pGL4.10 luciferase expression vector. The multiple cloning region is 
upstream of the Firefly luciferase gene, luc2, which has been modified to have a 
reduced number of transcription factor consensus sites. The vector also contains an 
Ampicillin resistance gene (Ampr) as a selective tool for transformed. The KpnI and 
XhoI restriction enzyme sites (highlighted) were used for the insertion the TNFα 
promoter inserts. Image from Promega (http://www.promega.com).  
 
2.2.13.8. Cloning into pGL4.10 
Ligation efficiency can be altered by the amounts of both insert and vector. A 
number of different insert: vector ratios were trialled using the formula below, 
with the 3:1 ratio using 25 ng vector found to be the most efficient. 
Amount of insert (ng) = Amount of vector (ng) x Length of insert (kb) x insert: vector 
     Length of vector (kb) 
 
25 ng of vector, 23.7 ng of insert, 1X ligase buffer (Promega, cat# C126B) and 3U 
T4 DNA ligase (Promega, cat# M180A) were made up to 10 µl with sterile water 
were incubated overnight at 4°C. 90 µl of Escherichia coli DH5α competent cells 
were mixed with 10 µl ligation mix, incubated on ice for 20 min, before the cells 
52 
 
were spread on pre-warmed 37°C LB/Amp plates and incubated at 37°C 
overnight.  
 
2.2.13.9.  Screening pGL4.10 constructs 
Colonies were screened for the construct via PCR as outlined in section 2.2.13.4 
using primers and conditions in appendix G. Colonies that screened positive 
with the PCR were cultured and the constructs isolated as per section 2.2.13.5. 
500 ng of the constructs were digested with 5U AvaI (NEB, cat# R0152L) in NEB 
buffer 2 and made up to 10 µl with sterile water. Samples were incubated at 
37°C for three hrs before being run on 1.0% TAE agarose at 150 mA for 45 min 
and positive colonies (as indicated by correct banding pattern) were sequenced 
(section 2.2.9.4). 
 
2.2.14. Transfecting human cell lines 
Three different cell lines with different tissue origins were used for the 
luciferase experiments. FuGENE HD (Promega, cat# E2311) was the transfection 
reagent used with optimal amounts obtained from the company 
(http://www.promega.com/techserv/tools/FuGENE HDtool/Default.aspx). All 
transfection experiments were performed in 96 well, flat-bottom, white tissue 
culture plates. Cells were seeded in 100 µl CM2 (appendix F), grown for 24 
hours before the media was removed, cells were washed with 1XPBS and 100 µl 
of Opti-MEM (Invitrogen, cat# 31985-070) or Opti-MEM containing 5mM ferric 
ammonium citrate (FAC, Sigma-Aldrich, cat# F5879-500g) was added. Each 
construct had four replicates per plate and was assayed on at least three 
different occasions. Transfection mix was prepared as per section 5.2.4. Plates 
were incubated for 48 hrs before the luciferase assays were performed. 
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2.2.15. Optimising luciferase vector ratios 
In luciferase assays, co-transfection with a control vector allows comparisons to 
be made between wells by controlling for transfection efficiency. In these 
experiments, the pGL4.10 vector contains the firefly luciferase gene and the 
control plasmid contains the Renilla luciferase gene under the control of the 
CMV promoter (pRL-TK). There is potential for trans effects to occur between 
the two transfected vectors which may impact on results, therefore it is 
important to optimise the vector ratio. Different ratios of pGL4.10: pRL-TK were 
transfected into each of the cell lines, a luciferase assay performed after 48 hrs 
and the ratio which produced the most consistent results across wells was 
chosen as the optimal ratio. In this case it was 40:1 for all cells. 
 
2.2.16. Performing Luciferase assays 
Each Dual-luciferase reporter assay kit (Promega, cat# E1910) contained all 
necessary reagents. 48 hrs after transfection, the media was removed from the 
cells, they were washed with 100 µl 1XPBS before 20 µl of 1X passive lysis buffer 
(diluted from 5X stock with sterile water) was added per well. Cells were placed 
on a room temperature shaker for at least 15 min in order to completely lyse 
the cells. 45 µl per well of the LARII reagent was added, the plate was sealed 
with an optical plate sealer and firefly luciferase measured using a Promega 96 
microplate Glomax luminometer. 45 µl well of freshly diluted Stop+Glo was then 
added, the plate was again sealed and the Renilla luciferase was measured on 
the luminometer. Further information on the analysis of the results is outlined 
in section 5.2.  
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2.3. General statistical methods 
2.3.1. Allele frequencies 
Allele frequencies for all markers (microsatellites and SNPs) were estimated by 
counting, and compared using the Fisher’s exact test for small cell numbers or 
the Chi square test as appropriate. Population allele frequencies for all markers 
were estimated from the control individuals. 
 
2.3.2. Hardy Weinberg Equilibrium (HWE) 
Genotypes for controls and patients for each marker (microsatellites and SNPs) 
were tested for deviation from Hardy-Weinberg Equilibrium (HWE). The 
expected number of alleles for each genotype was calculated in Excel, and 
compared to the observed number for each genotype using a Chi-square test of 
independence. Genotype and allele frequency comparisons between patients 
and controls for the polymorphisms studied were compared using a Chi-square 
test of independence or Fisher’s exact test, as appropriate. 
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3. Chapter 3. Study of SNPs in iron metabolic 
pathway genes previously associated with 
serum iron indices 
3.1. Introduction 
Although a HH susceptibility gene was associated with the HLA region on the 
short arm of chromosome 6 in 1976 (Simon, Bourel et al. 1976), it was not until 
1996 that HFE was positively identified as the cause of HH (Feder, Gnirke et al. 
1996). This twenty year delay in the identification of the causal gene can be 
attributed to the high degree of linkage disequilibrium (LD) in the region (de 
Bakker, McVean et al. 2006). Subsequent studies revealed decreased 
penetrance of the causative C282Y mutation and this has stimulated the search 
for modifier genes.  
 
Genome wide association studies have been applied extensively and 
successfully in the search for quantitative trait loci (reviewed in (Stranger, Stahl 
et al. 2010)). These studies can produce genotype data from hundreds of 
thousands of SNPs across the genome and may implicate a number of loci for 
the particular trait being analysed. Marker selection is important and may 
include SNPs in genes of a particular pathway, such as within iron metabolic 
pathways. Choosing one pathway allows greater coverage across 
predetermined genes of interest, which reduces the possibility of missing 
potential modifiers within these genes. On the other hand, consideration of 
polymorphisms across the whole genome allows the identification of variants in 
genes that have not yet been ascribed a role in the pathway of interest, but 
relies on the “common disease-common variant” hypothesis (reviewed in 
(Bodmer and Bonilla 2008; Cazier and Tomlinson 2010)). Both methods have 
been applied to the identification of modifier genes in HH, with recent studies 
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implicating SNPs in genes that are components of the iron metabolic pathway, 
and thus may modify elements of the serum iron phenotype in HH. These genes 
include Transferrin (TF), the iron carrier protein in the body (SNPs rs1799852, 
rs3811647 and rs2280673) (Benyamin, McRae et al. 2009), CYBRD1, a 
ferrireductase enzyme (rs884409) (Constantine, Anderson et al. 2009), and the 
transmembrane serine protease 6 gene (TMPRSS6, rs4820268) which is involved 
in the regulation of HAMP signalling (Benyamin, Ferreira et al. 2009; Chambers, 
Zhang et al. 2009; Constantine, Anderson et al. 2009). The aim of this aspect of 
the current study was to genotype these SNPs in C282Y homozygotes and in 
controls that do not carry the mutation in an attempt to replicate some of the 
previous results.  
 
3.2. Materials and Methods 
3.2.1. Samples from the Canberra Region 
Haemochromatosis Database (CRHD) 
Up to 404 individuals of Caucasian descent from the Canberra Region 
Haemochromatosis database (CRHD) were available for this study. For the 
replication studies, a total of 206 unrelated individuals from the CRHD, for 
which serum ferritin (SF) values were available, were analysed. Individuals 
excluded on the basis of family were chosen randomly and not based on gender, 
age, SF, genotype or any other factor so as not to bias results.  
 
Females were excluded from the detailed analysis due to complications arising 
from the effects of menstrual and menopausal status on iron loading. Within 
the CRHD samples, 108 were male C282Y homozygotes. Samples were excluded 
if they were not iron loaded as indicated by a pre-treatment serum ferritin (SF) 
>300μg/L (i.e. above the normal range). Exclusion criteria also included the 
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presence of complicating co-morbidities (such as cancer, hepatitis, alcoholism or 
steatohepatitis) or only one symptom (such as lethargy) that was not clearly 
related to iron loading. In addition, no two individuals from the same family 
were permitted in the same study group, but family members were accepted 
across study groups. Of the remaining 72 iron loaded male C282Y homozygotes 
available for detailed study, fifty two had presented with clinical 
signs/symptoms consistent with haemochromatosis including one or more of 
the following: joint pain, lethargy, loss of libido, bronzing, abdominal pain, 
weight loss, and shortness of breath; while twenty were, despite their increased 
SF, asymptomatic patients who were identified because of incidental 
biochemical diagnosis or through family screening.  
 
Pre-treatment SF levels were measured by ACT Health Pathology Laboratories 
or obtained (with consent) from the patient’s medical records. SF values were 
log10 transformed so that their distribution was (approximately) normal to 
simplify statistical analyses. SF levels were used as a surrogate marker of total 
body iron loading as discussed previously (Thomas, Fullan et al. 1998; Kohgo, 
Ikuta et al. 2008). While transferrin saturation (TfSat) levels may also be used to 
define iron overload, this value was unavailable for many samples and so the 
log10SF values were used as the best surrogate measure of iron load. 
 
3.2.2. Control Samples 
212 control samples (including blood donors and healthy controls) of mixed HFE 
genotype were available for study. For comparison to the male C282Y 
homozygotes, a control population of 101 anonymous male blood donors who 
did not possess the C282Y mutation were obtained from the Australian Red 
Cross Blood Service (ARCBS). As the control samples were blood donors and 
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information regarding donation frequency was unavailable, analysis of the SF 
levels in the context of the SNPs in these samples was inappropriate. 
 
3.2.3. Genotyping 
Genotyping for the C282Y mutation of HFE was carried out as described in 
appendix G. SNPs were chosen based on previous association with SF in a 
number of recent studies (Benyamin, Ferreira et al. 2009; Benyamin, McRae et 
al. 2009; Constantine, Anderson et al. 2009). All SNPs except rs2280673 were 
available as standard Taqman(R) assays from Applied Biosystems. The sequence 
surrounding rs2280673 was submitted to Applied Biosystems for manufacture 
of a custom assay. All allelic discrimination assays were performed on the 
Applied Biosystems 7300 Real Time PCR System with amplification conditions 
and assay details presented in section 2.2.9.3 and table G.4 (appendix).  
 
3.2.4. Analysis and statistics 
Comparison of log10SF between groups was performed using the unpaired 
student t-test. Deviations from HWE for the SNPs were determined via Chi-
square analyses (with amalgamation of cells when values did not exceed five) or 
Fisher’s exact test. Results were considered significant at p<0.05. 
 
3.3. Results 
3.3.1. SF levels in HH patients and blood donor controls 
Both symptomatic and asymptomatic male C282Y homozygotes had significantly 
higher mean SF levels than controls (p<0.0001 for each comparison). This is 
unsurprising given that the controls are blood donors and a selection criterion 
for the cases was high SF level. Furthermore, symptomatic C282Y homozygotes 
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had significantly higher SF than asymptomatic C282Y homozygotes (p=0.0054). 
There were no significant differences in mean age among any of the three 
groups that could account for these differences (p>0.05, Table 3.1). This is the 
first time this phenomenon has been noted. 
 
Table 3.1. The average log10SF and age of the control group (blood donors with no 
C282Y mutations) and the haemochromatotic C282Y homozygotes subdivided into 
symptomatic and asymptomatic groups. All samples were male. SEM represents 
standard error of the mean. 
 Controls 
C282Y homozygotes 
Symptomatic Asymptomatic 
n 101 52 20 
Log10 SF ± SEM 1.559 ± 0.040 3.153 ± 0.049*
# 2.911 ± 0.049* 
Age (years) ± SEM 49.1 ± 1.3 45.6 ± 1.5 42.7 ± 3.4 
*p<0.0001 compared to the control group 
# p<0.0054 compared to asymptomatic C282Y homozygotes 
 
3.3.2. Allele frequencies in patients and controls  
Allele frequencies for each of the SNPs were calculated from 190 unrelated 
controls that did not possess the C282Y mutation, a mixed CRHD sample of 206 
individuals and the symptomatic and asymptomatic C282Y homozygotes (table 
3.2). The populations did not deviate from genotype proportions expected 
under Hardy-Weinberg Equilibrium (HWE) for any SNPs. The CRHD and C282Y 
homozygote population samples were not significantly different from the 
controls in terms of allele frequencies. The CRHD and C282Y homozygotes could 
not be compared directly as there was some sample sharing between the 
groups, but removal of these samples from the analysis revealed there were no 
significant differences in allele frequencies.  
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Table 3.2. Allele frequencies for the SNPs in controls, samples from the CRHD and 
C282Y homozygotes (YY). YY_S are the male symptomatic C282Y homozygotes; YY_AS 
are the asymptomatic male C282Y homozygotes. Sample sizes are in parentheses after 
the sample group name. ‘1’ represents the common allele and ‘2’ the rarer allele. 
Gene Chr. SNP Allele 
Controls 
(n=190) 
CRHD 
samples 
(n=206) 
YY_S 
(n=52) 
YY_AS 
(n=20) 
TMPRSS6 22 rs4820268 
1 
2 
0.534 
0.466 
0.585 
0.415 
0.664 
0.356 
0.525 
0.475 
TF 
3 rs2280673 
1 
2 
0.675 
0.325 
0.670 
0.330 
0.740 
0.260 
0.700 
0.300 
3 rs3811647 
1 
2 
0.641 
0.359 
0.677 
0.323 
0.683 
0.317 
0.650 
0.350 
3 rs1799852 
1 
2 
0.887 
0.113 
0.867 
0.133 
0.827 
0.173 
0.975 
0.025 
CYBRD1 2 rs884409 
1 
2 
0.839 
0.161 
0.859 
0.141 
0.856 
0.144 
0.800 
0.200 
 
3.3.3. Single SNP analysis in a heterogeneous 
population 
Previous studies of these SNPs (Benyamin, McRae et al. 2009; Constantine, 
Anderson et al. 2009) did not select for male gender, HFE status or high SF 
levels. Therefore, 206 unrelated samples from the CRHD of mixed gender, HFE 
genotype and extent of iron loading were analysed for the effect, if any, of each 
of the SNPs on SF levels.  
 
3.3.3.1. TMPRSS6 (rs4820268), TF (rs2280673) and CYBRD1 
(rs884409) SNPs are not associated with SF levels 
The results from previous studies indicating an association of the TMPRSS6 
(rs4820268), TF (rs2280673) and CYBRD1 (rs884409) SNPs with SF were not 
replicated in this study. Results are presented in figure 3.1.  
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Figure 3.1. The average log10SF results by genotype at the SNPs rs4820268 (A), 
rs2280673 (B), and rs884409 (C). 11 represents samples homozygous for the common 
allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. There were no 
significant differences between genotypes at any of the SNPs. Error bars represent the 
SEM. 
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3.3.3.2. rs3811647 in TF is associated with decreased SF levels 
The results for rs3811647 are presented in figure 3.2. The average SF of the 
heterozygotes was not significantly different from the homozygotes for the 
common allele. The SF of the homozygotes for the rare allele was significantly 
different from the homozygotes for the common allele (p=0.0263). The 
difference between the homozygotes for the rare allele and the heterozygotes 
approached significance (p=0.0516). This data does not replicate previous 
studies (Benyamin, McRae et al. 2009; Constantine, Anderson et al. 2009) and in 
fact, is the opposite of the previously reported association of the rare allele with 
increased SF. Reasons accounting for these differences are addressed in the 
discussion.  
 
  
Figure 3.2. The average log10SF values for the heterogeneous population based on 
their genotype at rs3811647. 11 represents samples homozygous for the common 
allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. The 22 
samples had significantly lower SF compared to the 11 samples and the combined 
11/12 samples (p=0.0273, indicated by an asterisks). Error bars represent the SEM.  
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3.3.3.3. rs1799852 in TF is associated with increased SF levels 
The rare allele at rs1799852 was associated with increased SF levels in the 
heterogeneous sample population. The heterozygotes had significantly higher 
SF than the homozygotes for the common allele (p=0.0179, figure 3.3). There 
were only three homozygotes for the rare allele and the SF results were quite 
variable (as indicated by the error bars in figure 3.3) and did produce any 
significant results. However, inclusion of this data with the heterozygotes in a 
comparison with the homozygotes for the common allele, yielded a significant 
result (p=0.015). It is unclear from this data whether there is an additive effect 
of the rare allele on SF.  
 
 
Figure 3.3. The average log10SF values for the heterogeneous population based on 
their genotype at rs1799852. 11 represents samples homozygous for the common 
allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. The SF value of 
the homozygotes for the common allele was significantly lower than the SF of the 
other samples combined (p=0.015, marked by an asterisks). Error bars represent the 
SEM.  
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3.3.4. Single SNP analysis in C282Y homozygotes 
As the control samples were blood donors and information regarding donation 
frequency was unavailable, analysis of the SF levels in the context of the SNPs in 
these samples was unsuitable. Given the significant difference between the SF 
levels in the symptomatic and asymptomatic C282Y homozygotes established 
above, these two groups were analysed separately.  
 
3.3.4.1. rs4820268 in TMPRSS6, and rs2280673 and rs3811647 
in TF are not associated with SF in the C282Y homozygotes 
As was found for the heterogeneous sample population, there was no 
association of rs4820268 or rs2280673 with SF in the C282Y homozygotes. The 
results for rs3811647 in the C282Y homozygotes were also not significantly 
associated with SF, despite an observed association in the heterogeneous 
population. There was a trend for the homozygotes for the rare allele to have a 
lower SF value in the symptomatic C282Y homozygotes, however there were 
only four samples in this group (see figure J.3). Therefore increasing the sample 
size may validate whether there is a difference in the symptomatic C282Y 
homozygotes samples or not.  
 
3.3.4.2. rs1799852 in TF is not associated with SF levels  
Comparison of allele frequencies between the symptomatic and asymptomatic 
C282Y homozygotes revealed a significant difference for the rs1799852 SNP. 
There was only a single heterozygote in the asymptomatic group and the 
remaining samples in this group were homozygous for the common allele. The 
minor allele frequency in the asymptomatic group was 0.025 compared to 0.173 
in the symptomatic samples. It is unclear whether this is a real effect or a 
consequence of low sample size of the asymptomatic samples. Analysis of the 
SF levels in the symptomatic samples revealed no significant difference in SF 
65 
 
levels between the different genotypes; however, the samples with the rare 
allele had, on average, an increased SF compared to those without it (figure 
3.4). This is consistent with the results from the heterogeneous population 
(figure 3.3). The apparent decreased SF of the samples homozygous for the 
common allele presented the possibility that the overall decreased SF level in 
the asymptomatic samples was a consequence of genotype at the rs1799852 
SNP. To address this, an unpaired t-test was performed between the SF levels of 
the asymptomatic samples homozygous for the common allele versus the SF 
levels in the symptomatic samples of the same genotype. The result was 
significant (p=0.0244). This suggests that the low SF in the asymptomatic 
samples is independent of the genotype at rs1799852 in C282Y homozygotes. 
 
 
Figure 3.4. The average log10SF levels for male C282Y (YY) homozygotes who were 
asymptomatic (blue) or symptomatic (purple) based on their genotype at rs1799852 in 
TF. 11 represents samples homozygous for the common allele, 12 are heterozygotes 
and 22 are homozygotes for the rare allele. The number of samples in each group is 
indicated in parenthesis after the genotype. There were no significant differences in SF 
within either the asymptomatic or asymptomatic samples. Error bars represent the 
SEM. 
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3.3.4.3. rs884409 in CYBRD1 is associated with decreased SF 
levels 
In the symptomatic C282Y homozygotes, samples homozygous for the rare 
allele at rs884409 had significantly lower log10SF levels than those who were 
homozygous for the common allele (p=0.0479, figure 3.5). The heterozygotes 
had similar levels to the homozygotes for the common allele but the difference 
between the heterozygotes and the homozygotes for the rare allele was not 
significant (p=0.1421). There were no rare allele homozygotes within the 
asymptomatic samples and although the heterozygotes tended to have 
decreased SF level compared to the common allele homozygotes, the results 
were not significant (p=0.1875).  
 
 
Figure 3.5. The average log10SF levels for male C282Y (YY) homozygotes who were 
asymptomatic (blue) or symptomatic (purple) based on their genotype at rs884409 in 
CYBRD1. 11 represents samples homozygous for the common allele, 12 are 
heterozygotes and 22 are homozygotes for the rare allele. The number of samples in 
each group is indicated in parenthesis after the genotype. The asterisk indicates the 
average SF level of the 22 individuals was significantly different from the 11 individuals 
in the symptomatic C282Y homozygotes (p=0.0479).  
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3.4. Discussion 
3.4.1. Serum ferritin levels in patients and controls 
The SF level in male C282Y homozygote patients was significantly higher than 
controls (p<0.0001) but given the control population were blood donors (and 
therefore can be expected to experience regular loss of iron through regular 
blood donation), this difference was expected. If the control population were 
not blood donors, we would still expect HH patients to have a significantly 
higher SF but perhaps the difference would not be as large as that observed 
here.  
 
Within the iron loaded C282Y homozygous males (SF>300µg/l) a significant 
difference in SF levels was observed between individuals who reported 
symptoms associated with HH compared to those who did not report 
symptoms. The difference was not associated with age so it is not the time 
taken to accumulate iron stores, nor was it associated with therapeutic 
phlebotomy because the SF levels were those determined before treatment 
commenced. This suggests that there is a threshold above which symptoms 
occur. There were no indications however, that once the threshold was 
reached, a higher SF would result in more symptoms, nor were any specific 
symptoms associated with higher SF. A recent study has reported similar 
findings, with the authors suggesting that C282Y homozygotes are at a low risk 
of developing symptoms when the SF is less than 1000µg/L (Allen, Bertalli et al. 
2010). The average SF for the asymptomatic C282Y homozygotes presented in 
this chapter was 920µg/L, and the average for the symptomatic patients was 
1940µg/L which is consistent with the theory proposed by Allen et al. If the 
presence of a threshold is confirmed in larger scale studies, it may have an 
impact on therapeutic guidelines for phlebotomy. 
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3.4.2. Allele frequencies of the SNPs in patients and 
controls 
There were no significant differences in the allele frequencies between the 
C282Y homozygotes, the CRHD sample or the controls for any of the SNPs, as 
expected. The minor allele frequencies (MAFs) of most of the SNPs 
corresponded well with HapMap and with previously reported frequencies 
(Benyamin, McRae et al. 2009; Chambers, Zhang et al. 2009; Constantine, 
Anderson et al. 2009) with the exception of rs1799852. The MAF for this SNP in 
the current study was over three times as high as that reported in HapMap 
(0.133 in the CRHD samples versus 0.04 in HapMap) but previous studies have 
also reported frequencies higher than those in HapMap (0.099 and 0.09 in 
Constantine et al and Benyamin, McRae et al respectively). Both the C282Y 
homozygotes and the controls were in HWE for all SNPs and there were no 
significant differences between these two populations.  
 
3.4.2.1. rs1799852 (TF) in C282Y homozygotes 
The frequency of the rare allele of rs1799852 in the asymptomatic C282Y 
homozygotes was significantly lower than that in the symptomatic individuals. 
SF analyses revealed that the overall difference in the SF levels between the 
asymptomatic and symptomatic C282Y homozygotes was independent of 
rs1799852 genotype. This SNP may still be a contributing factor to the 
decreased SF observed in asymptomatic samples, although analysis within the 
symptomatic samples supported the lack of significant association of rs1799852 
with SF levels. However, increasing the sample size may implicate the rare allele 
as it did in the heterogeneous population.  
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The differences between results obtained here and the previous study that 
found an association of this SNP with SF levels (Benyamin, McRae et al. 2009), 
are difficult to explain without knowing the full details of the previous study 
population (such as gender ratio, presence/absence of symptoms, etc). 
However it could be postulated that if asymptomatic C282Y homozygotes have 
a reduced frequency of the rare allele (and it is not simply a consequence of 
sample size) then the rare allele may be positively associated with higher SF 
levels in a population in which the C282Y homozygotes are analysed as one 
group. This is simply because the symptomatic samples have inherently higher 
SF compared to asymptomatic samples.  
 
3.4.3. No association of TMPRSS6 rs4820268 or TF 
rs2280673 with SF levels 
Despite previously published reports predicting an association of the rs4820268 
and rs2280673 SNPs with SF levels, this was not replicated in the current study. 
There are many potential reasons for this but perhaps the most likely is the 
population stratification differences between the studies. The main differences 
revolve around gender (males only in this study, previous studies used both 
genders), HFE genotype (only C282Y homozygotes in this study versus a range of 
genotypes previously) and the phenotypic expression of HH; both the use of 
iron loaded samples only in this study versus a range of SF values previously, as 
well as the availability of data on expression of symptoms that permitted 
division into symptomatic and symptomatic samples groups (Benyamin, Ferreira 
et al. 2009; Benyamin, McRae et al. 2009; Constantine, Anderson et al. 2009).  
 
 
 
70 
 
3.4.4. TF rs3811647 and SF levels 
The rs3811647 SNP was associated with SF levels in the heterogeneous 
population but not specifically within the C282Y homozygotes, although the 
trend was similar. Interestingly, the association is in the opposite direction to 
previously published reports of the rare allele being associated with increased 
iron loading. The allele frequencies were comparable between the current study 
and previous ones so it is unlikely that the difference in SF is a consequence of 
genotyping errors. This SNP previously associated with transferrin levels more 
strongly than it did to SF levels (Benyamin, McRae et al. 2009), however, it 
would be expected that SF and transferrin levels would generally be positively 
correlated. The sample size including 20 rare-allele homozygotes in the 
heterogeneous population is large enough to suggest that the population size is 
not influencing results. Further studies are required into the effect of this SNP 
across populations to elucidate any effect on SF values.  
 
3.4.5. CYBRD1 rs884409 as a modifier of SF levels in 
C282Y homozygotes 
There were no significant differences in allelic frequencies of the rs884409 SNP 
across any of the populations, and all populations were in HWE. However, 
symptomatic C282Y homozygotes that were homozygous for the rare allele had 
significantly lower SF than those homozygous for the common allele. This 
direction change is consistent with the original study in which an association 
with SF was established; however, that study found that the rare allele was 
associated with decreased SF levels even in heterozygotes (Constantine, 
Anderson et al. 2009). In the results presented above, the heterozygotes are 
indistinguishable from the homozygotes for the common allele in terms of SF, 
and there is no intermediate phenotype. The lack of association of the 
heterozygotes is likely a consequence of the population stratification issues 
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outlined above. Furthermore, as there were no significant differences in SF 
levels within the heterogeneous population sample, the effect of rs884409 on 
SF was specific to the C282Y homozygotes, as previously reported (Constantine, 
Anderson et al. 2009) 
 
The rs884409 SNP lies at -326 upstream relative to the transcription start site of 
CYBRD1 and luciferase assays previously performed in Caco-2 cell lines indicated 
that the rare allele was associated with decreased expression compared to the 
common allele (Constantine, Anderson et al. 2009). As mentioned in their 
paper, this is consistent with lower SF results associating with the rare allele. 
CYBRD1 is a membrane ferrireductase that converts non-heme iron (Fe3+) to 
Fe2+ so it can be transported through DMT1 into the cell (see section1.1.2). If 
there is less CYBRD1 being expressed then presumably there is less bioavailable 
iron for absorption thus resulting in decreased SF. Perhaps in vitro studies of the 
expression levels of the gene in biopsies such as enterocyte or liver, would 
confirm a role for this SNP in the regulation of CYBRD1. 
 
3.4.6. Alternate function for rs2280673? 
Previous reports have described the rs2280673 SNP as TF associated (Benyamin, 
McRae et al. 2009); however, it actually resides within an intron of the member 
of the RAS oncogene family (RAB6B) gene around 25kB downstream of TF on 
chromosome 3. RAB6B is involved in retrograde transport with the Golgi and 
although the expression patterns of the gene product are primarily in neuronal 
cells, there is some expression in the colon adenocarcinoma cell line, Caco-2 
(Opdam, Echard et al. 2000). The results presented in this chapter did not find 
any significant associations of rs2280673 with SF levels; however, previous 
studies suggest it may be more relevant to transferrin levels (Benyamin, McRae 
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et al. 2009). If the rs2280673 SNP is found to be significantly associated with 
iron parameters in subsequent studies, the potential role of RAB6B in the iron 
metabolic pathway would need to be explored.  
 
3.5. Conclusions 
A significant difference was observed in SF between asymptomatic and 
symptomatic C282Y homozygotes, suggesting a threshold level of SF above 
which symptoms occur. This finding forms a major basis of the subsequent 
chapters in this thesis. For the SNP analyses, there were no significant 
associations between rs4820268 (TMPRSS6) or rs2280673 (TF) and SF levels. 
The SNP rs3811647 (TF) does not influence SF levels within C282Y homozygotes, 
although it may in other genotypes. Further study of this SNP is required given 
the discordance between this and previous studies. The frequency of the rare 
allele at rs1799852 (TF) was significantly lower in the asymptomatic C282Y 
homozygotes compared to the symptomatic C282Y homozygotes. This may 
contribute to the decreased SF levels seen in the asymptomatic samples given 
that the rare allele is associated with increased SF. Symptomatic C282Y 
homozygotes that were homozygous for the rare allele at rs884409 (which 
resides in the promoter of CYBRD1) had significantly lower SF levels compared 
to those homozygous for the common allele. As there were low sample 
numbers for the homozygotes, further replication studies are crucial to 
understanding of the role of rs884409 in HH. As will be shown in subsequent 
chapters, it is likely that there are a number of factors that contribute to 
reduced penetrance in HH and it is possible that rs1799852 and rs884409 
contribute to that reduced penetrance. 
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4. Chapter 4. TNFα as a modifier gene of 
hereditary HFE-associated haemochromatosis 
4.1. Introduction 
The search for modifiers of the phenotypic penetrance of HH has led to 
suggestions that one such modifier may reside within the 6p21.3 region near 
HFE (Pratiwi, Fletcher et al. 1999; Vieira, Cardoso et al. 2007) but a specific locus 
has yet to be identified. Tumour necrosis factor alpha (TNFα) lies ca. 5.5Mb 
downstream of HFE on 6p21.3 and is integral to the immune system as a 
proinflammatory cytokine. It is produced predominantly by activated 
macrophages in response to bacterial infection (Paul, Gohil et al. 2006) but may 
also be produced by other immune cells and has additional roles in 
proliferation, differentiation and apoptosis. TNFα has been implicated in a 
myriad of disease states including both immune mediated disorders such as 
arthritis (Sarzi-Puttini, Atzeni et al. 2005), systemic lupus erythematosus (van 
der Linden, van der Slik et al. 2001), Crohn’s disease (O'Callaghan, Adams et al. 
2003; Ferreira, Almeida et al. 2005), multiple sclerosis (Favorova, Favorov et al. 
2006), and Type I Diabetes (Das, Baniasadi et al. 2006); but also in non-immune 
diseases such as myocardial infarction (Bennet, van Maarle et al. 2006). TNFα is 
also thought to play a central role in the anaemia of chronic inflammation which 
is characterised by decreased serum iron in the presence of adequate iron 
stores (Feelders, Vreugdenhil et al. 1998). Evidence from both human samples, 
cell lines, and animal studies suggest the expression of DMT1, FPN1, TFRC and 
FTH1 in particular are influcened by TNFα (Johnson, Bayele et al. 2004; Nanami, 
Ookawara et al. 2005; Laftah, Sharma et al. 2006) further advocating a role for 
this gene in iron homeostasis. 
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The TNFα promoter contains numerous SNPs and it is these polymorphisms 
which are most often associated with disease phenotypes. Whether any of 
these SNPs play a role in the phenotypic expression of HH is controversial 
(Gordeuk, Ballou et al. 1992; Fargion, Valenti et al. 2001; Distante, Elmberg et al. 
2003) with a recent study suggesting the rare allele at the -308 promoter SNP 
was associated with increased iron loading in C282Y homozygotes (Krayenbuehl, 
Maly et al. 2006). This is consistent with previous results from the MGRU lab 
suggesting TNFα may be a modifier of HH (Walker 2005). The aim of the present 
study was to examine the promoter region of TNFα in more detail in both 
haemochromatosis patients and in a control population. As single SNP analysis 
may fail to identify associations with phenotype, a haplotype approach was also 
utilised in this study to provide a more comprehensive analysis. Five of the most 
variable (in the Caucasian population) TNFα promoter SNPs (-1031, -863, -857, -
308 and -238) were analysed for their impact on iron loading, as measured by 
SF, in a collection of well studied C282Y homozygotes and C282Y controls. 
 
4.2. Materials and Methods 
4.2.1. Samples 
190 unrelated control samples that did not contain the C282Y mutation and 119 
unrelated C282Y homozygotes were used to establish SNP allele frequencies. 
Studies on SF levels were performed on iron loaded males only (SF>300µg/L) 
and of the 72 available, fifty two had presented with clinical signs/symptoms 
consistent with haemochromatosis; while twenty were, despite their increased 
SF, asymptomatic patients who were identified because of incidental 
biochemical diagnosis or through family screening. See section 3.2.1 for more 
information on C282Y homozygote samples. Furthermore microsatellite 
genotyping was performed on family members where available when results 
would assist in assigning phase to genotypes and/or haplotypes.  
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4.2.2. TNFα SNPs and microsatellite markers 
The five TNFα promoter SNPs included in the study were rs1799964, rs1800630, 
rs1799724, rs1800629 and rs361525 at positions relative to the transcription 
start site of -1031, -863, -857, -308 and -238 respectively (figure 4.1). All were 
genotyped via Taqman assays on the Applied Biosystems 7300 Real Time PCR 
System with the exception of the -863 SNP which was genotyped via PCR-RFLP 
analysis. Primer sequences and amplification conditions are outlined in section 
2.2.9.3 and appendix G. The primer sequences for D6S258 and D6S265 came 
from GDB (www.gdb.org, no longer functional), D6S105 from NCBI 
(http://www.ncbi.nlm.nih.gov/unists) and D6S1019 and D6S1281 were part of 
the Cooperative Human Linkage Center (CHLC) human screening set 6.  
 
 
Figure 4.1. Position of the TNFα promoter SNPs and the microsatellites studied relative 
to the HFE and TNFα genes. The two genes are around 5.5Mb apart. Not drawn to 
scale. Definitive positions are presented in table 4.1.  
 
Five microsatellite markers (D6S105, D6S258, D6S265, D6S1019, and D6S1281) 
were amplified by PCR and genotyped by polyacrylamide gel electrophoresis 
(PAGE). Information regarding the sizing and allocation of allele numbers of the 
microsatellites was obtained from the CEPH website (http://www.cephb.fr), 
with CEPH samples then included in the PCRs as control samples. No sizing 
information was available for the D6S105 marker, so sizing was achieved by 
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comparison of CEPH samples to a ladder of known size. Allele numbers were 
then allocated by comparison of control population frequencies with the given 
CEPH frequencies, as previous results in the MRGU laboratory suggest the 
Australian frequencies are very similar (unpublished data). Primer sequences, 
PCR parameters and PAGE conditions are presented in appendix G. The position 
of the SNPs and microsatellites relative to TNFα and HFE are outlined in table 
4.1 and diagrammatically in figure 4.1. 
 
Table 4.1. The positions of the microsatellite and SNP markers used in this study in 
relation to the primary reference assembly on NCBI (GRCh37 NT_007592.15). 
Marker Rs/sts number Position (bp) 
D6S1281 UniSTS:45995 25297027-25297215 
HFE gene  -  26027447..26037058 
HFE C282Y rs1800562 26093141 
D6S105 UniSTS:48772 27771274-27771402 
D6S258 UniSTS:46654 29020799-29020995 
D6S265 UniSTS:480392 30019453-30019634 
TNFα-1031 rs1799964 31542308 
TNFα-863 rs1800630 31542476 
TNFα-857 rs1799724 31542482 
TNFα-308 rs1800629 31543031 
TNFα-238 rs361525 31543101 
TNFα gene  -  31543349-31546111 
D6S1019 UniSTS:65555 38978439-38978668 
 
4.2.3. Haplotype construction 
Haplotypes for both the TNFα promoter SNPs and the microsatellite markers 
were constructed from family data where possible and undetermined 
haplotypes were phased using the PHASE version 2.1 haplotyping program 
(http://depts.washington.edu/uwc4c/express-licenses/assets/phase/; 
(Stephens, Smith et al. 2001; Stephens and Donnelly 2003)). This program uses a 
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Bayesian approach to call haplotypes and has the advantage over other 
programs that it is able to incorporate different types of markers including those 
with more than two alleles such as microsatellites (Adkins 2004; Sabbagh and 
Darlu 2005). Any missing data was inferred by Phase. 
 
4.2.4. Linkage Disequilibrium 
Linkage Disequilibrium (LD) was analysed by running samples through the 
Genepop software (http://genepop.curtin.edu.au/ (Raymond and Rousset 
1995)) which analyses the extent of LD between all markers in a population 
sample and returns a significance value as a result. To accurately calculate LD, 
unrelated samples must be used, so only a single member was included from 
each family except when unrelated parents, spouses or siblings discordant for 
HFE genotype (e.g. C282Y and C282Y homozygotes) were available. Discordant 
siblings were included as they inherited different chromosomes/chromosomal 
segments at HFE... 
 
4.2.5. Statistical analyses 
Comparison of log10SF between groups was performed using the unpaired 
student t-test. Deviations from HWE for the SNPs, microsatellites and 
haplotypes were determined via Chi-square analyses (with amalgamation of 
cells when values did not exceed five) or Fisher’s exact test. Results were 
considered significant at p<0.05. The previous chapter established a significant 
difference in the SF levels of C282Y homozygotes that were symptomatic versus 
those that were asymptomatic, therefore these samples were analysed 
separately for any SNP effects on SF. 
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4.3. Results 
4.3.1. TNFα promoter SNP analysis 
4.3.1.1. Single SNP analysis 
The allele frequencies for the TNFα SNPs are given in table 4.3. Population allele 
frequencies for the TNFα SNPs were calculated from 190 unrelated control 
samples that did not possess the C282Y mutation and compared to frequencies 
calculated from 119 unrelated C282Y homozygotes (male and female). The 
C282Y homozygotes were further categorised as males reporting symptoms and 
those who were asymptomatic (see section 4.2.1). The observed frequencies did 
not differ from those expected under HWE (p>0.05 student t-test or Fisher’s 
exact test as appropriate) for all groups and there were no significant 
differences between any sample group.  
 
Table 4.2. Allele frequencies for the TNFα SNPs in controls and C282Y homozygotes 
(YY). ‘1’ represents the common allele and ‘2’ the rarer allele. YY_S are the male 
symptomatic C282Y homozygotes; YY_AS are the asymptomatic male C282Y 
homozygotes. Sample sizes are in parentheses after the sample group name. There is 
no significant difference in allele frequencies between the groups for any of the SNPs 
(p>0.05).  
SNP Allele Controls (190) YY (119) YY_S (52) YY_AS (20) 
-1031 
(rs1799964) 
1 
2 
0.810 
0.190 
0.802 
0.198 
0.788 
0.212 
0.725 
0.275 
-863 
(rs1800630) 
1 
2 
0.861 
0.139 
0.868 
0.132 
0.865 
0.135 
0.800 
0.200 
-857 
(rs1799724) 
1 
2 
0.913 
0.087 
0.949 
0.051 
0.971 
0.029 
0.925 
0.075 
-308 
(rs1800629) 
1 
2 
0.805 
0.195 
0.863 
0.137 
0.837 
0.163 
0.925 
0.075 
-238 
(rs361525) 
1 
2 
0.950 
0.050 
0.931 
0.069 
0.923 
0.077 
0.900 
0.100 
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The effect, if any, of each SNP on SF levels in the two patient groups (i.e. 
symptomatic and asymptomatic C282Y homozygotes) was analysed. Due to the 
lack of information regarding blood donation frequency in the controls, the 
available SF data are likely to be compromised and so the analysis was not 
performed on this group. In the symptomatic C282Y homozygotes, the presence 
of the rare allele at -1031 was associated with a higher SF level compared to 
those without it (p<0.044) as was the presence of the rare allele at -238 
(p<0.024) (figure 4.2). Neither of these results were replicated in the 
asymptomatic individuals but this may be due to the low sample number in this 
group (n=20). The other three SNPs showed no significant association with SF in 
either study group.  
 
 
Figure 4.2. Average log10SF levels in symptomatic C282Y homozygotes with and 
without the rare allele at the TNFα -1031 (blue) and -238 (purple) promoter SNPs. 
Error bars represent the SEM. Note the axis does not start at zero. *p<0.05 compared 
to homozygotes for the common allele. 
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4.3.1.2. TNFα promoter SNPs haplotype 
4.3.1.2.1. Linkage disequilibrium and number of haplotypes 
Haplotypes were recorded in chromosomal order from -1031 to -238 with a ‘1’ 
representing the common allele and ‘2’ representing the rare allele at each SNP. 
Samples that could not be phased by family data were run through the 
haplotyping program PHASE (version 2.1). A total of 431 unrelated individuals of 
mixed HFE genotype were used to calculate haplotype frequencies of the TNFα 
SNPs and to perform LD analysis.  
 
The frequencies of the haplotypes on normal C282Y chromosomes and C282Y 
chromosomes are shown in figure 4.3. There are thirty-two possible haplotypes 
from the five SNP loci however given the close proximity of the SNPs and low 
recombination frequency in the MHC region (Martin, Mann et al. 1995) it was 
expected that there would be some LD influencing haplotype structure. Indeed 
of the 862 chromosomes analysed, only five haplotypes were identified, namely 
11111, 22111, 11121, 11211, and 21112 in order of decreasing frequency on 
normal chromosomes. The low haplotype number was reflected in LD analyses 
with significant LD found between most SNP pairs. There was a significant 
difference between the haplotype frequencies on the control and C282Y 
chromosomes for all bar the 21112 haplotype. This may reflect the relatively 
young age of the C282Y mutation, with a higher frequency of the most common 
haplotype suggesting it arose on this background and decreased recombination 
in the area means it has not yet had the time to equilibrate to the frequencies 
observed on the control chromosomes. There was some evidence for LD 
between C282Y and the -857 SNP and this may be a consequence of the low 
minor allele frequency of -857 which can result in overestimation of LD (Reich, 
Cargill et al. 2001). 
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Figure 4.3. The frequencies of the different TNFα promoter haplotypes in the control 
(blue) and C282Y homozygote (purple) chromosomes. There was a significant 
difference (p<0.05) between the frequencies of all haplotypes except for 21112. 
 
4.3.1.2.2. TNFα Haplotypes and log10SF in male C282Y homozygotes 
The TNFα promoter haplotypes were analysed for association with SF in the 
C282Y homozygotes. Single SNP analysis revealed the rare allele at -238 was 
associated with increased SF in the symptomatic C282Y homozygotes. This SNP 
occurs exclusively on the 21112 haplotype, and thus this haplotype was 
significantly associated with increased SF in this group (p=0.024 Student t-test, 
figure 4.4A). As there was only one individual that was homozygous for the 
21112 haplotype in this group, the potential additive effect of the haplotype on 
SF could not be determined; however, given the SF of the homozygote was not 
higher than the heterozygotes, an additive effect seems unlikely. In terms of 
raw SF data, the seven patients with the 21112 haplotype all had SF levels 
greater than 1500μg/l. This is considered severe iron loading and in contrast, 
only 18/45 (40%) of samples that did not possess the 21112 haplotype had raw 
SF values >1500μg/L. The average log10SF value in the asymptomatic samples 
with the 21112 haplotype was slightly higher than the samples without this 
haplotype (2.94 vs. 2.90). This difference was not significant, but it may reflect 
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the low sample numbers in this group (only 3/20 with the 21112 haplotype). 
Similarly, there were insufficient female C282Y homozygotes with the 21112 
haplotypes for analysis. It therefore remains unclear whether the observed 
effect of the 21112 haplotype on SF applies to all individuals with the haplotype 
or whether it is specific to the symptomatic C282Y homozygotes.  
 
The single SNP analysis also indicated that the rare allele for the -1031 SNP was 
associated with higher SF. Apart from 21112, the only other haplotype to 
contain this rare allele, namely 22111, showed no association with increased SF. 
When samples possessing the 21112 haplotype were excluded from the -1031 
single SNP analyses, samples possessing the rare allele no longer had 
significantly higher SF than those without it (figure 4.4B). This suggests that the 
21112 haplotype is unique in the effect it has on SF. 
 
  
Figure 4.4. The average log10SF levels associated with TNFα promoter haplotypes 
containing the rare allele at -1031 in symptomatic C282Y homozygotes. (A) The 
presence of the 21112 haplotype is associated with a significantly higher log10SF 
compared to the other haplotypes combined (p<0.05, student t-test, indicated with an 
asterisk). (B) The 22111 haplotype is not associated with increased SF compared to 
controls. Error bars represent the SEM. 
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4.3.2. Microsatellite markers 
The C282Y mutation is on a microsatellite defined ancestral haplotype that has 
previously been associated with more severe iron loading (Barton, Harmon et al. 
1996). In order to ascertain whether the association of the TNFα 21112 
promoter haplotype with high SF in the symptomatic C282Y homozygotes was a 
reflection of the impact of the ancestral haplotype, three microsatellite markers 
between TNFα and HFE and one on the other side of each gene were studied 
(figure 4.1). D6S105, D6S258 and D6S265 have previously been associated with 
the ancestral haplotype, in particular D6S105 allele 8 (Pratiwi, Fletcher et al. 
1999). All symptomatic and asymptomatic C282Y homozygotes used in the TNFα 
haplotype study and family members whose genotype could assist in 
haplotyping were genotyped for the microsatellites. A population of control 
samples (blood donors and healthy volunteers) with mixed TNFα haplotypes 
were also included to investigate the ancestral microsatellite haplotype on the 
C282Y chromosomes in comparison to normal chromosomes in this study 
population. 
 
4.3.2.1. Microsatellite allele frequencies  
The microsatellite allele frequencies were significantly different between 
normal chromosomes and C282Y chromosomes for all markers except D6S1019 
(Fisher’s exact test, p<0.05). The allelic frequency distributions for the 
microsatellites are presented in figure 4.4 where different patterns are 
observed between the control and the C282Y chromosomes for all markers 
except D6S1019. These differences can be explained by the presence of an 
ancestral haplotype containing D6S105-8, D6S258-1, D6S265-2 and D6S1281-
5/6. D6S1019 is relatively far away from the other markers (approximately 9Mb 
from D6S265, total distance between the other four microsatellites is ca. 4.8Mb) 
and therefore serves as a control marker for allele frequencies.  
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D6S105 allele 8 has previously been associated with a more severe phenotype in 
C282Y homozygotes; however, that association was not replicated in this study. 
Interestingly, there was a significant difference between the allele frequencies 
at D6S258 for symptomatic and asymptomatic C282Y homozygotes. This was 
the result of a reduced frequency of allele 1 and increased frequency of allele 2 
in the asymptomatic individuals, but the other alleles were of a similar 
frequency to the symptomatic samples. Despite this, this marker is not 
associated with SF and the difference may reflect the low sample size of the  
85 
 
 
Figure 4.5. Allele frequencies for the microsatellites on C282Y homozygotes (purple) 
and control chromosomes (blue). There was a significant difference in the frequencies 
for all loci except D6S1019 (Fisher’s exact test, p<0.05).  
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symptomatic C282Y homozygotes for the other markers studied and both 
populations conformed to HWE for all markers.  
 
4.3.2.2. A primer mutation – D6S265 
Upon analysing the data for D6S265, a family consisting of both parents and two 
offspring showed inconsistent transmission of the D6S265 marker while all 
other markers were internally consistent. This suggested the presence of a null 
allele for D6S265 and further examination of the literature revealed that the 
particular primer set used in the current study (obtained from GDB), contained 
mismatches in the reverse primer that likely prevented amplification in some 
cases. One paper suggested this was a polymorphism in itself (Pyper, Burt et al. 
1995). In the data presented in this chapter, the non-amplification would result 
in an overestimation of all other allele frequencies in samples for which 
homozygosity could not be confirmed by family studies. However the impact on 
the results appear to be minimal as observed frequencies are comparable to 
other studies and reduction of the ancestral haplotype to include only D6S105 
and D6S258 did not alter results obtained with the extended haplotype.  
 
4.3.2.3. Microsatellite haplotype analysis 
There is a clear ancestral haplotype on the C282Y chromosomes consisting of 
the alleles 8, 1 and 2 (i.e. haplotype 8-1-2) for D6S105, D6S258 and D6S265 
respectively. In addition, more than 75% of the C282Y chromosomes possessed 
one of two D6S1281 alleles (200bp and 204bp) which are only one repeat apart. 
There is strong LD between C282Y and D6S105, D6D258, D6D265 and D6S1281; 
however, while the three markers distal to C282Y show LD between each other, 
they show no LD with D6S1281. Therefore, ancestral haplotype analyses were 
only performed in regards to the 8-1-2 haplotype, excluding D6S1281. D6S1019 
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was not part of the ancestral haplotype either with evidence of crossing over 
events within families consistent with the lack of LD associated with this marker. 
 
There were 45 different microsatellite haplotypes (D6S105, D6S258 and 
D6S265) on 155 C282Y chromosomes, 24 of which occurred only once. In 
contrast, 109 control chromosomes presented with 51 different haplotypes, 32 
of which occurred only once. In contrast to previous studies, the ancestral 
C282Y haplotype was seen on six control chromosomes. Five of these came 
from control samples in which the haplotypes were imputed due to lack of 
family data; however, one individual was homozygous across the three loci 
leaving no room for misinterpretation. 
 
The ancestral 8-1-2 haplotype was present on around 34% of C282Y 
chromosomes and it was not associated with increased SF in the C282Y 
homozygotes (p>0.05). There was also no difference when only the 8-1 
haplotype (D6S105-D6S258) was analysed, omitting the results of D6S265 to 
account for potential mis-typing due to the primer mutation. The 8-1-2 
haplotype was present on 7/16 (44%) C282Y chromosomes on which the TNFα 
21112 haplotype was also present and while this percentage was a little higher 
than that seem on the C282Y chromosomes with other TNFα promoter 
haplotypes (46/139, 33%), the difference was not significant (p>0.05). The 
association of the TNFα 21112 haplotype with increased SF is therefore 
independent of the ancestral microsatellite haplotype in C282Y homozygotes.  
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4.4. Discussion 
4.4.1. TNFα and SF levels 
Several studies have addressed the possibility of TNFα promoter SNPs 
influencing iron homeostasis; however, a definitive answer remains elusive. 
Recently Krayenbuehl et al reported the rare allele at the -308 TNFα SNP was 
associated with increased iron loading in a population of haemochromatotics 
(Krayenbuehl, Maly et al. 2006). This was not replicated in the data presented in 
this chapter and this discrepancy most likely stems from methodological 
differences between the studies, most notably that the Krayenbuehl study 
combined males and females for analysis despite a previously established 
significant difference between the genders (Olynyk, Cullen et al. 1999; 
Cassanelli, Pignatti et al. 2001). Patient selection also differed with over half of 
the individuals included in their study having secondary causes of iron overload 
(such as some with considerable alcohol intake), individuals who would have 
been excluded from the present study.  
 
In the data presented above, both the -238 and -1031 SNPs showed association 
with SF levels and this was found to be the result of a single haplotype across 
the region that included the rare allele at both -1031 and -238 and the common 
allele at the other three loci. Several studies have examined the effect of one or 
two TNFα promoter SNPs in HH; however this is the first study to examine a 
broad haplotype across the region. As the rare allele at -238 occurs on only one 
haplotype, it is possible to compare the results from this chapter with previous 
studies in which only the -238 SNP was analysed, as long as the samples were of 
the same ethnicity. No previous studies have reported an association between 
SF levels and the -238 SNP (Fargion, Valenti et al. 2001; Acton, Barton et al. 
2010), however a trend for increased SF in samples with the rare allele at -238 
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was observed in two studies (Beutler and Gelbart 2002; Distante, Elmberg et al. 
2003).  
 
There were only five TNFα promoter haplotypes observed across all populations 
from 32 potential haplotypes (from the five two-allele loci), reflecting the high 
LD within the region. The haplotypes observed are consistent with results from 
previous studies of the TNFα promoter (Morgan, Adamson et al. 2005; Shirts, 
Bamne et al. 2006) with additional low frequency haplotypes found in some 
studies (Kim, Lee et al. 2003; Posch, Cruz et al. 2003). The lack of family data to 
aid in the haplotyping process may have contributed to haplotyping errors in 
some studies (Liu, Metter et al. 2008).  
 
The TNFα 21112 haplotype was associated with increased SF levels in iron 
loaded C282Y homozygotes but was not tested in controls due to a lack of 
information regarding their blood donation frequency. It therefore remains to 
be determined whether the haplotype is specific to the C282Y homozygote 
genotype, the iron-loaded phenotype or whether it affects SF irrespective of 
these two variables. This question is addressed in the subsequent chapters. 
 
4.4.2. Microsatellite analysis 
Microsatellites were used historically in attempts to map the causal gene in HH 
and much of the early LD data suggested the gene was close to D6S105. 
However, comparisons of the data in this study to previously generated 
microsatellite frequencies were somewhat difficult due to the inconsistencies in 
the literature in the allocation of alleles to PCR product sizes. These differences 
are predominantly due to differential primer sequences resulting in 
inconsistencies between databases (such as the CEPH website and GDB) leading 
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to variable estimates of allele frequencies. As the frequency of the most 
common allele on C282Y chromosomes is fairly consistent among populations of 
Celtic origin, the allele number assigned was ignored and the frequencies 
compared on that basis. The frequency of 61.9% for the D6S105-8 allele on 
C282Y chromosomes in the present study compares well with previous 
frequencies of 62.8% in an Australian population (Jazwinska, Lee et al. 1993) 
and 63.6% in French patients of Celtic ancestry (Gandon, Jouanolle et al. 1996). 
The control frequencies have been more variable with 22.9% in the current 
study, 11.6% and 19.1% in the Australian and French studies respectively 
(Jazwinska, Lee et al. 1993; Gandon, Jouanolle et al. 1996) and 29% in Welsh 
controls (Worwood, Raha-Chowdhury et al. 1994). Frequencies for D6S258 in 
both controls and HH samples compared well with previous studies (Raha-
Chowdhury, Bowen et al. 1995) as did the D6S265 frequencies (Raha-
Chowdhury, Bowen et al. 1995; Raha-Chowdhury, Bowen et al. 1995; Seese, 
Venditti et al. 1996). There are conflicting results when the microsatellite 
D6S1281 is included in the ancestral haplotype with some studies indicating no 
association (Pratiwi, Fletcher et al. 1999) whilst others incorporated it in the 
ancestral haplotype (Seese, Venditti et al. 1996; Thomas, Fullan et al. 1998). In 
the current study this marker did not demonstrate positive LD with the D6S105, 
D6S258 or D6S265 and it was not included in the ancestral haplotype. There is 
no published information on the allelic association of D6S1019 in HH as this 
marker is over 10Mb from HFE and this marker is not informative with respect 
to the ancestral haplotype since frequencies between the affected and 
unaffected chromosomes in this study are very similar.  
 
The ancestral haplotype was found on 34% of C282Y chromosomes which is 
consistent with a previous Australian study performed prior to the discovery of 
the C282Y mutation (Jazwinska, Pyper et al. 1995) where it was found on 33% of 
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haemochromatosis chromosomes. In the present study there were only 16 
unrelated C282Y chromosomes with the TNFα 21112 haplotype for which 
microsatellite haplotype frequencies could be compared. The prevalence of the 
ancestral haplotype was somewhat higher on these chromosomes (7/16 or 
43.8%) compared to C282Y chromosomes with other TNFα haplotypes (46/139 
or 33.1%) but this was not significantly different. Regardless of this, the 
ancestral haplotype showed no association with SF levels in the male C282Y 
homozygotes. While this haplotype has previously been associated with a more 
severe phenotype as characterised by the number of phlebotomies required to 
reduce iron levels (Barton, Harmon et al. 1996; Piperno, Arosio et al. 1996) and 
by the extent of liver damage (Crawford, Powell et al. 1995), such data was 
unavailable for the samples in the current study and so comparable analyses 
could not be performed. 
 
4.4.3. TNFα and iron metabolism 
The mechanism of the TNFα haplotype influence on iron loading remains 
unclear and while this is addressed in the following chapters, it is briefly 
discussed here. The TNFα haplotype is not associated with the C282Y mutation 
or the ancestral microsatellite haplotype. Promoter SNPs are often intuitively 
associated with variable expression of the gene they precede (addressed in 
future chapters) however the precise mechanism of the association may not be 
so direct. Lymphotoxin-alpha (LTα) is around 1.3kb upstream of TNFα and there 
have been suggestions that polymorphisms in the promoter region of TNFα may 
influence the expression of LTα (Knight, Keating et al. 2003). The close proximity 
of LTα to TNFα may mean that there is LD between TNFα SNPs and LTα, 
however there is no strong evidence of LD for the more common LTα SNPs 
studied and TNFα (Howell, Turner et al. 2002; Posch, Cruz et al. 2003; Sharma, 
Sharma et al. 2006). Functionally LTα is part of the larger TNF family but 
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operates predominantly in the development and homeostasis of lymphoid 
tissue (Ware 2005). There has not been any suggestion of a role of LTα in iron 
homeostasis to date so it is difficult to imagine a role for this gene in the 
phenotypic expression of HH at this stage. The gene on the other side of TNFα 
(2.2kb downstream) is Lymphotoxin-beta (LTβ) which is in the opposite 
orientation to TNFα and is functionally similar to LTα so the relevance to iron 
storage in HH is doubtful at this stage. Nevertheless expression studies of these 
two genes in cell lines with and without the 21112 haplotypes may clarify this 
issue. The question of TNFα promoter haplotypes in long range expression has 
not been explored – but the existence of SNPs that interfere with expression of 
genes at great distance is now well established. Such sites that modify 
expression have proved to be both in gene deserts and within coding regions of 
other unrelated genes. Further study of the 21112 haplotype is required. 
 
4.5. Conclusion 
The TNFα 21112 promoter haplotype was associated with increased SF in 
symptomatic male C282Y homozygotes. This has not previously been reported. 
The prevalence of the ancestral microsatellite haplotype of the C282Y mutation 
in the current study was similar to published reports; however, it was not 
associated with either SF levels or the TNFα haplotype. This suggests that the 
novel association of the TNFα 21112 haplotype with SF is independent of 
previously described loci in the 6p21.3 region. The mechanism of this 
association is addressed in subsequent chapters including by measuring the 
expression of a reporter gene under the control of the different TNFα promoter 
haplotypes to determine any differences. Expression levels of a number of 
genes in the iron pathway including TNFα will be explored in lymphoblastoid cell 
lines from haemochromatotics and controls in the context of the TNFα 
promoter haplotype.  
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5. Chapter 5. Expression of the TNFα promoter 
haplotypes in a luciferase system  
5.1. Introduction 
The previous chapter established the presence of only five of the potential 25 
TNFα promoter haplotypes in the population (11111, 11121, 11211, 22111 and 
21112) encompassing five SNPs, namely -1031, -863, -857, -308 and -238. 
Furthermore the 21112 haplotype was associated with an increased SF level in 
symptomatic male C282Y homozygotes. This result suggests that circulating 
serum ferritin levels may be regulated by differential expression of TNFα. As 
mentioned previously, TNFα is a pro-inflammatory cytokine that is 
predominantly produced by macrophages but can also be secreted by other cell 
types. It is a relatively small gene consisting of four exons; the first exon 
encodes a signal peptide, and cleavage of this causes TNFα to become a 
secreted protein (Ihnatko and Kubes 2007). TNFα signals through two main 
receptors, TNF receptor superfamily 1a and 1b (TNFRSF1a and TNFRSF1b, 
formally known as TNFR1 and TNFR2). Each receptor exerts a different biological 
function with TNFRSF1A associated with the apoptotic pathway and TNFRSF1B 
is associated with tissue repair and angiogenesis (Bradley 2008). The tissue 
distribution of the receptors reflects the functional roles they perform. Like 
TNFα, however, they can also be cleaved to form soluble receptor fragments 
that can act as an antagonist to TNFα (Ihnatko and Kubes 2007). 
 
A number of diseases are associated with perturbed TNFα expression (reviewed 
in (Hajeer and Hutchinson 2001; Balkwill 2009)). The complexity and tissue-
specific nature of gene regulation means that it can be problematic to study in 
vitro. The aim of this chapter was to determine whether TNFα promoter 
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haplotypes associated with different serum ferritin levels in males are 
associated with differential expression levels in a reporter gene system. By 
inserting a promoter sequence of interest upstream of an easily quantifiable 
reporter gene, expression levels dictated by different promoter sequences can 
be assessed.  
 
5.2. Materials and methods 
5.2.1. Luciferase constructs 
A 1,348bp fragment spanning the -1125 to +203 region of the TNFα promoter 
region that included the five SNPs genotyped in chapter 3 was inserted 
upstream of a firefly luciferase reporter gene (luc2) in the pGL4.10 vector. In 
addition to the five naturally occurring TNFα promoter haplotypes (which were 
amplified from homozygous individuals), site directed mutagenesis was 
performed to create the 21111 and 11112 haplotypes to determine whether 
any effect of the 21112 haplotype could be simplified to a single SNP effect. See 
section 2.2.13 for more details on the constructs. A second plasmid containing a 
Renilla luciferase reporter gene was used to control for transfection efficiency. 
 
5.2.2. Cell lines  
Previous studies have produced variable results regarding the influence of TNFα 
SNPs on the expression of a reporter gene, and much of this variation is due to 
the diverse cell types used. Three different commercially available cell lines 
were utilised in this study: human embryonic kidney (HEK293H), heterogeneous 
human epithelial colorectal adenocarcinoma cells (Caco-2) and human 
Caucasian hepatocyte adenocarcinoma (HepG2). The latter two are particularly 
relevant in iron storage and absorption respectively and HEK293H were 
included as they are readily transfected with high efficiency.  
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5.2.3. Iron challenge of the cell lines 
To determine the influence, if any, of iron loading on the expression of TNFα in 
this system, cells were treated with ferric ammonium citrate (FAC) as a 
substitute for non-heme (ferric) iron. A FAC concentration gradient covering 
0mM, 0.002mM, 0.05mM, 0.2mM, 1mM and 5mM was tested against cell death 
as estimated via trypan blue exclusion after 48 hours incubation. The 
transfection protocol suggests a 24-48hour incubation time to allow expression 
of the reporter gene (Technical Manual, FuGENE HD transfection reagent, 
Promega). Previous work in the laboratory utilised the 48 hour time point 
(unpublished results); thus this was the time point utilised in the current study. 
The FAC did not affect cell viability at any of the concentrations tested and the 
5mM concentration was chosen in the final experiments to replicate extensive 
iron loading, as may be seen in the C282Y homozygotes in which the TNFα 
haplotype was associated with iron loading. Therefore at the time of 
transfection, each construct was incubated with both standard media and 
media containing 5mM FAC.  
 
5.2.4. Transfections 
FuGene HD (Promega, Madison USA cat#E2311) is a proprietary blend of lipids 
and other components and is used for the transfection of a wide range of 
eukaryotic cells, for cellular analysis and protein expression. Transfection 
protocols were based on the recommended protocols by Promega 
(http://www.promega.com/techserv/toolsFuGENE HDtool/Default.aspx), which 
were trialled before being implemented. The optimised pGl4.10: pRL-TK ratio 
(to reduce trans effects between the two plasmids, see section 2.2.15) was 40:1 
as this produced the most consistent results for the constructs tested.  
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For each construct, enough transfection mix was prepared for eight wells of a 
96-well plate with four wells containing standard media and four wells 
containing media supplemented with 5mM FAC. Cells were seeded 24hours 
prior to transfection in 96 well white bottom plates at the densities indicated in 
table 5.1. Opti-MEM media contains a low level of serum and was used to 
maximise transfection efficiency. The transfection mix was prepared by addition 
of the DNA to the media before mixing in of the FuGENE HD and finally 
incubating the mix for a certain amount of time before addition to cells, this 
time period was dependent on the cell line (table 5.1). Before transfection, cells 
were washed in 1XPBS and 50µl of the appropriate media (with or without 5mM 
FAC) was added before 5µl/well of the transfection mix was thoroughly mixed 
in.  
 
Table 5.1. Transfection parameters of the cell lines used for the luciferase assays. Both 
the volume of Opti-MEM and the amount of FuGENE HD were enough for eight wells 
in a 96 well plate. After the incubation period, 5µl of transfection mix was added to 
each well which already contained 50µl of the appropriate media. *cells were seeded 
24 hours prior to transfection. 
Cell line Seeding 
density* 
pGL4.10 
construct 
pRL-TK Opti-MEM 
+/-FAC 
FuGENE 
HD 
Incubation 
time 
Caco-2 1 x 104 858.5ng 2.5ng Up to 41µl 2.6µl 10mins 
HepG2 2 x 104 858.5ng 2.5ng Up to 40µl 4.0µl 15mins 
HEK293H 2 x 104 858.5ng 2.5ng Up to 41µl 2.6µl 5-10mins 
 
5.2.5. Luciferase Assays 
Approximately 48 hours after transfection, a luciferase assay was performed on 
the cells using a Dual-luciferase reporter kit as outlined in section 2.2.16. Briefly, 
the media was removed and cells were washed with 1XPBS, lysed, and the 
firefly luciferase followed by the Renilla luciferase was measured using a Glomax 
97 
 
microplate luminometer. The Raw data for both firefly and Renilla luciferase 
were expressed in relative light units (RLU).  
 
5.2.6. Analysis and Statistics 
To normalise the results for transfection efficiency, the ratio of firefly: Renilla 
luciferase was calculated for each well, and then this value was normalised to 
the average result for the empty pGL4.10 vector (set at a value of 1) for each 
experiment. All values for a construct were run through the Grubbs test 
(GraphPad, www.graphpad.com/quickcalcs/Grubbs1.cfm) to remove any 
significant outliers, which was defined as values that were not within two 
standard deviations of the mean (Grubbs 1950). The relative expression levels of 
the different constructs across all experiments were compared via a generalised 
linear model in the PASW Statistics 18 program using the day of the experiment, 
the haplotype and/or SNP genotype as the predictors as appropriate. Data was 
considered significant at p<0.05.  
 
Based on the number of statistical tests performed, a corrected p value was 
calculated for each set of analyses by applying the Bonferroni correction. This is 
calculated by dividing alpha, or the p value at which a result is determined to be 
significant (in this case it would be 0.05), by the number of tests to be 
performed. The conservative nature of the Bonferroni correction method can 
induce type II errors, that is, accepting the null hypothesis when it should be 
rejected and thus Bonferroni corrections are not universally accepted as 
appropriate (Perneger 1998). Nonetheless the correction was applied to the 
data presented, and uncorrected p values are also presented.  
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5.2.7. TFBS prediction 
To identify putative transcription factor binding sites (TFBS) in the TNFα 
promoter, in silico analysis was performed using a number of different 
programs. The four programs that were used were TESS (transcription element 
search system), MatInspector (version 8.0.3), TFSEARCH (version 1.3) and 
Consite (see Appendix A for website addresses). The underlying algorithms vary 
between the programs and results were assessed accordingly. For example, the 
MatInspector program uses matrices based on reported findings to reduce the 
number of false positive TFBS (Cartharius, Frech et al. 2005) so all results from 
this program were included in the analysis. The other programs have less 
stringent criteria and results for potential TFBS were limited to human sites with 
a matrix similarity of at least 80% (Schug 2008). Functional roles for the 
predicted sites were determined using NCBI Gene and literature searches. 
  
5.3. Results 
Statistical analyses of expression levels were performed for haplotypes and also 
for individual SNP alleles irrespective of their haplotype to ensure that potential 
SNP effects were not overlooked. There was some variability in the number of 
wells analysed among the different cell lines and conditions (table 5.2). The 
majority of data sets contained at least 10 replicates with the exception of some 
of the iron challenged Caco-2 and HepG2 constructs. These analysis points 
frequently required additional replicates due to insufficient transfection as a 
consequence of the high iron in the media. The iron challenge did not increase 
the proportion of dead cells as this was evaluated before the transfections were 
performed (data not shown). The reduced transfection is therefore likely to be 
due to decreased cell division as rapidly dividing cells are the most readily 
transformed. A firefly luciferase reading of 5000 RLU was observed to be the 
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threshold of reliable transfection and wells with a reading below this level were 
omitted from the results.  
 
Table 5.2. The total number of useable replicates for each construct under normal and 
high iron (5mM FAC) conditions in each of the cell lines. Samples were omitted if they 
were outliers (Grubbs test) or in the case of the FAC treated cells, if there was 
insufficient transfection to produce reliable results (as indicated by a firefly luciferase 
reading of <5000 RLU).  
Haplotype 
HEK293 Caco-2 HepG2 
Normal 5mM 
FAC 
Normal 5mM 
FAC 
Normal 5mM 
FAC 
11111 12 12 16 9 15 5 
11121 12 11 16 12 15 11 
11211 12 11 16 11 16 8 
22111 12 12 16 8 16 8 
21112 12 12 16 7 16 8 
21111 12 12 16 8 16 11 
11112 12 12 16 11 16 9 
pGL4.10 12 11 15 10 15 12 
Total 96 93 127 68 125 72 
 
5.3.1. Allele specific effects on expression  
The effect of individual SNPs were analysed prior to analyses of entire 
haplotypes. To do so, expression levels of the haplotypes were pooled and each 
SNP was analysed for allele specific effects on expression. For example, the 
results for 21112, 21111 and 22111 were pooled and compared to those from 
11111, 11112, 11121 and 11211 for analysis of the -1031 SNP. Results are 
outlined in figure 5.1. The p values are presented in table 5.3 with values which 
remained significant (p<0.05) after Bonferroni corrections in bold and italicised. 
The results from the Caco-2 cells are perhaps the most interesting with all 
except the -238 SNP showing allele specific differences in expression in the 
untreated cells. These differences were sustained in the -1031 and -863 SNPs 
after treatment. The HEK293H cells display a similar pattern to that seen in the  
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Figure 5.1. The effects of the different TNFα promoter SNPs on the expression of the 
luciferase reporter gene in each of the cell lines under normal transfection conditions 
(A) and under iron (5mM FAC) challenge (B). The solid bars represent the common 
allele and striped bars represent the rare allele at each locus. Blue represents the 
results from the Caco-2 cells, purple are the results from the HEK293H cells and green 
are the results from the HepG2 cell line. The bar for the rare allele at -863 in the iron 
treated Caco-2 cells is faded as the results obtained from the only construct containing 
this allele were highly variable and omitted from the analyses (see below). Note the 
scales of the y-axis are not the same between the graphs.  
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Table 5.3. The outcomes of pairwise significance testing between the alleles at each 
SNP in the cell lines in untreated and treated (5mM) conditions. Values that are in bold 
and italicised remained significant (p<0.05) when a Bonferroni correction was applied. 
The value for the -863 SNP in the treated Caco-2 cells was not analysed (NA) for 
significance given the highly variable expression associated with the rare allele, see 
text for details.  
  Cell line – Untreated Cell line – Treated 
SNP HEK293H Caco-2 HepG2 HEK293H Caco-2 HepG2 
-1031 .003 .000 .405 .003 .003 .973 
-863 .000 .000 .134 .000 NA .174 
-857 .563 .049 .325 .563 .206 .343 
-308 .164 .000 .134 .164 .134 .883 
-238 .199 .628 .001 .199 .745 .082 
 
Caco-2 cells although the differences do not all reach significance. The HepG2 
cells display a fairly uniform level of expression across the SNPs with only the -
238 SNP displaying any variable expression between the alleles. This difference 
in expression between SNPs is not maintained after treatment with iron. 
 
The magnitude of the expression levels for both the HEK293H and Caco-2 cells 
were similar; however, the level was around half as much for the HepG2 cells. 
The raw firefly luciferase readings for the empty pGL4.10 vector in the HepG2 
cells were around twice as high as the readings for this vector in the other cell 
lines, but the raw Renilla luciferase readings were constant across all cell lines. 
The raw firefly luciferase readings were similar within each construct across all 
cell lines. Therefore the higher firefly: Renilla ratio for the empty pGL4.10 in 
HepG2 cells led to decreased construct: pGL4.10 ratios compared to the other 
cell lines. 
 
The results for the 22111 haplotype in the iron treated Caco-2 cells were 
extremely variable and though repeated several times, the relative expression 
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ranged 10-fold from around 20 to 200. This variability was not a consequence of 
the construct as no other construct / cell type combination showed this degree 
of variation, nor was this phenomenon observed in the untreated cells. These 
results are included in the -863 SNP data presented in figure 5.1 as the 22111 
haplotype is the only one that contains the rare allele at -863. The column 
representing this data is faded to indicate these results were not included in the 
linear model analyses as the extreme variability abolished all significance in all 
comparisons. These results were also not included in any of the other SNP 
calculations, that is, they were not included in the results for the rare allele at -
1031 or the common allele at -857, -308 or -238.  
 
5.3.2. Caco-2 haplotype results 
Results for the Caco-2 cell line are presented in figure 5.2 and table 5.4. Under 
basal transfection conditions, the 11121 haplotype had the lowest level of 
expression which was significant for all haplotypes except 11112 and 11211. The 
haplotypes with the rare allele at -1031 had increased expression compared to 
the other haplotypes, and this was seen in the single SNP analysis above. The 
pattern in the treated cells was similar except that the 21111 haplotype was 
closer in magnitude to the haplotypes with low expression (11121, 11112, and 
11211) rather than those with high expression in contrast to the results in the 
untreated cells. As mentioned above, the results for the 22111 haplotype in 
response to iron were very unreliable so while they are presented in figure 5.2, 
they were not included in the mixed model analysis (this is why the bar 
representing these results is faded).  
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Figure 5.2. Relative expression of the TNFα promoter constructs in Caco-2 cell line. 
Untreated cells are blue and those incubated with excess iron (5mM FAC) are purple. 
Error bars represent the SEM. The bar for the 22111 haplotype in the treatment 
conditions is faded as the results from this construct were unreliable (see text).  
 
Table 5.4. The pairwise p values associated with haplotype expression levels in the 
Caco-2 cell line. The blue values are those without iron treatment and the purple 
values are those with iron (5mM FAC) in the media. Values in bold and italicised 
remained significant (p<0.05) when a Bonferroni correction was applied. The 
significance of the 22111 haplotype was not measured in the iron conditions. 
Caco-2 11111 11121 11211 22111 21112 21111 11112 pGL4.10 
11111 - .025 .047 NA .179 .090 .339 .000 
11121 .005 - .820 NA .001 .708 .176 .001 
11211 .121 .198 - NA .001 .866 .269 .000 
22111 .008 .000 .000 - NA NA NA NA 
21112 .139 .000 .002 .239 - .004 .025 .000 
21111 .334 .000 .012 .091 .608 - .414 .001 
11112 .263 .086 .668 .000 .009 .037 - .000 
pGL4.10 .000 .000 .000 .000 .000 .000 .000 - 
 
 
-20
0
20
40
60
80
100
120
140
pGL4.10 11111 11121 11211 22111 21112 21111 11112
R
el
at
iv
e 
ex
p
re
ss
io
n
TNFα promoter haplotype
Relative expression of the TNFα promoter haplotypes in Caco-2 
cells in untreated and high iron conditions
Untreated
Treated
104 
 
While the reduced magnitude of expression due to the iron treatment makes 
direct comparisons with the untreated expression problematic, the pattern and 
direction of the expression differences between the two conditions is 
interesting. The 21112 haplotype was least affected by the iron; its expression 
level in the iron treated cells was 76% of the untreated expression. The most 
severely affected haplotype (excluding 22111 due to the variability described 
above) is 21111 with the iron treated cells having a level of expression that was 
only 42% of the untreated cells. The other haplotypes fall in between these two 
values with levels of expression in the iron treated cells being 52% (11211), 58% 
(11121), 64% (11112) and 69% (11111) of the levels in the untreated cells. These 
results suggest that in this system, the 21112 haplotype does not respond to 
iron challenge to the extent that the other haplotypes do.  
 
5.3.3. HEK293H haplotype results 
The HEK293H cells were the only cells in which the addition of iron to the media 
did not appear to influence effectiveness of the transfection protocol as similar 
results were produced with and without it in the media. The directions of the 
expression changes were very similar between the HEK293H and Caco-2 cell 
lines, as demonstrated in figure 5.1. However, given the relative lack of 
significant differences in expression observed in the HEK293H cells, they will not 
be considered further. Results are presented in appendix L.  
 
5.3.4. HepG2 haplotype results 
As the SNP data shows, there is a minimal effect of SNP allele in the TNFα 
promoter on expression in HapG2 cells. This effect is mirrored in the haplotype 
analyses so these analyses are not presented in this chapter but are presented 
in appendix L. 
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5.3.5. TFBS predictions and potential function in TNFα 
regulation 
The various programs used to predict differences in potential TFBS as a 
consequence of sequence variation in the TNFα promoter region produced 
widely variable results. This variability is likely due to the different algorithms 
used by the programs and how current the information for each program is. For 
example, TESS makes use of often outdated nomenclature that leads to 
confusing results (e.g. use of HiNF-C now recognised as Sp1 (Birnbaum, Wright 
et al. 1995)). In addition, all programs predict TFBS changes in both the forward 
and reverse direction of the entered sequence; however, the results presented 
in figure 5.3 are only those on the sense strand as there is no evidence for anti-
sense transcripts of TNFα. Overall, the MatInspector software produced the 
most results followed by TESS, Consite and TFSEARCH.  
 
The TFBS presented in figure 5.3 do not necessarily reflect functional sites. The 
known functions of each transcription factor were investigated in order to 
determine their possible relevance to the regulation of TNFα, with results 
outlined in appendix M. For some sites there is little likelihood for a role in the 
expression of TNFα such as SRY (sex determining region Y), involved in sex 
determination in which TNFα plays no known part. For many of the sites there is 
a lack of information about their specific binding to the TNFα promoter region 
so by understanding established functional activities in terms of the types of 
pathways they are involved in, the likelihood of functionality in regards to TNFα 
regulation can be hypothesized. 
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Figure 5.3. A consensus of predicted TFBS changes as a result of each of the five SNPs in the TNFα promoter used in this study. Prediction programs 
used were MatInspector, TESS, Consite and TFSEARCH with search parameters outlined in the methods section (5.2.7). Information regarding the 
results from each program is presented in Appendix M. These TFBS changes are due to single SNP analyses but analyses of the whole haplotype 
sequences used in this study did not result in any additional changes.  
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5.4. Discussion 
5.4.1. Cell line differences in TNFα expression 
By studying biologically relevant cell lines, as well as those in which transfection 
is easily achievable, any expression differences in TNFα may be more easily 
related to iron homeostasis. The cell lines used in this study all express TNFα 
(Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/); however the 
determinants of this expression are unlikely to be identical between the cell 
types. Both HEK293H and Caco-2 cells showed allele (and haplotype) specific 
expression patterns which were not observed in the HepG2 cells. It is of course 
possible that the inserted promoter sequence is not an appropriate length to 
induce expression affected by polymorphisms in the HepG2s. It is more likely 
however, that expression of TNFα in HepG2 cells is simply not responsive to 
promoter allele differences. This has been demonstrated previously by (Kroeger, 
Steer et al. 2000) who showed that HepG2 cells were not responsive to the 
TNFα -308 polymorphism.  
 
The addition of iron to the media had a considerable effect on the reliability of 
transfection in both the HepG2 and Caco-2 cells. This may potentially be a 
consequence of reduced cellular proliferation due to such a high level of iron, as 
dividing cells are more amenable to the uptake of DNA (Fugene HD Transfection 
Reagent Application Note 1, Promega Corporation). The long incubation time of 
the cells with the excess iron was chosen to reflect the prolonged iron loading 
present in the symptomatic C282Y individuals. While time constraints did not 
permit it in this study, shorter incubation times (i.e. after the cells have been 
successfully transfected) with varying iron concentrations may provide 
additional information about the regulation of TNFα in response to iron.  
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The use of the luciferase reporter gene assay system to study promoter 
expression is well established and has been shown to be particularly informative 
in cellular modelling of the impact of promoter polymorphisms that have been 
linked to disease phenotypes (Shi, Misso et al. 2008; Smith, D'Aiuto et al. 2008; 
Kim, Yang et al. 2010; Zhang, Zhang et al. 2010). Differences in results between 
studies of TNFα promoter expression are a consequence of a number of factors, 
one of which is the length of the sequence that is inserted into the reporter 
vector. Finding a balance between the promoter segment being large enough to 
include all relevant TFBS but also limiting the size so as not to include irrelevant 
sites can be difficult. For TNFα, the -1031 SNP is included in some promoter 
studies (Haudek, Natmessnig et al. 1998; Baena, Mootnick et al. 2007) but not 
others (Leung, McKenzie et al. 2000). It is also important that the cell type 
chosen for such experiments should be based on the biological context and 
disease model. Ideally, iron absorption in HH should be studied in duodenal 
biopsies. Unfortunately these were not available in the current study; however 
previous results have indicated Caco-2 cells are comparable to biopsies for the 
expression of genes in the iron metabolic pathway (Sharma, Laftah et al. 2005).  
 
5.4.2. TFBS prediction programs 
The TFBS prediction programs facilitate identification of transcription factors 
that may be involved in the regulation of the gene of interest for subsequent 
experimental analysis. Unfortunately predictions are only as good as the 
underlying algorithms. For example, MatInspector failed to identify an Oct-1 site 
at -857 in the TNFα promoter which has been convincingly experimentally 
established (Hohjoh and Tokunaga 2001; van Heel, Udalova et al. 2002). In 
addition, these programs are limited because they have a reduced likelihood of 
detecting a transcription factor if it binds to a sequence as part of a larger 
complex (Cartharius, Frech et al. 2005). Nevertheless, these programs are a 
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useful guide for identifying potential TFBS involved in the regulation of the gene 
of interest.  
 
5.4.3. Factors influencing the observed changes in 
expression 
Previous studies have suggested that the segment of DNA 200 bp upstream of 
the transcription start site (TSS) (i.e. the core promoter) is sufficient to initiate 
maximum transcription of TNFα (Tsai, Falvo et al. 2000; Barthel, Tsytsykova et 
al. 2003). No polymorphisms have been described in the core promoter and the 
heritability of TNFα expression in monozygotic twins is 0.6 (Westendorp, 
Langermans et al. 1997). This suggests expression may be driven by polymorphic 
loci that alter transcription binding sites beyond this 200 bp region. This may 
predominantly be in the form of SNPs but other types of polymorphisms can 
also alter expression. For example, a recent study showed that the expression of 
IRGM, a gene involved in Crohn’s Disease risk, is regulated by a 20kb deletion 
that is 2.71kb upstream of the TSS of the gene (McCarroll, Huett et al. 2008). 
 
Environmental and cell specific signals may also impact upon the allele specific 
expression of SNPs so that relatively common polymorphisms only produce an 
effect in the presence of very specific signals. One example is a previous study 
of the TNFα -857 promoter SNP which found an allele specific difference in the 
expression of TNFα that was only evident in smokers, with no expression 
differences observed in non-smokers (Bennet, van Maarle et al. 2006).  
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5.4.3.1. The increased expression of haplotypes with the rare 
allele at -1031 
The individual SNP analyses revealed significantly different expression levels 
between the major and minor alleles at the -1031 SNP in Caco-2 cells. From 
figure 5.3, the TFBS that differ between alleles as a consequence of the -1031 
SNP include the presence of MECOM, GATA-2, GATA-3 and HSF1 sites with the 
common allele and THRB (T3R-β) occurring with the rare allele. MECOM (MDS1 
and EVI1 complex locus) can disrupt the functional consequences of TNFα by 
binding signalling proteins induced by TNFα, however there is no suggestion of a 
direct role for MECOM on TNFα expression (Kurokawa, Mitani et al. 2000; 
Wieser 2007). The GATA proteins function in hematopoietic, endothelial and T 
cell pathways and THRB is a thyroid hormone receptor (see appendix M); none 
of these functions are likely to be relevant to TNFα expression in the Caco-2 cell 
line.  
 
The -1031 SNP has not been studied as extensively as some of the other TNFα 
promoter SNPs such as -308 and -238 and so there is no experimental evidence 
for allele specific transcription factor binding at this locus. A recent study 
demonstrated decreased expression of a haplotype containing the rare alleles at 
both -1031 and -863 (i.e. analogous to 22111) compared to the haplotype 
including the common alleles (i.e. 11111) but functional studies revealed 
differential binding of transcription factors only at the -863 locus (Sharma, 
Sharma et al. 2006). A more recent study found homozygosity for the rare allele 
at -1031 was associated with increased serum TNFα compared to those without 
this allele (Sohail, Kaul et al. 2008), concordant with the results presented in this 
chapter.  
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Despite a lack of previous studies, the most likely candidate of the predicted 
TFBS changes at -1031 is HSF1 (heat shock factor 1) which is disrupted by the 
rare allele. HSF1 regulates genes in response to both heat and other cellular 
stresses and has been shown to bind to the murine TNFα promoter and reduce 
the expression of the gene under conditions of stress (Singh, He et al. 2002). If 
this pattern is also true in humans, then the absence of this site (with the rare 
allele) would lead to increased expression and this is consistent with the 
observations in this study. The results from the iron treated Caco-2 cells are 
mixed in terms of the support for HSF1 binding (assuming the stress of the 
excess iron induces HSF1 binding), with the 21112 haplotype showing increased 
expression compared to the other haplotypes (and therefore supporting a 
potential role for HSF1) but the 21111 haplotype having relatively low 
expression, opposing a role for HSF1. Further studies such as electrophoretic 
mobility shift assays (EMSA) could be performed (described below) to 
determine whether HSF1 is driving the allele specific expression seen at -1031 in 
both basal and iron induced stress conditions.  
 
5.4.3.2. Differential expression driven by -863? 
Single SNP analyses revealed the rare allele at -863 was associated with higher 
expression levels than the common allele under basal conditions (figure 5.1 and 
table 5.3). It was difficult to assess the true nature of this relationship as the 
rare allele occurred on only one haplotype (namely 22111) which also contained 
the rare allele at -1031. Nevertheless the 22111 haplotype showed a pattern of 
higher expression compared to the 21112 and 21111 haplotypes although this 
did not reach significance. The poor quality of the data for the 22111 haplotype 
in the iron treated Caco-2 cells makes interpretation of these results difficult but 
they suggest that the higher expression may be maintained with iron exposure. 
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There are a number of different TFBS that are predicted to be altered by the -
863 SNP (figure 5.3), some of which are known to influence TNFα expression. 
While GABP acts to enhance the expression of the murine TNFα gene, it does so 
through binding an intronic region rather than the promoter region (Tomaras, 
Foster et al. 1999). NFκB is essential for the expression of TNFα particularly in 
response to invading organisms, and while the rare allele at -863 eliminates an 
experimentally validated NFκB site (Skoog, Hamsten et al. 2006), previous 
studies found no expression differences between constructs containing the 
different -863 alleles in the presence of NFκB (van Heel, Udalova et al. 2002). 
None of the other predicted changes in TFBS’s (ZIC2, ZNF219, HMX3 or TFCP2) 
are likely to play a functional role in TNFα expression. Previously Oct-1 was 
found to preferentially bind to the rare allele (Skoog, Hamsten et al. 2006) and 
while this transcription factor is important in the response of TNFα to 
pathogens, the impact of Oct-1 is uncertain given that it has also demonstrated 
allele specific binding at the -857 SNP (van Heel, Udalova et al. 2002). Binding of 
Oct-1 at both -857 and -863 is associated with the rare alleles, which are 
present on exclusive haplotypes.  
 
5.4.3.3. Decreased expression with the rare allele at -308 
In the untreated Caco-2 cells, the expression of the rare allele at -308 was 
significantly associated with decreased expression levels compared to the 
common allele. Many previous studies have focussed on the -308 SNP with 
some suggesting no difference in the expression for the different alleles (Bayley, 
de Rooij et al. 2001; Kaijzel, Bayley et al. 2001) while others have suggested the 
rare allele is associated with increased TNFα expression (Kroeger, Carville et al. 
1997; Karimi, Goldie et al. 2009). There are a number of potential factors 
involved in differential expression, as outlined in figure 5.3. The transcription 
factors that are not present on the rare allele (AP-2α/β, Sp1 and MZF1) have all 
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previously been shown to have no binding role at the -308 SNP (Baseggio, 
Bartholin et al. 2004); however, that study was performed in monocytic and 
lymphocytic cells which may be differentially regulated compared to the Caco-2 
cells used in the current study. The other three predicted changes were to SPI-B 
(involved in dendritic cell development), VDR (vitamin D receptor) and PRDM5 
(a tumour suppressor gene and a transcriptional repressor) which were all 
present with the rare allele only. The function of PRDM5 as a transcriptional 
repressor (Meani, Pezzimenti et al. 2009) is consistent with the decreased 
expression of the haplotype with the rare allele, however PRDM5 has been 
shown to be down-regulated in a number of tumour types including colorectal 
and gastric cancer (Watanabe, Toyota et al. 2007) which may suggest that it is 
not functional in the Caco-2 cells.  
 
5.4.3.4. The 21112 haplotype and the influence on expression 
As the 21112 haplotype was associated with increased in vivo SF levels in the 
symptomatic C282Y homozygotes (chapter 4), the expression of this haplotype 
was of particular interest. The absolute expression of this haplotype was not 
markedly different from the other haplotypes, however the difference between 
its expression in the untreated and treated Caco-2 cells suggests that the 21112 
haplotype may not be able to respond to iron challenge to the same extent as 
the other haplotypes. While the significance of this difference remains to be 
determined, if it was validated then elucidating a possible mechanism may 
prove vital to understanding the increasingly complex patterns of TNFα 
regulation as both a modifier of iron stores in HH and in other diseases.  
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5.4.4. TNFα and iron homeostasis 
5.4.4.1. Overview of iron absorption and homeostasis 
An overview of iron absorption is outlined in chapter 1 (section 1.1.1.2) and in 
figure 1.2. Briefly, non-heme iron (Fe3+) in the intestinal lumen is reduced to Fe2+ 
by CYBRD1 and transported into the enterocyte via DMT1. Here it enters the 
labile iron pool where it can be stored in H-ferritin (FTH) or L-ferritin (FTL), 
utilised by the cell or exported out of the cell via FPN1. Just after transportation 
through FPN1, the iron is oxidized back to Fe3+ and binds to transferrin (TF). TF-
bound iron is then endocytosed by other cells via interactions with TFRC. The pH 
within the endosome causes transferrin to release the iron which is reduced to 
Fe2+ and transported out into the cytoplasm via DMT1. The iron is utilised, 
stored in ferritin or exported out of the cell via FPN1 and HFE, TFRC and TFR2 
are recycled back to the cellular membrane and TF is returned to the blood. As 
there is no physiological pathway for the excretion of iron, the uptake must be 
tightly regulated and the central regulator of this process is hepcidin. This 
protein is predominantly produced by the liver and binds and internalises FPN1 
on the enterocyte cell membrane which reduces iron efflux into the body.  
 
5.4.4.2. TNFα influence on iron homeostasis  
TNFα and iron are involved in a complex feedback system whereby TNFα alters 
iron levels via regulation of iron transport and storage proteins, iron influences 
TNFα levels via an unspecified pathway, and TNFα also regulates its own 
expression (Falvo, Tsytsykova et al. 2010). Cell lines have been utilised to help 
elucidate tissue specific roles of TNFα although there is some suggestion that for 
iron homeostasis, cell lines in isolation are unable to respond to iron challenge 
in the same manner as cells in vivo (Jacolot, Ferec et al. 2008). However, results 
from individual cell line studies have simply reinforced the complex relationship 
of iron and TNFα with not only tissue specific effects, but also concentration (of 
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both iron and TNFα) and incubation time effects. It is likely that proteins such as 
HFE can induce opposite effects depending on the cell type in which they are 
acting (Davies and Enns 2004). It is also likely that the effects can be 
differentiation-stage dependent with monocytes responding to iron by 
increased or decreased TNFα levels depending on their stage of differentiation 
(Scaccabarozzi, Arosio et al. 2000).  
 
Despite these issues, data produced from enterocytes suggest that increased 
TNFα (in an iron replete situation) decreases iron absorption by down-
regulating DMT1, TFRC and FPN1 (Johnson, Bayele et al. 2004; Ludwiczek, 
Theurl et al. 2004). In hepatocytes, TNFα increases iron absorption by increasing 
DMT1, TFRC and FTH (Hirayama, Kohgo et al. 1993; Tran, Eubanks et al. 1997; 
Ludwiczek, Theurl et al. 2004) and also chronic iron loading in the liver increases 
TNFα expression (Brown, Mathahs et al. 2006). In macrophages, TNFα induces 
cellular iron retention by up-regulating FTH and DMT1 but down-regulating 
TFRC and FPN1 (Fahmy and Young 1993; Ludwiczek, Aigner et al. 2003). In 
biological terms, TNFα decreases the amount of iron being absorbed from the 
diet while encouraging retention of iron in the macrophages with increased 
traffic to the liver where iron is incorporated into ferritin. This is consistent with 
the induction of hypoferremia (low serum iron) by TNFα as a mechanism to 
prevent replication by invading pathogens (Pieracci and Barie 2005) and 
suggests that the immune and iron regulatory pathways of TNFα are closely co-
regulated.  
 
5.4.4.3. TNFα and haemochromatosis 
This balance of TNFα and iron is impaired in HH with low basal serum TNFα 
levels (Gordeuk, Ballou et al. 1992) and expression of DMT1 and FPN1 in the 
duodenum at levels which mimic those seen in iron deficiency anaemia (IDA) 
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patients (i.e. those trying to promote iron uptake) (Stuart, Anderson et al. 
2003). Functional HFE is required to mediate hypoferremia in response to LPS, 
(Roy, Custodio et al. 2004) probably via a TNFα mediated pathway, and the lack 
of functional HFE in HH explains the altered TNFα expression levels. The non-
functional HFE also disrupts hepcidin signalling in HH (Bhatt, Horgan et al. 2009) 
and suggests the presence of an important feedback loop involving iron, TNFα 
and hepcidin.  
 
The results presented in this chapter indicate that compared to the common 
allele, rare alleles at both -1031 and -863 in the TNFα promoter may increase 
TNFα expression in Caco-2 cells and that the rare allele at -308 may decrease 
expression. While the specific factors responsible for this differential regulation 
remain elusive, the effect this has on the iron regulatory pathway in HH can be 
explored. As described above, normal (i.e. not affected by HH) enterocytes 
exposed to TNFα should decrease iron absorption thus decreasing bodily iron 
load. From chapter 4, the rare allele at -1031 (particularly as part of the 21112 
haplotype) is associated with increased SF levels and increased bodily iron 
stores, the opposite effect to what is expected based on the increased 
expression of this allele in the luciferase results. However a ‘normal’ response 
cannot be initiated in HH as the mutant HFE disrupts normal signalling processes 
and so these cells cannot respond appropriately to TNFα to decrease iron 
uptake. There is still likely to be some function retained, otherwise patients with 
HH would present at a much earlier age, so there is merely a reduced response 
compared to normal. When the cells were treated with high levels of iron, the 
21112 haplotype was unable to respond to the extent that the other haplotypes 
could. If there is already a dampened response due to the C282Y mutation, a 
haplotype that further impairs this response will exacerbate the negative effects 
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of it. In this case, further impairment of the cell’s ability to decrease iron 
absorption will result in an increase in iron loading over time.  
 
5.4.5. Future directions 
There are many questions concerning the role of TNFα in HH that future studies 
should address, which are beyond the scope of this study. Firstly replication of 
the association of the TNFα promoter haplotype with increased SF in a larger 
population of HH patients is essential. The population would need to be 
stratified as it has been in this study, with analysis by gender and also 
separation of asymptomatic and symptomatic C282Y individuals. It would also 
be interesting to address whether TNFα behaves as a modifier in the different 
Hfe KO strains of mice that exhibit differential iron loading in a more 
comprehensive study than that previously performed (Iraqi and Teale 1999). 
That particular study searched for promoter SNPs in twelve mouse strains via 
restriction enzyme digestion, so a study to sequence these regions is more likely 
to identify promoter polymorphisms.  
 
The SNPs associated with altered expression of TNFα in this study (namely -
1031, -863 and -308) need to be explored further in terms of whether there is 
allele-specific binding of transcription factors causing the altered expression. 
While this has been addressed previously for other TNFα promoter SNPs, 
especially -308 and -857 (van Heel, Udalova et al. 2002; Baseggio, Bartholin et 
al. 2004), there is little information regarding transcription factor binding at -
1031 and -863 particularly in tissues relevant to iron homeostasis in response to 
variable environmental iron. The -308 SNP also has not been fully examined in 
these cell types or conditions so it would be important to include this SNP in 
future studies. Electrophoretic mobility shift assays (EMSA) involve the 
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incubation of nuclear extracts (containing the protein/transcription factors) with 
allele specific probes to the loci of interest and stabilisation of the protein-DNA 
interactions. Samples are then electrophoresed and differences in the migration 
of DNA with and without protein bound allows for the detection of allele 
specific transcription factor binding at a particular locus (Hart, Haugen et al. 
2008). The nuclear extracts used in EMSA allow for cell and stimulus specific 
differences in transcription binding to be determined. To further evaluate TNFα 
in iron loading, it would be pertinent to examine hepatic tissue, duodenal 
enterocytes and monocytic cell types under conditions where iron was low, 
replete and high in both normal and haemochromatotic tissues. If any allele 
specific differences are noted, antibodies specific to the transcription factor of 
interest can be incorporated into the EMSA assay to confirm interaction of the 
factor with the promoter. Another method based on similar principles is DNase I 
footprinting (Cardew and Fox 2010). 
 
The above methods may demonstrate allele specific binding, but they do not 
necessarily identify the consequences of the binding in terms of the expression 
differences between the alleles. Few methods are able to quantitate transcript 
levels associated with promoter polymorphisms unless they are in LD with a 
transcribed polymorphism, however one method that can do this is haploChIP 
analysis (Knight, Keating et al. 2003). Standard ChIP (chromatin 
immunoprecipitation) involves treating cells to crosslink the proteins to the 
DNA, isolating the nuclear cell fraction, sonication to fragment the DNA, 
followed by purification of the chromatin. Specific antibodies are then used to 
pull down DNA associated with the protein of interest. HaploChIP uses 
antibodies against specific phosphorylated residues on the RNA polymerase II 
enzyme that are exclusively associated with initiation of transcription, thereby 
immunoprecipitating active promoters only. The protein in the 
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immunoprecipitated complexes is removed via digestion and the allelic ratio of 
the remaining DNA fragments can be quantitated. There are a number of ways 
to perform the quantification including mass spectrometry, but allele-specific 
PCR methods can also be employed and may be more accessible than mass 
spectrometry. The haploChIP method is advantageous over the other 
mentioned methods as it can utilise the whole promoter haplotype or individual 
SNPs as required – it must, however, be performed in heterozygous cells. Again 
the nature of both the tissue and the stimulus used are important in application 
of the results to a biological setting so both must be accounted for when 
assessing the role of TNFα as a modifier gene in HH.  
 
5.5. Conclusions 
The results presented in this chapter address the functional consequences of 
the TNFα promoter SNPs in an in vitro luciferase assay based system. Results 
from the Caco-2 cell line indicate that rare alleles at both -1031 and -863 may 
increase expression of the TNFα gene while the rare allele at -308 may decrease 
the expression. In silico analysis identified HSF1 at the -1031 SNP as a potential 
regulator of this difference, with no clear candidate at -863 or -308. The 
haplotype analysis revealed that the 21112 haplotype appears to have a 
decreased response to iron challenge compared to the other haplotypes, but 
the overall expression levels were not different. A mechanism through which 
this response could account for the increased SF observed in symptomatic 
C282Y homozygotes possessing this haplotype (chapter 4) is presented as well 
as a number of future studies to confirm these associations and validate TNFα 
as a modifier gene in HH.  
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6. Chapter 6. Expression studies on selected genes 
in the iron metabolic pathway  
6.1. Introduction 
The variable penetrance of the C282Y mutation in HH may be the consequence 
of polymorphisms in other genes in the iron pathway. Previous studies have 
sequenced genes including HAMP, TFRC, TFR2, DMT1, FTH1, FTL, FPN1 and 
CYBRD1 in HH patients but failed to identify any polymorphisms associated with 
the penetrance of the C282Y mutation (Lee, Gelbart et al. 2001; Lee, Gelbart et 
al. 2002). Genome-wide studies have also implicated SNPs within iron metabolic 
pathway genes; and this is discussed in chapter 3. One approach that has been 
under-utilised in the search for modifier genes is the analysis of expression 
levels to identify differentially regulated genes in HH which might contribute to 
the variable penetrance of the C282Y mutation. One impediment to the 
application of this technique is in obtaining both appropriate tissue(s) as well as 
a suitable number of samples. Since haemochromatosis is a disease of iron 
absorption and storage, duodenal biopsies would be the ideal tissue but are 
rarely collected in HH. On the other hand, liver biopsies have historically been 
taken more frequently, but are likely to be compromised since the biopsy is 
taken specifically to determine the extent of liver damage. Even if these tissues 
were available, it is extremely difficult to obtain well matched control samples 
for comparison. One method to circumvent these problems of sample 
attainment is the use of lymphoblastoid cell lines (LCLs) which can be 
established from blood samples from both patients and controls. The collection 
of blood is far less invasive than biopsies and the immortalised B lymphocytes 
are a perpetual source of DNA, RNA and are also amenable to experimental 
manipulation.  
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A method for establishing LCLs was developed nearly forty years ago (Glade and 
Broder 1971). Several studies have supported the use of LCLs in expression 
based studies (Cheung, Conlin et al. 2003; Bolt, Douglas et al. 2010; Hartman, 
Pelleymounter et al. 2010). Advantages of this in vitro system include the 
genome wide range of polymorphisms that can be studied and the study of 
genes in an intact cell approach rather than genetic constructs. More recently, 
the use of LCLs as a pharmacogenetics tool for assessing the effectiveness of 
certain drugs relative to different genetic polymorphisms is becoming 
increasingly common (Shukla and Dolan 2005; Morag, Kirchheiner et al. 2010). 
In the current study, LCLs were treated with iron and the responses in the 
expression of a number of genes in the iron pathway were measured to 
determine whether any genotype or phenotype correlations could be 
established in HH patients compared to controls.  
 
6.2. Materials and Methods 
6.2.1. Samples 
All LCLs were established in the laboratory between 2005 and 2009, and were 
from the blood of male subjects who were recruited to the Canberra Region 
Haemochromatosis database or were recruited as blood donors at the ARCBS. 
Once transformed, cells were stored in the vapour phase of liquid nitrogen until 
they were required. See sections 2.2.4 and 2.2.5 for detailed information on the 
preparation and storage of cell lines. The properties of the samples used are 
presented in table 6.1 in terms of HFE genotype, TNFα haplotype and the 
presence or absence of symptoms of HH in the C282Y homozygotes. The 
numbers differ slightly from those analysed in chapter 4 as not all samples were 
available for generation of cell lines, or blood was available but the 
transformation process failed. This chapter also includes samples for which 
there was incomplete data for the full analysis in chapter 4. The overall number 
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of C282Y homozygotes is higher than the other samples to allow a more in-
depth analysis of the TNFα haplotype and the symptomatic phenotype in these 
samples.  
 
Table 6.1. The properties of the LCLs used in the current study including HFE genotype, 
TNFα haplotype and the presence of symptoms in the C282Y homozygotes. All samples 
were male.  
 Controls  
(CC) 
C282Y heterozygotes 
(CY) 
C282Y homozygotes 
(YY) 
Number 
Symptomatic 
Asymptomatic 
TNFα 21112 haplotype 
 •Symptoms/no symptoms 
Other TNFα haplotype 
 •Symptoms/no symptoms 
8 
-  
-  
4 
-  
4 
-  
10 
-  
-  
2 
-  
8 
-  
18 
13 
5 
9 
5/4 
9 
8/1 
 
6.2.2. Determination of the iron dosage range for the 
LCLs 
The cellular response to iron load was assessed by dosing the cells with Ferric 
ammonium citrate (FAC) as a surrogate for non-heme (Fe3+) iron. Optimal 
experimental conditions were identified by incubating the cells with varying 
concentrations of FAC across a number of different time points and assessing 
cell viability (via trypan blue exclusion) with increasing iron concentrations. The 
iron did not affect cell viability (data not shown) and two concentrations were 
chosen based on the ranges used in previous studies (0.2mM) (Qi, Jamindar et 
al. 1995; Park, Lee et al. 2000; Fargion, Valenti et al. 2001) and to replicate 
conditions of extreme iron overload (5mM). A preliminary set of experiments 
were used to determine time of exposure: a subset of cells were treated with 
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the iron across four time points (2 hr, 6 hr, 12 hr and 24 hr) and the expression 
of all genes involved in the study was measured by qPCR. The results from the 6 
hr incubation time appeared to produce the most consistent results (data not 
shown) and this time point was utilised in the experimental protocol.  
 
6.2.3. Growth and iron treatment  
LCLs were revived from liquid nitrogen (see section 2.2.5.5) and grown in 
antibiotic free media (see appendix F) as previous studies have suggested an 
interaction between penicillin and iron (Conrad, Umbreit et al. 1994). Once cells 
had reached at least 2.0 x 107 cells they were plated in eight wells each of a 24 
well culture plate (MP Biomedicals, Solon USA, cat#76-063-05) at 2x106 
cells/well in 0.5ml media. Cells were incubated under standard conditions (37°C 
10% CO2) for at least 12 hrs. After this time, 0.5ml of fresh media was added as 
well as concentrated FAC (made up in sterile water) or sterile water to produce 
final FAC concentrations of 5mM, 0.2mM and 0mM. Cells were returned to the 
incubator for 6 hrs before harvesting. Foetal calf serum (FCS) contains trace 
amounts of iron and to ensure results were not affected by differences in FCS; 
one batch of media was prepared and used for all experiments. This supplement 
was not excluded from the growth media because the absence of FCS may 
impact on cell growth and viability.  
 
After the 6 hr incubation, cells were collected into sterile 10ml tubes, vortexed 
to a single cell suspension and a 10 µl aliquot was counted. Cells were washed 
with cold 1XPBS (appendix D), centrifuged for 5 min at 1100 RPM at 10°C 
(Beckman Coulter Allegra R6 centrifuge). Cells were then resuspended in 
approximately 1 ml of 1XPBS and transferred to a 1.5 ml tube being centrifuged 
at 13200 RPM at 4°C for 5 min to pellet the cells. The PBS was discarded and 
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cells were resuspended in 0.5 ml RNAlater and stored at -70°C until the RNA was 
extracted.  
 
6.2.4. RNA extraction and cDNA synthesis 
RNA extraction was carried out as per section 2.2.8 and quantified using a 
spectrophotometer. In order to determine the amount of RNA required for the 
expression analyses, amounts from 50-500 ng were used as a template in the 
cDNA reaction (section 2.2.8.2), diluted 1:10 with sterile DEPC-water and the 
expression analyses of all genes used in this study were performed. A quantity 
of 200 ng of RNA was sufficient for detecting expression of all assays in the cell 
lines tested and thus this amount was used as a template in the cDNA reaction 
for all the samples.  
 
6.2.5. Real time PCR 
6.2.5.1. Performing the assays 
All real time PCRs were carried out on the Applied Biosystems 7300 system and 
performed in at least triplicate for each sample in 96 well plates. The 18S RNA 
was used as the endogenous control gene as previous work in the laboratory 
established this as the most appropriate control in LCLs (unpublished results). 
The gene of interest (GOI) was multiplexed with the 18S RNA assay in each well. 
The expression levels of HFE, TFRC, TFR2, HAMP and TNFα were measured and 
the amplification conditions are presented in appendix G. All assays were 
purchased from Applied Biosystems. If multiple assays were available for any 
gene, the assay that detected all transcripts was purchased and if not, the assay 
covering the largest number of transcripts was chosen.  
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6.2.5.2. Calculating ∆CT values 
To allow comparisons between plates, at least one sample per plate was 
duplicated on another plate. The automated analyses did not produce 
consistent results so the expression threshold and baseline for each gene were 
set manually. Thus all results for a particular gene analysed with a single 
threshold and baseline. The threshold value is an arbitrary point determined 
empirically for each gene and was set in the logarithmic phase of the 
amplification at a point which minimised the intra-sample variation. The 
baseline value reflects background fluorescence and this value was set based on 
information in the Applied Biosystems Relative Quantification Getting Started 
Guide available on the Applied Biosystems website (appendix A).  
 
Once the baseline and threshold had been set, the ∆CT value was calculated for 
each well by subtracting the threshold value for 18S (i.e. the cycle number at 
which the 18S gene crosses the set threshold) from the threshold value of the 
GOI (see table 6.3). Samples were repeated if the ∆CT values for the triplicate 
wells were not within 1 cycle of each other, including failure to amplify. The 
∆CTs were then averaged for use in the analyses. The standard deviation of the 
CT’s for each gene within a sample were used to generate the standard 
deviation of the ∆CT as recommended by Applied Biosystems using the formula 
outlined below. An example is given in table 6.2. Samples were repeated if the 
standard deviation exceeded 0.5.  
Standard deviation (s.d.) ∆CT = ((s.d. 18S)2 + (s.d. GOI)2)1/2 
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Table 6.2. An example of the calculation used to generate the standard deviation (s.d.) 
for the ∆CT values. GOI = gene of interest.  
 18S GOI 
s.d. 0.094 0.310 
(s.d.)2 0.0088 0.0961 
(s.d. 18S)2 + (s.d. GOI)2 0.104936 
((s.d. 18S)2 + (s.d. GOI)2)1/2 0.324 
 
6.2.5.3. Calculation of the relative expression (2-ΔΔCT) 
The 2-ΔΔCT method was utilised to determine the effect of iron on the expression 
of each gene. For each of the cell lines, the average ∆CT value was calculated for 
each experimental condition (no iron, 0.2mM FAC or 5mM FAC). To generate 
the -∆∆CT value, the average ∆CT value for the basal (i.e. no iron) conditions 
was subtracted from each of the FAC treatment ∆CTs. The negative of this value 
was taken and the relative expression was calculated as 2-∆∆CT. Results were 
graphed using a logarithmic scale. An example calculation is outlined in table 
6.3. 
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Table 6.3. The steps involved in the calculation of the relative expression (2-∆∆CT) of 
genes in response to iron using an example from the results. Note that within both the 
basal and iron treated conditions, the ∆CT values are no more than one cycle apart. 
Calculation Basal conditions Iron treatment 
∆CT 
(GOI – 18S) 
31.34 – 20.45 = 10.89 
31.95 – 20.51 = 11.44 
31.74 – 20.33 = 11.41 
34.37 – 19.91 = 14.46 
34.73 – 20.21 = 14.52 
34.44 – 20.22 = 14.22 
Average ∆CT 11.25 14.40 
∆∆CT 14.40 – 11.25 = 3.15 
-∆∆CT -3.15 
2-∆∆CT 0.112656 
 
6.2.6. Analysis and statistics 
∆CT values from cells under basal conditions may be compared to determine 
whether there are differences in the basal expression of the genes as a 
consequence of either genotype or phenotype in terms of the presence or 
absence of symptoms. The appropriate comparison for determining differential 
response to iron load is to compare 2-∆∆CT values (Applied Biosystems, ‘Guide to 
Performing Relative Quantitation of Gene Expression Using Real-Time 
Quantitative PCR). That is, the magnitude of expression change in each cell line 
in response to iron in relation to the expression levels under basal conditions, 
with a value of 1 indicating no change in the expression level. The expression of 
each gene was analysed in the context of HFE genotypes at C282Y, TNFα 
promoter haplotype (across all samples and also within the C282Y 
homozygotes) and between symptomatic and asymptomatic C282Y 
homozygotes. Unpaired t-tests were performed on the means to compare 
results for both basal and iron treatment expression. To determine whether 
there was a difference in the response between the 0.2mM and 5mM FAC 
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treatments, paired t-tests were performed. A p value less than 0.05 was 
considered significant for both types of t-test. 
 
A Grubbs test was performed on all values (both ∆CT and 2-∆∆CT) before analysis 
to remove any outliers with results considered significant at p<0.01. This p value 
was used because the data is generated from multiple individuals rather than 
being replicates of the same sample, so a lowered p value was used to allow 
biological variability.  
 
6.3. Results 
Due to the complexity of the data presented in this chapter, a summary of the 
results is presented first (in section 6.3.1) followed by a more in-depth analysis. 
For simplicity, analyses performed that did not produce significant results are 
presented in Appendices N-R. The omission (if any) of samples as outliers is 
indicated in the relevant gene analyses. There was one sample from the 5mM 
FAC treatment which was not included in any of the analyses as the RNA quality 
was unsatisfactory.  
 
For all subsequent analyses, it is important to note that a reduced ∆CT value 
indicates increased expression of the GOI as it reflects detection of the product 
at an earlier cycle in the PCR reaction. In all figures, the number of samples 
analysed is indicated in parentheses after the group descriptor.  
 
6.3.1. Variable expression of the genes 
The ∆CT values from all cell lines under basal, 0.2mM FAC and 5mM FAC 
conditions are outlined in figure 6.1. These figures were generated by  
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Figure 6.1. The distribution of the ∆CT values for each of the genes, under basal 
conditions (A), with 0.2mM FAC (B), and with 5mM FAC (C). The x-axes represent the 
∆CT values (GOI – 18S) which are grouped by 0.5 cycle units to aid visualisation. The y-
axes represent the number of samples that had a ∆CT in the particular range.  
 
0
2
4
6
8
10
12
14
16
n
∆CT
Basal gene expression
TNFα TFR2
TFRC HFE
HAMP
0
2
4
6
8
10
12
14
16
n
∆CT
Gene expression, 0.2mM FAC
TNFα TFR2
TFRC HFE
HAMP
0
2
4
6
8
10
12
14
16
n
∆CT
Gene expression, 5mM FAC
TNFα TFR2
TFRC HFE
HAMP
A 
C 
B 
130 
 
categorising the samples based on their ∆CT in 0.5 cycle groups and counting 
the number of samples within each group. The critical information in these 
graphs is the distribution pattern and range of expression for each gene across 
thirty six cell lines with and without iron treatment. The distributions of TFRC 
and TNFα were almost identical under basal conditions, while TFR2 showed a 
similar distribution pattern but was expressed at lower levels as the curve is 
shifted to the right (indicating higher ∆CT values). The expression pattern of 
these three genes approximates a normal distribution. The distributions of both 
HFE and HAMP expression were much broader and much lower than TFRC, TFR2 
and TNFα. The expression pattern of TFRC was reduced substantially with iron 
treatment, but changes in the other genes in response to iron were not as 
evident. 
 
6.3.2. Expression of HFE in LCLS 
HFE is not very abundant in LCLs as indicated by the high ∆CT values, especially 
when compared to TNFα, TFRC and TFR2. The ∆CT values for both the basal 
expression and the expression in response to iron are presented in figure 6.2, as 
well as the expression of HFE when the samples are separated by HFE genotype. 
It is difficult to compare the distribution of the ∆CT values between the different 
genotypes due to the low sample number in the controls and heterozygotes. 
There were no outliers present in the data. Non-significant results are presented 
in appendix N.  
 
6.3.2.1. Expression of HFE under basal conditions 
To determine whether there was a difference in the basal expression of HFE 
based on HFE genotype, the ∆CT values from each genotype were pooled and 
compared via a t-test. There were no significant differences. There were also no 
significant differences in the basal expression of HFE between symptomatic and  
131 
 
  
 
 
Figure 6.2. The distribution of the ∆CTs for HFE expression in LCLs. Results are 
presented for all samples (A), controls that do not contain the C282Y mutation (B), 
C282Y heterozygotes (C); and C282Y homozygotes (D). The values for the x-axis in 
graphs B-D are identical to that in A which represents the ∆CT in 0.5 cycle groups. In all 
graphs the blue line represents the data generated from basal conditions, the purple 
line represents cells treated with 0.2mM FAC and the green line represents the results 
from cells treated with 5mM FAC.  
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asymptomatic C282Y homozygotes, and the presence or absence of the TNFα 
21112 haplotype also did not impact upon the expression of HFE. 
 
6.3.2.2. Expression of HFE in response to iron 
Comparisons of the 2-∆∆CT values for HFE expression in response to 0.2mM FAC 
showed a significant difference between the controls and the C282Y 
heterozygotes (p=0.0276). The expression in the control cells was slightly 
increased on average and both the C282Y heterozygotes and the C282Y 
homozygotes showed an average decrease in the expression of HFE (figure 6.3), 
which was much more pronounced in the heterozygotes. The relative 
expression of the controls and the C282Y homozygotes was not significantly 
different (p=0.2904).  
 
 
Figure 6.3. The expression of HFE in LCLs treated with 0.2mM FAC relative to the 
untreated cells. Samples were grouped based on their HFE genotype where CC 
represents the controls that do not possess C282Y, CY are the C282Y heterozygotes 
and YY the homozygotes for C282Y. The relative expression of the C282Y 
heterozygotes was significantly lower than the controls (p=0.0276, marked with an 
asterisks). Error bars represent the SEM. The number of samples analysed in each 
group is indicated in parentheses after the group name.  
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As shown in Chapter 4, the presence of the 21112 TNFα promoter haplotype 
was associated with increased SF levels in C282Y homozygotes. In cells treated 
with 0.2mM FAC the relative expression of HFE was found to be significantly 
higher in samples with the TNFα 21112 haplotype compared to those without it 
(p=0.0201, figure 6.4). The iron loaded samples with the 21112 haplotype 
demonstrated little change in the expression compared to basal conditions, 
whereas the samples without the haplotype had reduced HFE expression. This 
analysis was performed on all samples, irrespective of HFE genotype (this group 
consisted of 9/15 or 60% C282Y homozygotes). When the HFE genotypes were 
analysed separately for any effect of the 21112 haplotype, there were no 
significant differences; however, the average relative expression level for the 
21112 samples was higher than that of the other samples in all cases, consistent 
with the combined data.  
 
 
Figure 6.4. The average relative expression of HFE in response to 0.2mM FAC with 
respect to the TNFα 21112 promoter haplotype. All samples were included in the 
analysis, irrespective of HFE genotype. There was a significant difference in the relative 
expression between the two groups (p=0.0201). Error bars represent the SEM. The 
number of samples analysed in each group is indicated in parentheses after the group 
name. 
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None of the other associations tested produced significant results, including all 
analyses performed on the data from the 5mM FAC treatment which perhaps 
reflects the increased (albeit slight) variability in HFE expression at 5mM (see 
figure 6.2). Paired t-tests to measure whether the expression responses were 
different at 0.2mM and 5mM yielded no significant results (data not shown).  
 
6.3.3. Expression of TFRC in LCLs 
The expression of TFRC, along with TNFα, was the highest of the genes tested 
under basal conditions. Its expression is quite obviously affected by the 
presence of iron in the media with a decrease in expression as indicated by 
increased ∆CT values (figure 6.5). This pattern is clearly observed in the C282Y 
homozygotes, although it is less clear for the other HFE genotypes. Non-
significant results are presented in appendix O. 
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Figure 6.5. The distribution of the ∆CTs for TFRC expression in LCLs. Results are 
presented for all samples (A), controls that do not contain the C282Y mutation (B), 
C282Y heterozygotes (C); and C282Y homozygotes (D). The values for the x-axis in 
graphs B-D are identical to that in A which represents the ∆CT in 0.5 cycle groups. In all 
graphs the blue line represents the data generated from basal conditions, the purple 
line represents cells treated with 0.2mM FAC and the green line represents the results 
from cells treated with 5mM FAC. 
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6.3.3.1. Expression of TFRC under basal conditions 
Comparisons of the ∆CT values for TFRC under basal conditions revealed a 
significantly higher expression (i.e. a lower ∆CT) in the C282Y heterozygote 
samples compared to the rest of the samples (p=0.0126, figure 6.6). The 
expression of the controls and the C282Y homozygotes was very similar, but 
only the homozygotes were significantly different from the heterozygotes. This 
may be a reflection of the lower sample numbers for the controls (eight 
samples) and the heterozygotes (ten samples) compared to the C282Y 
homozygotes (eighteen samples). There were no significant differences in the 
basal expression for any of the other associations tested.  
 
 
Figure 6.6. The basal expression levels of TFRC in LCLs of different HFE genotypes. The 
C282Y heterozygotes (CY) had a significantly higher expression level (i.e. a lower ∆CT 
value) when compared to the pooled controls (CC) and C282Y homozygotes (YY). This 
is indicated by the asterisks (p=0.0126). Error bars represent the SEM. The number of 
samples analysed in each group is indicated in parentheses after the group name. 
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6.7A). A closer inspection of the C282Y homozygotes revealed no significant 
difference between the asymptomatic and symptomatic samples, but the 
samples that possessed the TNFα 21112 haplotype showed a significantly 
reduced response compared to those that did not possess this haplotype 
(p=0.0304, figure 6.7B). Furthermore, the C282Y homozygotes with the 21112 
haplotype who were also symptomatic had a significantly reduced response 
compared to the asymptomatic C282Y homozygotes with the 21112 haplotype 
(p=0.0483, figure 6.7C). This provides additional evidence that the TNFα 21112 
haplotype can modify the HH phenotype and that it is moderated at least in part 
through the TFRC gene.  
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Figure 6.7. The relative expression of TFRC in response to 0.2mM FAC in LCLs by HFE 
genotype (A), in C282Y homozygotes with or without the TNFα 21112 haplotype (B) 
and in C282Y homozygotes with the 21112 haplotype with the presence or absence of 
symptoms (C). Asterisks indicate a significant difference between the marked sample 
and the other groups within the graph. Error bars represent the SEM. The number of 
samples analysed in each group is indicated in parentheses after the group name. 
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heterozygotes showed no difference in expression levels between the two iron 
concentrations and the overall response in the C282Y homozygotes was to 
decrease expression (closer to a normal response), but this reduction was 
significantly different only from the levels at 0.2mM FAC in the C282Y 
homozygotes with the 21112 TNFα haplotype who were symptomatic 
(p=0.0055) (figure 6.8B). That is, none of the other C282Y homozygotes showed 
a significant difference in their TFRC expression response at 0.2mM and 5mM 
FAC. This indicates that the modification of the TFRC response in samples with 
the TNFα 21112 haplotype is dependent upon the concentration of iron.  
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Figure 6.8. The relative expression changes of TFRC due to the different FAC 
concentrations, by HFE genotype (A) and in C282Y homozygotes with the TNFα 21112 
haplotype (B). CC are the controls without the C282Y mutation, CY are heterozygous 
for C282Y and YY are the homozygotes for C282Y. Asterisks indicate the response at 
5mM FAC was significantly different to that at 0.2mM FAC. Error bars represent the 
SEM. The number of samples analysed in each group is indicated in parentheses after 
the group name. 
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6.3.4. Expression of HAMP in LCLs 
The HAMP assay was not as robust as the other assays, with a considerable 
degree of variability in the expression both within and across samples. This may 
have been an inherent quality of the assay itself or of the LCL model. Five 
samples were omitted in entirety as the results for the basal expression failed to 
meet the stringent limits placed upon the data (as outlined in section 6.2.5., 
page XX). One sample produced highly variable results at the 0.2mM treatment 
and was omitted but was included in the basal expression and 5mM analysis. 
Outlier analysis of the relative expression results at 0.2mM revealed that three 
of the thirty samples could be statistically classified as outliers. Omission of 3/30 
or 10% of the samples as outliers seems unreasonable and may suggest that 
there is a biological reason for the altered expression. As a result no samples 
were omitted from the analyses at 0.2mM. There was one sample that was 
omitted as an outlier from the 5mM FAC analyses. The variability across samples 
in the expression pattern of HAMP is shown in figure 6.9. There is no obvious 
peak for the basal and 0.2mM FAC treatments when all samples are analysed 
together or when grouped by HFE genotype. Non-significant results are 
presented in appendix P. 
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Figure 6.9. The distribution of the ∆CTs for HAMP expression in LCLs. Results are 
presented for all samples (A), controls that do not contain the C282Y mutation (B), 
C282Y heterozygotes (C); and C282Y homozygotes (D). The values for the x-axis in 
graphs B-D are identical to that in A which represents the ∆CT in 0.5 cycle groups. In all 
graphs the blue line represents the data generated from basal conditions, the purple 
line represents cells treated with 0.2mM FAC and the green line represents the results 
from cells treated with 5mM FAC. The number of samples analysed in each group is 
indicated in parentheses after the group name. 
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6.3.4.1. Expression of HAMP under basal conditions 
Analysis of the ∆CT values of HAMP under basal conditions revealed the 
expression of the C282Y heterozygotes was higher than the C282Y homozygotes 
(p=0.0298) (figure 6.10). Despite the control samples having a higher average 
∆CT than the C282Y homozygotes, the difference between the controls and the 
heterozygotes was not significant, most likely because the control group 
contained only five usable samples.  
 
 
Figure 6.10. The expression of HAMP under basal conditions, analysed by HFE 
genotype. The C282Y heterozygotes had significantly higher expression (i.e. lower ∆CT) 
than the C282Y homozygotes (p=0.0298, indicated by the asterisks), but not the 
controls and may be a consequence of low sample numbers in the controls and 
heterozygotes. Error bars represent the SEM. The number of samples analysed in each 
group is indicated in parentheses after the group name. 
 
The basal expression levels of HAMP were also increased in symptomatic C282Y 
homozygotes that possessed the TNFα 21112 haplotype compared to the 
asymptomatic samples of the same genotype (p=0.042, figure 6.11). Again, 
given the inconsistencies surrounding this assay, this result must be taken with 
caution, but it would help explain the increased SF observed in the symptomatic 
19.50
20.00
20.50
21.00
21.50
22.00
22.50
23.00
23.50
24.00
CC (n=5) CY (n=10) YY (n=16)
∆
C
T
HFE genotype
Basal HAMP expression
* 
* 
144 
 
samples. There were no other significant differences in the expression of HAMP 
under basal conditions. 
 
 
Figure 6.11. The average basal expression of HAMP in C282Y homozygotes that 
possess the TNFα 21112 promoter haplotype, with and without the presence of 
symptoms. Sample numbers are indicated in brackets after the group description. The 
expression of samples that presented with symptoms was significantly higher than 
those without symptoms as indicated by the asterisks. The number of samples 
analysed in each group is indicated in parentheses after the group name. 
 
6.3.4.2. Expression of HAMP in response to iron 
Samples that possessed at least one copy of the C282Y mutation had a reduced 
response to iron in terms of HAMP expression when compared to the control 
samples (p=0.0487, figure 6.12). The control cell lines (no C282Y mutation) on 
average displayed two times the HAMP expression compared to basal 
conditions whereas the samples with the C282Y mutation (one or two copies) 
barely increased the expression. The error bars on the control cells are large as 
there were only five samples in this group. 
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Figure 6.12. The difference in HAMP expression response to iron in LCLs of differing 
HFE genotypes. The samples that do not possess the C282Y mutation (controls) show 
increased expression compared to those that do (heterozygotes and homozygotes, 
p=0.047 asterisk). Error bars represent the SEM. The number of samples analysed in 
each group is indicated in parentheses after the group name. 
 
When the relative HAMP expression in response to 0.2mM was compared based 
on the TNFα haplotype, the samples with the 21112 haplotype showed a 
significantly increased response compared to those without it (p=0.0331, figure 
6.13). A similar pattern was observed within the different HFE genotypes, but 
none reached significance (data not shown). There was no expression difference 
between the symptomatic and asymptomatic C282Y homozygotes.  
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Figure 6.13. The relative expression changes of HAMP in response to iron in samples 
with and without the TNFα 21112 promoter haplotype. Samples possessing the 
haplotype had significantly increased response compared to those without the 
haplotype (p=0.0331, asterisk). Error bars represent the SEM. The number of samples 
analysed in each group is indicated in parentheses after the group name. 
 
There were no significant differences in the relative expression of HAMP after 
treatment with 5mM FAC for HFE genotype, TNFα haplotype or the presence of 
symptoms in the C282Y homozygotes. When paired t-tests were performed to 
determine whether the relative expression changes were different between the 
0.2mM and 5mM treatments, a significant difference was observed for the 
C282Y heterozygotes (p=0.0136, figure 6.14). Whilst the average response at 
0.2mM was a slight decrease in expression, there was an even slighter increase 
at 5mM.  
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Figure 6.14. The changes in the relative expression of HAMP for the C282Y 
heterozygotes at 0.2mM and 5mM FAC. There was a significant difference in the 
response (p=0.0136, asterisk). Error bars represent the SEM. The number of samples 
analysed in each group is indicated in parentheses after the group name. 
 
6.3.5. Expression of TFR2 in LCLs 
The distributions of the ∆CT values for the expression of TFR2 are outlined in 
appendix Q. Comparisons of the ∆CT values under basal conditions did not 
reveal any significant differences nor were there any differences in response to 
iron for any of the comparisons performed. This was true for both the 0.2mM 
and 5mM FAC treatments with both unable to induce a substantial change in 
TFR2 expression (on average). One sample was omitted as an outlier from each 
of the iron response analyses.  
 
6.3.6. Expression of TNFα in LCLs 
TNFα was expressed at similar levels to TFRC in the LCLs (see appendix R). Like 
both HAMP and TFRC, the C282Y heterozygotes had significantly increased 
expression of TNFα under basal conditions compared to controls (p=0.0107, 
figure 6.15). There were no other significant associations under basal conditions 
nor were there any significant differences with the iron treatment. One sample 
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was omitted as an outlier from all analyses. There was little change in the 
expression of TNFα on average at both the 0.2mM and 5mM FAC.  
 
 
Figure 6.15. The basal expression level of TNFα analysed by HFE genotype. The C282Y 
heterozygotes (CY) had a significantly higher expression level (i.e. a lower ∆CT value) 
when compared to the pooled controls (CC) and C282Y homozygotes (YY). This is 
indicated by the asterisks (p=0.0126). Error bars represent the SEM. The number of 
samples analysed in each group is indicated in parentheses after the group name. 
 
6.3.7.  Results summary 
The results presented above are summarised in table 6.4. The iron response 
refers to those results from the 0.2mM FAC treatment except where specified 
as the 5mM response. No significant differences were detected in TFR2 
expression levels. Generally, most significant differences were observed when 
the cells were treated with iron rather than under basal conditions.  
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Table 6.4. A summary of the significant expression results (p<0.05) under both basal 
and iron treated (0.2mM FAC unless stated otherwise) conditions in LCLs for all the 
genes tested. CC represents samples that do not possess the C282Y mutation, CY are 
heterozygotes and YY are homozygous for this mutation. No significant results are 
indicated by n/a.  
Gene Basal conditions Iron response 
HFE n/a 
• CY lower response than controls 
• TNFα 21112 higher expression 
TFRC 
• CY higher expression than 
other samples 
 
• YY lower response than other samples 
- TNFα 21112 lower than others 
- Symptomatic 21112 lower than 
asymptomatic 
5mM:  
• CC show further reduction in transcript 
levels 
• YY 21112 all show similar response 
HAMP 
• CY higher than YY 
• YY symptomatic 21112 
lower than asymptomatic 
21112 
• CY/YY lower than CC response 
• 21112 higher than other haplotypes 
5mM:  
• CY lower response compared to 0.2mM 
TFR2 n/a n/a 
TNFα •CY higher than controls n/a 
 
 
6.4. Discussion 
The aims of this set of experiments were to determine whether a selection of 
genes involved in the iron metabolic pathway are differentially expressed in 
LCLs established from males of different HFE genotype, TNFα haplotype and in 
the case of the C282Y homozygotes, phenotypic expression of HH. The roles of 
the genes chosen are detailed in chapter 1, but briefly, they are as follows; 
HAMP has been called the master regulator of iron homeostasis and functions 
by preventing iron export from enterocytes and macrophages; HFE and TFR2 are 
cell surface molecules that are involved in iron sensing and signalling to HAMP; 
TFRC is involved in the receptor mediated endocytosis of transferrin-bound iron 
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into the cell; and TNFα can induce hypoferremia via the regulation of iron 
metabolic pathway proteins.  
 
There were fewer significant results generated from the 5mM FAC treated cells 
compared to the 0.2mM treatment. The reason for this apparent inconsistency 
remains unclear however given that 5mM FAC is an extremely high 
concentration of iron. It is likely that the cellular response mechanisms to iron 
were saturated and unable to respond appropriately. While this concentration 
did not induce toxicity in the preliminary dose response studies, it may be that 
this dose would have been lethal if the times of exposure had been extended 
beyond 24 hrs – and that the responses recorded in this study were signs of 
early toxicity. Previous studies addressing the role of iron on different cellular 
functions have typically utilised FAC concentrations up to 0.5mM (Richardson 
and Baker 1992; Park, Lee et al. 2000; Fargion, Valenti et al. 2001) although 
concentrations as high as 10mM have been used (Qi, Jamindar et al. 1995). This 
disparity should be addressed in subsequent experiments but are beyond the 
scope of this study.  
 
6.4.1. The LCL model – relevance to iron homoeostasis? 
All results in this chapter relate to the expression of genes in the LCL 
experimental system. One of the major reasons for utilising this model is that it 
incorporates individual variability that cannot always be accounted for in other 
model systems including other cell types. Nevertheless, the relevance of using 
this type of cell line in the study of iron homeostasis may be questioned. 
Obviously the use of enterocytes or hepatocytes would be ideal, but these 
samples are difficult to obtain with issues of sample quality and quantity. All of 
the genes utilised in the current study are expressed in LCLs; however, this does 
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not necessarily mean that they will respond identically to enterocytes or 
hepatocytes. The results generated from this system need to be validated in 
more relevant iron homeostasis related tissues. However, the LCLs do present a 
starting point and depending on the results of the validation studies, may prove 
to be a model system for iron homeostasis. 
 
6.4.2. Expression results in the C282Y heterozygotes 
The expression results from the C282Y heterozygotes produced some 
unexpected results under both basal conditions and upon treatment with iron. 
The heterozygous individuals from whom the LCLs were established were drawn 
from the Canberra Region Haemochromatosis Database (CRHD), some of whom 
sought clinical advice because they were symptomatic and iron loaded, while 
some were identified through family screening. Given there were no significant 
differences in expression between the samples with high SF compared to those 
with normal levels for any of the genes studied (data not shown), it is likely that 
the observed expression differences are not a consequence of the SF profile. 
However it would be pertinent to increase the sample size to more fully address 
this question.  
 
6.4.2.1. Expression under basal conditions 
Under basal conditions the expression of HAMP, TFRC and TNFα were up-
regulated in the C282Y heterozygotes compared to the other genotypes. The 
expression of HFE and TFR2 were not different. The HAMP and TFRC results are 
biologically consistent with each other as increased TFRC expression leads to 
increased cellular iron uptake and assuming the cells are in an iron replete state, 
the increased iron would result in signalling to HAMP to increase its expression 
and therefore decrease the cellular iron efflux via binding to FPN1. Evidence 
suggests that LCLs lack FPN1 expression (GEO dataset GDS1369) so in a situation 
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where the basal expression of TFRC was elevated, the expression of HAMP 
would also be high. The reason for the increased TFRC is unclear but may be 
related to the decreased HFE on the cell surface (as the C282Y mutated protein 
remains in the ER). For example, HFE is usually dislodged from its association 
with TFRC by iron, so increased unbound HFE indicates iron uptake into the cell. 
TFR2 is thought to detect unbound HFE as an indicator of cellular iron uptake. If 
there is a decreased amount of HFE on the cell surface (due to the one mutated 
copy of the gene trapped in the ER and no evidence of increased transcription), 
the decreased amount bound to TFR2 may result in signalling to increase iron 
uptake via increased TFRC. This feedback loop may require at least some HFE on 
the cell surface to be functional which may explain why there is no such up-
regulation of TFRC in the C282Y homozygotes. The reason for the increased 
TNFα expression is unclear but again may be a consequence of the decreased 
HFE on the cell surface.   
 
6.4.2.2. Expression in response to iron  
In terms of the expression of HFE in response to iron challenge, the C282Y 
heterozygotes appeared to down-regulate HFE compared to the other 
genotypes which maintained a similar level to those seen under basal 
conditions. If this is repeatable in a larger sample size (discussed above) it raises 
a number of questions about iron regulation in heterozygotes. Decreased HFE 
levels on the cell membrane lead to increased iron uptake (as demonstrated in 
HH) so the pertinent question in the heterozygotes is whether the observed 
expression changes are allele-specific. That is, it needs to be determined 
whether the ratio of the C: Y transcripts is one and whether this ratio is altered 
under iron loading conditions. The allelic ratio has previously been studied in 
Italian HH patients where there was no difference between the mRNA copy 
number per allele (Vercesi, Cerani et al. 2000), however only three samples 
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were heterozygous for C282Y and the haplotype across the region as well as the 
aetiology of HH in Italians differs to those with a Celtic heritage (the ancestry of 
most of the HH in the CRHD). This experiment therefore needs to be repeated 
as the ratio of the two alleles could influence the iron uptake of cells. LCLs are 
clearly an ideal system in which to test this. 
 
6.4.3. Basal expression of genes in the iron metabolic 
pathway in C282Y homozygotes and controls 
The C282Y mutation renders the HFE protein non-functional, unable to leave 
the endoplasmic reticulum and thus it does not traffic to its functional location 
on the cell membrane (Feder, Tsuchihashi et al. 1997). It may have therefore 
been expected that the expression of HFE would have differed among the three 
HFE genotypes assuming the lack of membranous protein acts as a signal (either 
directly or indirectly) to increase expression. This was not the case. Given the 
low levels of HFE in the cells (as indicated by the high ∆CT values especially 
compared to TFRC, TFR2 and TNFα), the absence of expression differences may 
simply reflect a minimal role for HFE in basal iron homeostasis in LCLs.  
 
6.4.4. Gene expression in response to iron in C282Y 
homozygotes and controls 
6.4.4.1. TFR2 expression is unresponsive to iron 
There were no significant changes in the TFR2 expression in response to iron. 
This is consistent with a previous study that demonstrated that hepatic TFR2 
remains unaffected by iron challenge (Fleming, Migas et al. 2000) and suggests 
that the absence of expression differences in LCLs may not be model derived. 
The role of TFR2 in iron homeostasis involves binding to HFE proteins that have 
been displaced from TFRC by TF when iron is abundant, thus initiating a 
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signalling cascade to increase HAMP expression and therefore decrease 
enterocyte iron efflux. If HFE is the limiting factor in this process as has been 
proposed (Chloupkova, Zhang et al. 2010) then TFR2 may not be required to 
regulate its expression. Rather it could maintain a constant level on the cell 
surface, which is sufficient to detect sudden dissociation of HFE from TFRC (as a 
consequence of increased iron) and initiate a much more rapid response 
compared to a situation where there was a limited basal level of TFR2.  
 
6.4.4.2. Reduced HAMP response in C282Y homozygotes 
Previous studies have indicated that the circulating levels of HAMP are reduced 
in haemochromatotics compared to controls (Ganz and Nemeth 2010), due to 
an inability to signal HAMP transcription as a consequence of the absence of 
HFE on the cell surface. The results obtained for the C282Y homozygotes in the 
current study are consistent with this finding. The expression of HAMP was 
decreased under basal conditions in the symptomatic C282Y homozygotes with 
the TNFα 21112 haplotype compared to the asymptomatic samples of the same 
genotype. This difference was not maintained in response to iron which may 
indicate that the results are a consequence of the reduced assay reliability and 
low sample numbers. Increasing the sample size will help address this issue.  
 
6.4.4.3. Expression of TFRC in response to iron and in relation 
to the TNFα 21112 haplotype in C282Y homozygotes 
As TFRC is the main mediator of transferrin-bound iron uptake in the body, it is 
reasonable to expect that the expression of this gene would be down-regulated 
in response to iron load. This was generally observed, however the reduction 
was not consistent across all HFE genotypes. C282Y homozygotes had a 
significantly lower response compared to all other samples and closer 
examination of these results revealed that samples derived from symptomatic 
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subjects possessing the TNFα 21112 promoter haplotype demonstrated the 
lowest expression response of TFRC of all samples. This is consistent with the 
clinical results presented in chapter 4 in which an increased SF was observed in 
symptomatic C282Y homozygotes with the 21112 haplotype and confirms the 
finding that TNFα haplotype acts as a modifier of iron levels in HH.  
 
TFRC contains five IREs in the 3’ end of its mRNA. Iron responsive proteins (IRPs) 
bind to these IREs when iron levels are low, increasing the stability of the mRNA 
and up-regulating transcription and the amount of TFRC protein. When iron is 
abundant, IRPs will dissociate from the mRNA of TFRC. This in turn leads to 
degradation of the mRNA and decreased protein production and therefore a 
decrease in iron uptake (reviewed in (Muckenthaler, Galy et al. 2008)). Previous 
studies have indicated that IRPs show increased activity in HH (Recalcati, 
Alberghini et al. 2006), consistent with data indicating that IRPs are regulated by 
HFE (Riedel, Muckenthaler et al. 1999). This would explain why C282Y 
homozygotes have a decreased TFRC response upon iron challenge as the 
increased IRP activity stabilises the TFRC mRNA. Treatment of the cells with the 
5mM FAC removed the difference seen between the asymptomatic and 
symptomatic C282Y homozygotes with the 21112 haplotype. When iron is 
abundant, IRPs have a lower affinity to the IREs (Piccinelli and Samuelsson 
2007), and the results presented here indicate that this may be concentration 
dependent.  
 
6.4.5. Future directions 
The results presented in this chapter provide some quite unexpected findings 
and an interesting basis for future experiments. An increased sample size will 
help address a measure of uncertainty in some of the results (particularly for 
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the C282Y heterozygotes). Measuring the expression of an increased number of 
genes involved in the iron metabolic pathway could also be important in 
identifying potential modifier genes in HH. Genes such as those that code for 
the IRPs, ACO1 and IREB2 (for facilitating the response of TFRC and other genes 
with IREs); the two ferritin genes involved in iron storage (FTH1 and FTL); iron 
uptake transporter DMT1 and the associated ferric reductase CYBRD1; and 
perhaps the expression of FPN1 or lack thereof could also be verified. If tests 
confirm that FPN1 is not detected and therefore that HAMP is unable to 
influence iron regulation in LCLs, insights into the control of HAMP expression 
may still be achieved through the study of genes that are involved in the 
regulation of HAMP expression. Some of these genes include IL6, HJV, TMPRSS6 
and BMP6. Clearly this approach would be most efficiently addressed using 
array technology. 
 
The possibility of exploring analysing allele-specific transcription of the HFE gene 
should also be explored. Preliminary experiments to do this were unsuccessful 
and discontinued, but technical advances in the future may enable this 
experiment. 
 
Another important experiment would be confirmation that the expression 
differences result in differences in the protein levels, and this may be measured 
using Western Blots. Previous studies have indicated a good correlation 
between transcript changes and corresponding changes in protein for genes in 
the iron pathway (Johnson, Bayele et al. 2004; Nanami, Ookawara et al. 2005), 
however this may not be true in LCLs or as clear for TNFα (Wang, Johnson et al. 
2008). If possible (depending on antibodies available) it may also be useful to 
determine the relative expression of different isoforms of the same protein 
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when they exist, such as membrane-bound and secreted forms of TNFα and the 
transcripts of DMT1 and FPN1 with and without the IRE present. This may be 
particularly important in the absence of mRNA changes. The cellular distribution 
of proteins can also affect functionality and this would be useful in determining 
the effects of iron on the gene products both in the absence and presence of 
transcript changes. Measuring these changes in cellular localisation would 
require methods such as confocal microscopy (Wang, Miller et al. 2008).  
 
6.5. Conclusions 
The data presented in this chapter outline both basal expression differences and 
also relative expression changes in response to iron challenge for the genes HFE, 
TFRC, TFR2, HAMP and TNFα in LCLs. Whilst the expression levels of TNFα did 
not appear to be relevant to HH, the presence of the 21112 TNFα promoter 
haplotype was associated with differential TFRC expression in C282Y 
homozygotes, thus confirming the modifier status of this haplotype in iron 
overload. The mechanism of the relationship between altered TFRC expression 
and the TNFα haplotype remains unclear but is likely to be mediated through 
the regulation of TFRC via the IRP/IRE pathway. The expression of HFE may also 
be affected by the TNFα 21112 haplotype. The relevance of this association 
remains to be determined since the HFE protein is not expressed on the cell 
surface and therefore apparently non-functional in C282Y determined HH. 
Significant changes were observed in HAMP expression but doubts over the 
reliability of the assay means that these results must be interpreted with 
caution. Finally the lack of any changes in TFR2 expression is likely to be an 
inherent quality of the function of the protein rather than a reflection on the 
model system used.  
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7. Chapter 7. General Discussion and Conclusions 
The main aims of this study were to identify modifier genes that influence the 
penetrance of HFE-associated hereditary haemochromatosis. The major findings 
are highlighted and discussed below. Potential applications of these results and 
possible future directions are also considered.  
 
7.1. Increased SF in symptomatic C282Y homozygotes 
compared to asymptomatic C282Y homozygotes 
Initial studies on the population of iron-loaded, male C282Y homozygotes from 
the Canberra Region Haemochromatosis Database (CRHD) found that 
individuals presenting with symptoms had increased SF compared to those that 
did not report symptoms. This has recently been described in another cohort of 
Australian HH patients (Allen, Bertalli et al. 2010) with a SF of 1000µg/l found as 
the limit above which symptoms develop, but prior to this it had not been 
reported. The level of 1000µg/l correlates well with the data in the current 
study and represents an amount of iron that is around three times the 
recommended SF level in males (<300µg/l). This threshold suggests that the 
body can compensate for excess iron up to around three-fold the normal level 
before being overwhelmed. The resulting free iron causes tissue damage via 
redox reactions and eventually symptoms develop. In terms of therapeutic 
guidelines, it would be ideal to treat all C282Y homozygotes before this 
threshold is reached to eliminate or at least reduce the onset of symptoms. The 
application of this in the clinical setting is problematic as it requires an 
underlying knowledge of a patient’s C282Y status and regular tests for SF levels. 
While some people are identified through family screening or incidental 
biochemical diagnosis before the development of symptoms, most people are 
diagnosed as a result of symptomatic presentation. This then raises the question 
of population screening to identify C282Y homozygotes before they become 
159 
 
symptomatic. This has been discussed extensively in the past with a lack of 
understanding of the mechanisms underlying the reduced penetrance of the 
HFE mutations being one of the main drawbacks to large scale screening. It has 
recently been suggested that screening of Caucasian males only would be 
appropriate as they are the main sufferers of disease (Adams, Barton et al. 
2009), and this approach may well be worth considering into the future. 
 
7.2. Replication of previous association studies 
between SNPs in candidate modifier genes and iron 
indices  
Many potential modifier genes have been associated with the variable 
phenotypic presentation of HH (see table 1.2) but few have maintained their 
significance in replication studies. Much of this variability may be accounted for 
by population stratification differences, particularly in reference to the iron 
parameters studied (i.e. SF, TfSat, TF), the gender ratios of the study group and 
the phenotypic (and genotypic) definition of disease. The current has 
highlighted the importance of defining samples in terms of whether they are 
iron loaded.  
 
A number of SNPs previously identified in Australian populations as being 
associated with serum iron indices were tested in the CRHD sample. 
Polymorphisms in TF, CYBRD1 and TMPRSS6 were analysed, with mixed results 
in terms of replication of previous studies, most likely due to population 
stratification differences outlined above. Only one of the SNPs was associated 
with SF in the C282Y homozygote samples, namely rs884409, which resides in 
the promoter region of CYBRD1. CYBRD1 is a ferric reductase on the surface of 
cells which is important in reducing non-heme (Fe3+) iron to Fe2+ to allow it to be 
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trafficked into the cell by DMT1. Analysis of rs884409 and the surrounding 
sequence in the TFBS prediction programs MatInspector, TESS, Consite and 
TFSEARCH yielded a single result for a (potential) site that is altered as a 
consequence of the SNP. The site, NR1D1 (nuclear receptor subfamily 1, group 
D, member 1) is abrogated due to the rare allele at rs884409. NR1D1 is involved 
in maintaining circadian rhythms and while this does not immediately suggest a 
role in iron homeostasis, the high expression levels of this transcription factor in 
the liver and the ability of heme to alter its function (reviewed in (Duez and 
Staels 2009)) make this somewhat unlikely protein a very interesting candidate 
for future studies into the penetrance of the C282Y mutation. It would be very 
interesting to study the effect of this SNP on the expression of CYBRD in LCLs, 
particularly in the context of both C282Y homozygotes and controls. As DMT1 is 
in close proximity to CYBRD1 on the basolateral membrane of the enterocyte, 
analysis of the expression of DMT1 may provide information about potential co-
regulation of DMT1 and CYBRD1. 
 
The other gene that was implicated in altered iron indices in the above studies 
was Transferrin. Two of the SNPs within this gene region (rs3811647 and 
rs1799852) showed association with SF levels in a heterogeneous population, 
but not specifically within the C282Y homozygotes. Functionally, rs1799852 
causes a synonymous coding change (Leu247Leu) and rs3811647 resides in an 
intronic region of TF. A more comprehensive coverage of the region in terms of 
variation may identify an extended haplotype that affects the function of TF as 
these two SNPs appear to have limited functional consequences. 
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7.3. TNFα as a modifier gene in HH 
7.3.1. Genetic association of the promoter haplotype 
with SF levels 
The major finding presented in this study is the confirmation that TNFα is a 
modifier gene in a population of Australian haemochromatotics. Previous 
studies have produced mixed results regarding TNFα as a modifier gene of HH, 
with some positive associations (Gordeuk, Ballou et al. 1992; Fargion, Valenti et 
al. 2001; Krayenbuehl, Maly et al. 2006) but also some studies which have found 
no associations (Beutler and Gelbart 2002; Distante, Elmberg et al. 2003). The 
current study is the first in which a haplotype across the promoter region has 
been analysed in HH patients. A single haplotype (21112) encompassing the five 
SNPs studied (-1031, -863, -857, -308 and -238) was found to be significantly 
associated with increased iron loading in a population of male, symptomatic 
C282Y homozygotes. No additive effect of the haplotype was visible with the 
only homozygote for the haplotype presenting with a SF value that was within 
the range of those obtained from the heterozygotes. Subsequent studies 
(outlined below) revealed that the haplotype effect was specific to the male 
symptomatic C282Y homozygotes.  
 
7.3.2. Functional evidence – the TNFα 21112 haplotype 
is associated with the expression of TFRC in LCLs 
The expression studies in LCLs produced the most exciting results in terms of 
the TNFα 21112 haplotype and HH phenotype. In response to iron challenge, 
male symptomatic C282Y homozygotes possessing the 21112 haplotype were 
unable to decrease the expression of TFRC to the same extent as samples 
possessing the other TNFα haplotypes. That is, these cells had increased levels 
of TFRC compared to other cells. This would result in increased uptake of iron 
and this is consistent with the increased SF observed in the symptomatic male 
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C282Y homozygotes that possess this 21112 TNFα haplotype. This is the first 
time an association between TNFα and TFRC has been established as a process 
to modify the phenotypic expression of HH.  
 
7.3.3. How does the TNFα 21112 promoter haplotype 
influence the expression of TFRC? 
7.3.3.1. Variable expression of TNFα 
The TNFα 21112 promoter haplotype may alter the expression levels of the 
TNFα gene, leading to the association of this haplotype with TFRC transcript 
levels. However, there were no significant differences in TNFα expression 
between LCLs that did and did not possess the 21112 haplotype. As this may be 
a consequence of the model, the luciferase results in the Caco-2 cells must also 
be considered. These results indicate that there may be promoter allele-specific 
effects on the expression of TNFα, particularly for the -1031, -863 and -308 
SNPs. While these results are intriguing in terms of the regulation of TNFα, there 
was a lack of a definitive difference in the expression of 21112 compared to the 
other haplotypes. This suggests that differences in transcript level associated 
with the 21112 haplotype are not contributing to the altered TFRC expression 
observed in the symptomatic C282Y homozygotes. Future studies (as outlined in 
chapter 5) addressing the responsiveness of the haplotype to iron exposure are 
important in the confirming this.  
 
7.3.3.2. Altered TNFα protein function 
The results from the LCLs show the TNFα 21112 haplotype modulates TFRC 
expression in response to iron in male symptomatic C282Y homozygotes but 
this does not occur through altered TNFα transcript levels. However TNFα can 
be extensively regulated at the post-transcriptional and post-translational level 
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(Stamou and Kontoyiannis 2010). This can alter the functional consequences of 
the protein without altering the overall abundance of the transcript. Evidence 
from a previous study utilising luciferase assays found that there was 
differential expression of the -308 TNFα promoter SNP only when the 3’UTR was 
included in the construct (Kroeger, Steer et al. 2000). This suggests that a 
regulatory element in the 3’UTR may somehow interact with the promoter 
sequence to modulate expression.  
 
If TNFα is involved in modulating the expression of TFRC in response to iron, it 
would make sense that TNFα itself is responsive to iron. One of the most 
important regulatory mechanisms in the response of genes to iron is that driven 
by the IRPs (iron responsive proteins) (see section 1.1.4.1). Binding of IRPs to 
IREs (iron responsive elements) in the mRNA of genes such as TFRC, DMT1, 
FPN1 and FTH1 allows rapid changes in protein levels as a result of fluctuations 
in environmental iron levels. IREs are stem loop structures that require a very 
specific sequence to form. A recently developed program, SIRES 
(http://ccbg.imppc.org/sires/), can predict the presence of IREs in any given 
input sequence (Campillos, Cases et al. 2010). When the TNFα gene sequence 
(NG_007462.1) is entered in this program, an IRE is predicted within the 3`UTR 
of the mRNA sequence. The numerical value associated with the prediction is 
high suggesting it is at an increased likelihood of being functional compared to a 
lower score. The structure of the predicted loop is presented in figure 7.1. A 
pertinent question to ask is whether the presence of an IRE within the 3’UTR of 
TNFα mRNA corresponds with the known biological actions of TNFα expression. 
The answer is both yes and no, depending on the tissue in question. Under low 
iron conditions, IRPs bind to the IREs in the 3’UTR to stabilise the mRNA and 
enhance expression. This is consistent with data from hepatocytes (where TNFα 
increases the expression of DMT1, TFRC and FTH1) but not for enterocytes and 
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monocytes (both of which decrease TFRC expression in response to TNFα). 
These differences do not reduce the possibility of a functional IRE in TNFα, they 
merely suggest tissue specific differences in the 3’UTR of TNFα. If these 
differences are associated with the promoter haplotype, this may drive the 
differences seen in the TFRC expression.  
 
 
Figure 7.1. The structure of the predicted IRE in the 3’UTR of TNFα. The diagram was 
created by the SIRES program (http://ccbg.imppc.org/sires/) using the genomic TNFα 
sequence (NG_007462.1) as the input sequence. The yellow circle indicates a 
mismatch, the red circles are the apical loop, and the green C8 is a bulge that is 
necessary for interaction with the IRPs.  
 
The role of TNFα signalling should also be considered when the functional 
differences associated with the TNFα protein are being contemplated. As 
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mentioned in chapter 5, TNFα signals through two main receptors, TNF receptor 
superfamily 1a and 1b (TNFRSF1a and TNFRSF1b, formally known as TNFR1 and 
TNFR2). The two receptors function predominantly in the apoptotic and tissue 
repair/angiogenesis pathways respectively. However, tnfrsf1b KO mice have 
altered iron homeostasis indicating a role for this protein in the regulation of 
iron (Meyer, Gerhard et al. 2002). If TNFα signalling was skewed towards the 
use of this receptor, then differences in the expression of genes in the iron 
metabolic pathway may be anticipated. For this pathway to be functional in the 
LCL system TNFα must be either released from the cell or cells must be in close 
contact to allow interactions between TNFα and its receptor. This which may 
not be relevant in the LCL system and therefore by inference not necessarily 
relevant to the TFRC expression results. Nonetheless the relevance of altered 
TNFα signalling to the altered penetrance in C282Y homozygotes needs to be 
examined.  
 
7.3.3.3. Epigenetic modifications 
Epigenetic modifications can also be involved in the regulation of gene 
expression. A recent study has shown that liver tissue from iron loaded 
haemochromatotics has altered epigenetic modifications of a number of genes 
compared to normal liver tissue (Lehmann, Wingen et al. 2007). While TNFα was 
not reported in that study, TNFα can be differentially methylated in monocytes 
in response to bacterial endotoxin (El Gazzar, Yoza et al. 2007). In terms of the 
results presented in the present study, epigenetic influences on gene expression 
are unable to be measured in the luciferase assay system but it may be analysed 
in the LCL model. However, given the lack of differences in transcript level 
associated with the TNFα 21112 promoter haplotype compared to the other 
haplotypes, the role of epigenetics as a transcriptional modulator seems 
unlikely in this case.   
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7.3.3.4. Linkage disequilibrium with another loci on 6p21.3 
The TNFα 21112 promoter haplotype could be in LD with another locus on 
6p21.3 which is responsible for the apparent functional consequences of this 
haplotype on TFRC and affecting the penetrance of the C282Y mutation. The 
genetic studies presented in chapter four found no evidence of LD between the 
TNFα SNPs and the microsatellite markers studied. This may need to be further 
addressed in future studies by genotyping a number of markers within the 
region of the TNFα promoter to see whether the haplotype can be extended. It 
is possible that polymorphisms within the coding and 3’UTR sequences of TNFα 
itself could be important, although HapMap data indicates little evidence of 
strong LD between the promoter SNPs and coding SNPs.  
 
The TNFα 21112 haplotype may also be directly involved in modulating the 
expression of a gene other than TNFα, if it is functioning as a long range 
response element. The progesterone receptor, for example, has been shown to 
be regulated via the interaction of both proximal and distal (up to 311kb away 
from the TSS) oestrogen response elements (Boney-Montoya, Ziegler et al. 
2010). Identification of a possible candidate gene for which the TNFα 21112 
promoter haplotype confers altered expression levels may be possible using 
genome-wide expression data from samples with and without this haplotype.  
 
7.3.4. Significance of the TNFα 21112 promoter 
haplotype to the phenotypic variability in HH 
The significance of TNFα as a modifier gene in HH can be addressed in terms of 
how many patients it impacts upon. From chapter four, the frequency of the 
21112 haplotype on C282Y chromosomes was around 7%. As the haplotype 
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influenced iron loading when present in both the heterozygous and 
homozygous form, an estimated 13.5% of C282Y homozygotes will possess the 
21112 haplotype (based on haplotype frequency), consistent the data from the 
symptomatic C282Y homozygotes in this study (7/52 with the haplotype). Thus, 
while TNFα is a significant modifier of the phenotypic variability in HH, it does 
not account for all the variation, indicating the existence of other modifier 
genes. It is likely that there are multiple polymorphisms covering several genes, 
which may include be the aforementioned SNPs in CYBRD1 and TF, are 
interacting to cause the reduced penetrance associated with C282Y 
homozygosity. 
 
7.4. Personalised medicine and modifier genes in HH 
The concept of personalised medicine aims to individualise both treatment and 
preventative strategies based on patient-specific data. For example, breast 
cancers are tested for oestrogen-responsiveness as this determines which 
chemotherapy regime is more likely to be effective (Germano and O'Driscoll 
2009). By increasing our understanding of the proteins involved in the iron 
metabolic pathway and the interactions between them, new diagnostic tools 
and treatments for HH may be established. While many of the symptoms 
associated with HH will dissipate upon phlebotomy treatment, the arthropathy 
associated with the disease often remains and may worsen with time (reviewed 
in (Ines, da Silva et al. 2001)). Identification of modifier genes that specifically 
affect the development of arthropathy may allow for the development of novel 
treatment strategies for these patients.   
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7.5. Future directions in the identification of additional 
modifier genes in HH 
The complexity of the iron metabolic pathway means there are many genes in 
which functional polymorphisms may alter the penetrance of HH. The 
elucidation of all proteins in the pathway is not yet complete as there are still 
cases of severe iron overload with an apparent familial inheritance pattern in 
which no mutations have been discovered (unpublished results and Kristina 
Roberts, NC Andrews laboratory, personal communication). In the absence of 
environmental influences, this suggests the presence of mutations in genes that 
have an as yet undescribed role in iron homeostasis. One method that may be 
applied to these families to identify mutations, and which has gained in 
popularity and use, is exome sequencing. This approach of only sequencing 
exons is more cost-efficient than whole genome sequencing for the same 
number of samples. It has been used to successfully identify the causal genes in 
a number of rare disorders (Bolze, Byun et al. 2010; Haack, Danhauser et al. 
2010; Wang, Yang et al. 2010) but it can also be used to identify variants 
associated with complex disorders (Sanders 2010). Therefore, this method may 
be useful for the identification of both private familial mutations that cause iron 
overload and of modifier genes by comparing C282Y homozygotes discordant 
for symptomatic presentation (despite elevated SF).  
 
As mentioned above, there is evidence for differential epigenetic modifications 
of genes in HH compared to controls. Recently, a paper has described the 
analysis of SNPs in the context of parent of origin effects for a number of 
complex diseases, including breast cancer and type II diabetes (Kong, 
Steinthorsdottir et al. 2009). For at least one of the SNPs, a correlation between 
tissue-specific parent of origin epigenetic effects with expression levels was 
established. That is, a SNP was associated with altered expression levels but 
169 
 
only when inherited on the paternal chromosome for example. All the SNPs 
used in this study were within 500kb of a known imprinted region. There is no 
evidence for an imprinted region within 500kb of TNFα but there is a predicted 
imprinted gene around 700kb downstream (Luedi, Dietrich et al. 2007) which 
may warrant further studies into this mechanism of epigenetic modification. 
 
A study of haemochromatosis heterozygotes before the discovery of HFE 
suggested that paternal inheritance of the mutant allele was associated with 
increased phenotypic expression of disease (Bulaj, Griffen et al. 1996) but 
specific methylation/epigenetic effects were not described. Nevertheless, this 
may be important in the interpretation of the results for the expression in the 
heterozygous LCLs. Parental genotypes were unavailable for half of the C282Y 
heterozygotes used in this study, and of the remaining five samples, two 
inherited the C282Y mutation maternally and the other three paternally. This 
may suggest there is no role for parent of origin effects in these samples, but 
with data for only half the samples, this cannot be definitively concluded. 
Addressing the parent of origin effect in future studies by increasing the sample 
size and including samples for which the parental transmission of the C282Y 
mutation is known may be important. 
 
An aspect of HH that was beyond the scope of this thesis was the consideration 
of the H63D mutation in the context of the phenotypic expression of HH. While 
this mutation occurs at a higher population frequency than C282Y, there were 
only six homozygotes in the available CRHD samples, of which only two were 
male. This may reflect ascertainment bias towards the C282Y homozygotes or 
simply that the penetrance of the H63D mutation is not high enough for 
patients to present with symptoms. Either way, there were not nearly enough 
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samples on which to perform meaningful analysis. If more H63D homozygotes 
who present with iron loading both with and without clinical symptoms can be 
recruited, then these samples may be useful in the identification of additional 
modifier genes in HH. Similarly, if increased numbers of iron-loaded females 
with detailed menstrual and pregnancy histories become available, the results 
presented in this thesis may be further replicated.  
 
7.6. Conclusions 
The results presented in this thesis have advanced our understanding of the 
variable penetrance in HFE-associated haemochromatosis as a multifactorial 
phenomenon. The major results that support this conclusion are: 
 Male C282Y homozygotes who present with symptoms have elevated SF 
levels compared to asymptomatic male C282Y homozygotes. 
 The Transferrin SNP rs1799852 has a reduced frequency in the 
asymptomatic C282Y homozygotes which may be contributing (but not 
wholly) to the reduced SF observed in these samples.  
 The rare allele for the rs884409 CYBRD1 promoter SNP previously 
associated with SF levels was also associated with decreased SF in the 
male, symptomatic C282Y homozygotes when present in the 
homozygous form. Replication is necessary to validate this result as it is 
based on only two homozygous samples. 
 The TNFα 21112 promoter haplotype (covering the SNPs -1031, -863, -
857, -308 and -238) is associated with elevated SF within the male, 
symptomatic C282Y homozygotes 
 Expression of TFRC in an LCL system is down-regulated in response to 
iron 
o This response is decreased in male C282Y homozygotes who 
possess the 21112 haplotype, providing a functional mechanism 
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for the increased SF in these patients and confirming TNFα as a 
modifier gene in HH. 
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Appendices 
Appendix A.  Electronic links 
Applied Biosystems: http://www.appliedbiosystems.com.au/ 
CEPH: http://www.cephb.fr 
Consite: http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite 
Genepop: http://genepop.curtin.edu.au/ 
Genomatix website: http://www.genomatix.de/en/index.html 
GEO: http://www.ncbi.nlm.nih.gov/geo/ 
HUGO: http://www.hugo-international.org/ 
NCBI – dbSNP: http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp 
NCBI – Gene: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene 
NCBI: http://www.ncbi.nlm.nih.gov/ 
Outlier test: http://www.graphpad.com/quickcalcs/Grubbs1.cfm 
PHASE: http://depts.washington.edu/uwc4c/express-licenses/assets/phase/ 
Promega: http://www.promega.com 
Promega transfection: http://www.promega.com/techserv/toolsFuGENE 
HDtool/ Default.aspx 
SIRES: http://ccbg.imppc.org/sires/ 
Tess: http://www.cbil.upenn.edu/cgi-bin/tess/tess 
TFSearch: http://www.cbrc.jp/research/db/TFSEARCH.html 
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Appendix B.  Gene names and symbols 
Table B.1. Gene names and symbols used commonly throughout this thesis. 
Gene 
symbol 
used 
HUGO 
symbol 
Other 
acronyms 
Gene Name Chr MIM 
ACO1 ACO1 
IRP1, 
IREB1 
Aconitase 1 9p21.1 100880 
BMP4 BMP4 - 
Bone morphogenetic 
protein 4 
14q22-q23 112262 
BMP6 BMP6 - 
Bone morphogenetic 
protein 6 
6p24-p23 112266 
CYBRD1 CYBRD1 DCYTB Cytochrome b reductase 1 2q31.1 605745 
FTH1 FTH1 FTH, PLIF 
Ferritin, heavy 
polypefdnasptide 1 
11q13 134770 
FTL FTL - Ferritin, light polypeptide 19q13.33 134790 
HAMP HAMP LEAP1 
Hepcidin antimicrobial 
peptide 
19q13.1 606464 
HFE HFE HLA-H Haemochromatosis 6p21.3 613609 
HFE2 HFE2 
HJV, 
RGMC 
Haemochromatosis type 2 
(juvenile); also 
hemojuvelin 
1q21.1 608374 
IL6 IL6 BSF2 Interleukin 6 7p21 147620 
IREB2 IREB2 IRP2 
Iron responsive element 
binding protein 2 
15q25.1 147582 
DMT1 SLC11A2 
DMT1, 
DCT1, 
NRAMP2 
Solute carrier family 11 
(proton-coupled divalent 
metal ion transporter) 
member 2 
12q13 600523 
FPN1 SLC40A11 
IREG1, 
FPN1, 
MTP1, 
HFE4 
Solute carrier family 40 
(iron-regulated 
transporter), member 1 
2q32 604653 
TF TF - Transferrin 3q22.1 190000 
TFRC TFRC TFR1 Transferrin receptor 3q29 190010 
TFR2 TFR2 
HFE3, 
TFRC2 
Transferrin receptor 2 7q22 604720 
TMPRSS6 TMPRSS6  
Transmembrane protease 
serine 6 
22q12.3 609862 
TNFα TNF TNFα 
Tumour necrosis factor 
alpha 
6p21.3 191160 
TNFRSF1A TNFRSF1A TNFR1 
Tumour necrosis factor 
receptor superfamily 
member 1A 
12p13.2 191190 
TNFRSF1B TNFRSF1B TNFR2 
Tumour necrosis factor 
receptor superfamily 
member 1B 
1p36.22 191191 
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Table B.2. A list of genes which contain an IRE in the 5’UTR or 3’UTR and a brief description of 
the gene function. When iron levels are low, the iron responsive proteins bind to the IREs with 
high affinity and those in the 5’UTR block translation whilst those in the 3’UTR enhance mRNA 
stability and increase translation. Reviewed in (Piccinelli and Samuelsson 2007).  
Gene Number of IREs Name and Function 
IRE in the 3’UTR 
TFRC Five Transferrin receptor; receptor mediated endocytosis of 
TF-Fe 
DMT1 one Divalent metal trsnsporter-1; Iron uptake in 
enterocytes, iron efflux from endosome 
CDC42BPA/ 
MRCKα 
one CDC42 binding protein kinase alpha (DMPK-like); 
muscle contraction 
CDC14A one Cell division cycle 14 homologue A; involved in the 
regulation of critical cell cycle proteins and has been 
suggested to be a tumour suppressor  
   
IRE in the 5’UTR 
ACO2 
(eALAS) 
one Aconitase 2; tricarboxylic acid cycle enzyme 
dSDH one Drosophila succinate dehydrogenase;  
FPN1 one Ferroportin; Iron efflux into the body from enterocytes 
SNCA one α-synuclein; a presynaptic protein  
FTH1 one Ferritin heavy chain; Iron storage within the cell 
FTL one Ferritin light chain; Iron storage within the cell 
ALAS2 one Erythroid aminolevulinic acid synthase; first step in 
tetrapyrrole synthesis 
EPAS1 
(HIF2α) 
one Hypoxia inducible factor 2α; a transcription factor that 
is activated by lack of oxygen or iron 
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Appendix C. Mutations in HFE, HFE2, HAMP, TFR2, FPN1 and other genes 
that cause iron loading in humans 
Table C.1. Atypical mutations in HFE that cause iron overload 
Mutation Population Freq (normal) Reference 
G43D French n/a (Dupradeau, Pissard et al. 2008) 
V256I Brazilian n/a (Santos, Pereira et al. 2010) 
P160fs Caucasian n/a (Pointon, Lok et al. 2009) 
LL46W Portuguese 
 
0 
0 
0 
0 
(Mendes, Ferro et al. 2008) 
D129N 
Y23F 
Y138X 
Gene deletion Sardinia 0 (Le Gac, Congiu et al. 2009) 
R66C Italian n/a (Biasiotto, Belloli et al. 2003) 
R224G 
L183P Dutch 0.005 (Swinkels, Venselaar et al. 2007) 
A158fs Slovenia n/a (Cukjati, Koren et al. 2007) 
IVS5+1 G/A Vietnamese 0.002 (Steiner, Leiendecker-Foster et al. 
2007) 
I105T Caucasian (USA) 0 (Barton, Sawada-Hirai et al. 1999) 
G93R 0 
E168X 
W169X 
Italian n/a 
n/a 
(Piperno, Arosio et al. 2000) 
R330M Sth Africa 0 (de Villiers, Hillermann et al. 1999) 
Q127H 0 
R74X Caucasian (USA) n/a (Beutler, Griffin et al. 2002) 
E168Q Caucasian (SA) n/a (Oberkanins, Moritz et al. 2000) 
Q283P Caucasian 0 (Le Gac, Dupradeau et al. 2003) 
C282S  n/a (Rosmorduc, Poupon et al. 2000) 
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Table C.2. Mutations in HFE2 (hemojuvelin) that cause iron overload. 
Mutation Population Freq (normal) Reference 
C321X China n/a (Huang, Rubio-Aliaga et al. 2004) 
C80R 
Caucasian (USA) n/a (Lee, Beutler et al. 2004) L101P 
I222N 
G99V Greek 0 
(Papanikolaou, Samuels et al. 2004) 
I281T Greek 0 
G320V Greek 0 
R326X Greek 0 
C361fsX366 Greek 0 
S105L 
Caucasian 
0 
(Le Gac, Scotet et al. 2004) 
E302K 0.0015 
N372D 0 
R335Q 0 
N196K Italian 0 
(Biasiotto, Roetto et al. 2004) 
D149fsX245  0 
V74fsX113 English n/a 
(Lanzara, Roetto et al. 2004) 
S85P Italian n/a 
G99R Albanian n/a 
L101P Albanian n/a 
R131fsX245 Italian n/a 
D149fsX245 Italian n/a 
A168D Australian/English n/a 
F170S Italian n/a 
D172E Italian n/a 
W191C Italian n/a 
S205R Italian n/a 
G250V Italian n/a 
N269fsX311 English n/a 
R288W French n/a 
G319fsX341 Italian n/a 
R385X Italian n/a 
C119F German n/a 
(Gehrke, Pietrangelo et al. 2005) 
S328fsX337 Slovakia n/a 
G66X Romania n/a (Janosi, Andrikovics et al. 2005) 
Q116X Irish n/a (Daraio, Ryan et al. 2005) 
R176C Mixed European n/a (Aguilar-Martinez, Lok et al. 2007) 
L135R Spanish 0 (de Diego, Opazo et al. 2007) 
R54X West Indies n/a (Murugan, Lee et al. 2008) 
Q312X Japanese 0 (Nagayoshi, Nakayama et al. 2008) 
IVS+395C>G Portuguese 
 
0 
0 
(Mendes, Ferro et al. 2008) 
E275E 
C80Y Bangladesh 0 
(Lok, Merryweather-Clarke et al. 
2009) 
G99R Pakistan 0 
P192L Pakistan 0 
L194P Pakistan 0 
A343PfsX23 Sri Lanka 0 
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Table C.3. Mutations in HAMP that cause iron overload in humans. 
Mutation Population 
Freq 
(normal) 
Reference 
-153C/T French 0 (Island, Jouanolle et al. 2009) 
-72C>T Italian 0.008 (Biasiotto, Roetto et al. 2004) 
IVS2+7G>A Italian 0 (Biasiotto, Roetto et al. 2004) 
IVS2+1  0  
126-127delAG Pakistani n/a 
(Lok, Merryweather-Clarke et al. 
2009) 
5'-UTR+14 G>A Portuguese n/a 
(Matthes, Aguilar-Martinez et al. 
2004) 
M50del IVS2+1(-
G) North European 
0 (Merryweather-Clarke, Cadet et al. 
2003) 
G71D 0.003 
C70R Italian  (Majore, Binni et al. 2004) 
C78T Middle Eastern  (Delatycki, Allen et al. 2004) 
93delG 
Italian? 
0 
(Roetto, Papanikolaou et al. 2003) 
R56X 0 
-25G/A Portuguese  (Porto, Roetto et al. 2005) 
 
Table C.4. Mutations in TFR2 that cause iron overload in humans. 
Mutation Population Freq (normal) Reference 
R481H Taiwanese n/a (Hsiao, Tsai et al. 2007) 
N411del Italian n/a (Biasiotto, Camaschella et al. 2008) 
A444T n/a 
IVS17+5636G>A n/a 
p.R396X/c.1538-2 
A>G 
Italian n/a (Gerolami, Le Gac et al. 2008) 
M172K Italian 0 (Majore, Milano et al. 2006) 
Q690P Portuguese n/a (Mattman, Huntsman et al. 2002) 
c.614+a A>G Italian n/a (Pelucchi, Mariani et al. 2009) 
E60X Italian 0 (Roetto, Totaro et al. 2001) 
M172K 0 
Y250X Italian 0 (Camaschella, Roetto et al. 2000) 
F280L Portuguese 
 
0 (Mendes, Ferro et al. 2008) 
V22I Italian n/a (Biasiotto, Belloli et al. 2003) 
R105X French 0 (Le Gac, Mons et al. 2004) 
R396X Scottish n/a (Lee and Barton 2006) 
R455Q 
G792R 
L490R Japanese n/a (Koyama, Wakusawa et al. 2005) 
V561X 
AVAQ594-597del Japanese 0 (Hattori, Wakusawa et al. 2003) 
Q317X Italian n/a (Pietrangelo, Caleffi et al. 2005) 
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Table C.5. Mutations in FPN1 that cause iron overload in humans 
Mutation Population Freq (normal) Reference 
I152F Italian n/a (Girelli, De Domenico et al. 2008) 
L233P Italian n/a 
Y501C Italian  (Letocart, Le Gac et al. 2009) 
G468S Scottish/Irish n/a (Lee, Gelbart et al. 2007) 
C326S European n/a (Sham, Phatak et al. 2005) 
R489K ?European n/a (Griffiths, Mayr et al. 2010) 
D157N Italian 0 
0 
(Pelucchi, Mariani et al. 2008) 
V72F 
N185D Canadian 
(Scandinavian) 
 (Morris, Litvinova et al. 2005) 
V162del Caucasian 0 (Wallace, Pedersen et al. 2002) 
A77D Caucasian 0 (Montosi, Donovan et al. 2001) 
Q248H African 0 (Gordeuk, Caleffi et al. 2003) 
N144H Dutch 0 (Njajou, Vaessen et al. 2001) 
D157G  0 (Hetet, Devaux et al. 2003) 
Q182S  0 
G323V  0 
G490D Asian-Caucasian 0 (Jouanolle, Douabin-Gicquel et al. 
2003) 
N144T Solomon 
Islander 
n/a (Arden, Wallace et al. 2003) 
Y64N French-Canadian 0 (Rivard, Lanzara et al. 2003) 
D157A Caucasian n/a (Saja, Bignell et al. 2010) 
S338R Caucasian 0 (Wallace, Dixon et al. 2007) 
C326Y Thailand 0 (Lok, Merryweather-Clarke et al. 
2009) 
R88T Spanish 0 (Bach, Remacha et al. 2006) 
I180T 0 
D270V 
Black African 0 (Zaahl, Merryweather-Clarke et al. 
2004) 
 
Table C.6. Mutations in other genes that cause iron overload 
Gene Mutation Population Freq (normal) Reference 
DMT1 E399D Czech 0 (Mims, Guan et al. 2005) 
ALAS2 -34C/T (in IRE) Caucasian n/a (Lee, Rice et al. 2009) 
FTH A49U (in IRE) Japanese n/a (Kato, Fujikawa et al. 2001) 
CYBRD1 R226H 
IVS-4G>C 
 n/a (Zaahl, Merryweather-Clarke 
et al. 2004) 
 
Mutations disrupting the IRE/IRP interaction of FTL cause the rare disease hyper-ferritinemia 
cataracts syndrome (Millonig, Muckenthaler et al. 2010) which does not include an iron loaded 
phenotype. 
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Appendix D. Buffers and Chemicals 
Appendix D.1 5X TBE buffer 
0.089 M Tris (Amresco cat#0497) 
0.089 M Boric Acid (Amresco cat#0588) 
0.002 M EDTA pH 8.0 (Ajax, cat#180) 
Made to correct volume with distilled water and autoclaved. 
Dilute to 1X prior to using. 
 
Appendix D.2 50X TAE buffer 
2 M Tris 
1 M Glacial Acetic Acid (Ajax Fine Chemicals, cat# A1-500ml) 
0.05 M EDTA pH 8.0 
Made to correct volume with distilled water. 
Dilute to 1X prior to using. 
 
Appendix D.3 1XPBS 
Dulbecco's phosphate buffered saline (Sigma cat# D56-52) was dissolved in sterile 
distilled water, pH 8.0. Filter sterilise. 
 
Appendix D.4 Cell lysis buffer for DNA extractions (buffer A) 
320 mM sucrose (Amresco cat#0335) 
10 mM tris pH 7.5 (Amresco cat#0497) 
5 mM MgCl2 (Merck cat#10149) 
1% Triton X-100 (Amresco cat#0694) 
Add autoclaved sterile distilled water to correct volume. Store at 4°C 
 
Appendix D.5 Blood buffer B 
75 mM NaCl (Amresco cat#X190) 
25 mM EDTA (Univar cat#180) 
pH to 8.0. Add autoclaved sterile distilled water to correct volume. Store at 4°C 
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Appendix D.6 Phenol: chloroform 
Mix equal volumes of saturated phenol (Amresco cat#0945) and chloroform (Ajax 
cat#A152). Allow phases to settle before use.  
 
Appendix D.7 Ladders 
pBR322 (NEB cat# N3033L) digested with HaeIII (NEB cat#R0108L) with 1X NEB buffer 2 
at 37°C for 2 hrs before adding 1.5 µl 0.5 M EDTA. Heat inactivated 60°C 10 mins and 
water added to give a concentration of 0.065 µg/µl. Addition of loading dye leads to a 
final concentration of 0.05µg/µl. 
 
A 1kb DNA ladder (NEB, cat# N3232S) and a 100 bp ladder (NEB, cat# N3231S) were 
also utilised as required.  
 
Appendix D.8 Loading dyes 
Table D.1. Commonly used loading dyes for electrophoresis of PCR products. Two dyes were 
used to monitor the migration of nucleic acid in the gel with bromophenol blue migrating with 
ca. 350 bp fragments and xylene cyanol migrating with ca. 1.4 Kb fragments.  
Type I Type II Type III 
0.25% bromophenol blue 
(Sigma, cat# B-5525) 
0.25% bromophenol blue 
 
 
 0.25% xylene cyanol  
(Sigma, cat# X-4126) 
0.25% xylene cyanol 
 
30% glycerol in water 30% glycerol in water 30% glycerol in water 
Store at 4°C Store at 4°C Store at 4°C 
 
Appendix E. Bacterial cultures 
Appendix E.1 Luria broth 
1% Tryptone (Difco, cat# 0123-17-3) 
0.5% Yeast extract (Difco cat# 0127-17-9) 
0.5% Sodium chloride (Amresco cat# X190) 
0.001N NaOH (Merck cat# 1.06498.0500) 
Make up to desired volume with ddH2O 
Autoclave for 25 min 
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Add 0.1 mM Ampicillin (Sigma, cat# A9393) when cooled. Store at 4°C. 
 
Appendix E.2 Luria broth/Amp agar plates 
400ml Luria Broth 
2% Agar (Spectrum, New Bunswick, USA, cat# AG110)  
Autoclave for 15 min to dissolve agar. When cooled to less than 50°C, add 0.1 mM 
Ampicillin. Pour into petri dishes and cool under sterile conditions. Store at 4°C. 
 
Appendix F. Tissue culture reagents and media 
Appendix F.1 200mM (100x) L-glutamine  
Dissolve 300mg L-glutamine (Sigma cat# G8540) in 10ml sterile water and filter 
sterilise. Store at -20°C. 
 
Appendix F.2 100X Pen/Strep 
Penicillin G 10,000 units/ml (Sigma, cat# P-7794) 
Streptomycin 10 mg/ml (Sigma, cat# S-9137)   
Make up in 1XPBS. Filter sterilise. Store at -20°C. 
 
Appendix F.3 Heat-inactivated FCS (HI-FCS) 
Incubate 500 ml bottle of foetal calf serum (SAFC, cat#12003C) at 65°C for 30-45 min 
with occasional shaking before filter sterilising. Store one aliquot at 4°C, remaining at -
20°C.  
 
Appendix F.4 Transforming media (TFM) 
RPMI (Gibco cat#31800-105) + 2g/L NaHCO3 (Merck, BDH, 10247.4V) – JCSMR 
15% HI-FCS 
1% L-glutamine  
2% phytohemagglutinin (PHA, Gibco cat#10576-016) 
Filter sterilise. Add fresh L-glutamine every 10 days. 
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Appendix F.5 Culture Media (CM) for LCLs and B95-8 cells 
RPMI  
15% FCS 
1% L-glutamine  
1% Pen/Strep (*not added in the iron experiments due to potential effects of 
antibiotics on iron uptake) 
Filter sterilise. Add fresh L-glutamine every 10 days. 
 
Appendix F.6 Culture Media 2 (CM2) for HepG2, Caco-2 and HEK293H 
cells 
F15 MEM powder (Gibco cat # 41500-083) + 2.2g/L NaHCO3 (JCMSR) 
10% FCS 
1% L-glutamine  
Filter sterilise. Store at 4°C. 
 
Appendix F.7 Freezing media (FM) 
RPMI 
30% FCS 
10% Dimethyl sulfoxide (DMSO) (Ajax chemicals, cat# 2225) 
1% L-glutamine 
Filter sterilise. Store at -20°C. 
 
Appendix F.8 Wash media 
RPMI 1640 
15 % HI-FBS 
Filter sterilise. Store at 4°C. 
 
Appendix F.9 Trypsin 
0.25% Trypsin (Sigma cat# T-4799) 
0.53mM EDTA 
Filter sterilize. Store at -20°C.  
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Appendix G. PCR primers and conditions 
Table G.1. The primer sets used in the current study 
Amplified 
segment 
Forward primer (5’-3’) Reverse primer (5’-3’) PCR 
product 
size (bp) 
HFE C282Y TGGCAAGGGTAAACAGATCC TACCTCCTCAGGCACTCCTC 396 
HFE H63D ACATGGTTAAGGCCTGTTGC GCCACATCTGGCTTGAAATT 208 
TNFα -863 
(rs1800630) 
GGCTCTGAGGAATGGGTTAC CTACATGGCCCTGTCTTCGTTACG 125 
D6S105 GCCCTATAAAATCCTAATTAAC GAAGGAGAATTGTAATTCCG 115-137 
D6S258 CAAATCAAGAATGTAATTCCC CTTCCAATCCATAAGCATGG 189-207 
D6S265 ACGTTCGTACCCATTAACCT ATCGAGGTAAACAGCAGAAA 122-138 
D6S1019 Cooperative Human Linkage Center (CHLC) human screening set 6 212-234 
D6S1281 Cooperative Human Linkage Center (CHLC) human screening set 6 176-212 
IL1RA TCCTGGTCTGCAGGTAA CTCAGCAACACTCCTAT 
 
410-595 
D5S2497 TCCAACTCACCAGTATAGAATCA TTAGAATGGTAGCTCCCTAAGG 130-146 
D12S2070 GGGTCAGCGAATATTTCCTT TGGCTGACAGAGCCTAAAGT 86-101 
D16S2614 TTGTCAACCTCTGGAGGAAC GCCTCTGGTTGCAATATCAC 148-172 
Mycoplasma GGCGAATGGGTGAGTAACACG CGGATAACGCTTGCGACCTAT 500 
Colony 
screening –  
pGEMT 
TATTTAGGTGACACTATAG TAATACGACTCACTATAGGG 1510 
Colony 
screening – 
pGL4.10 
CTGAGAAGATGAAGGAAAAGTC CTCCCTGCTCCGATTCCGAGG 
 
~812 
Sequencing Primers for pGL4.10 constructs 
RVprimer3 CTAGCAAAATAGGCTGTCCC 
pGL4.10 GGTGGCTTTACCAACAGTAC 
insertF1 AGGCAATAGGTTTTGAGGGGCCA 
insertR1 GGGACACACAAGCATCAAG 
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Table G.2. PCR conditions for the primer sets. All PCRs were performed in Bioline 1X reaction buffer (10X: 160mM (NH4)2SO4, 670mM Tris-HCl (pH8.8 at 25°C), 
0.1% stabiliser) using BIOTAQ polymerase (Bioline, cat# BIO-21040). The final volume of each reaction was 12µl, *except this one which was 12.5µl. 
PCR Primer conc. MgCl2 
conc. 
BIOTAQ Amplification conditions Gel running conditions 
HFE C282Y 0.125µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 20”+ x 40 
*72°C 1’+ x 1 
5µl digest, 8% acrylamide, 70mAhrs 
HFE H63D 0.125µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 20”+ x 40 
*72°C 1’+ x 1 
5µl digest, 8% acrylamide, 80mAhrs 
TNFα -863 0.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 58°C 10” 72°C 15”+ x 35 
*72°C 1’+ x 1 
8µl digest, 8% acrylamide, 70mAhrs 
D6S105 0.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 10” 72°C 10”+ x 35 
*72°C 1’+ x 1 
8µl, 15% acrylamide, 400mAhrs 
D6S258 0.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 10” 72°C 10”+ x 35 
*72°C 1’+ x 1 
8µl, 10% acrylamide, 250mAhrs 
D6S265 10.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 65°C 10” 72°C 10”+ x 35 
*72°C 1’+ x 1 
5µl, 15% acrylamide, 400mAhrs 
D6S1019 0.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 10” 72°C 10”+ x 35 
*72°C 1’+ x 1 
10µl, 10% acrylamide, 400mAhrs 
D6S1281 0.42µM 2.9mM  1U *94°C 1’+ x 1 
*94°C 10” 60°C 10” 72°C 10”+ x 35 
*72°C 5’+ x 1 
2.5µl, 12% acrylamide, 400mAhrs 
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PCR Primer conc. MgCl2 
conc. 
BIOTAQ Amplification conditions Gel running conditions 
IL1RA 0.33µM 2.9mM  1U *95°C 5’+ x 1 
*94°C 1’ 50°C 20” 70°C 35”+ x 35 
*72°C 5’+ x 1 
1.5% agarose, 100mAhrs,  
D5S2497 0.25µM 2.9mM  1U *95°C 5’+ x 1 
*94°C 1’ 50°C 20” 70°C 35”+ x 35 
*72°C 5’+ x 1 
12% acrylamide, 3µl, 187.5mAhrs 
D12S2070/ 
D16S2614 
(duplex) 
0.25µM/ 0.21µM 2.9mM  1U *95°C 5’+ x 1 
*94°C 1’ 50°C 20” 70°C 35”+ x 35 
*72°C 5’+ x 1 
12% acrylamide, 3µl, 187.5mAhrs 
Mycoplasma/ 
H63D*  
 
0.21µM/0.14µM 3.0mM  1.25U *95°C 5’+ x 1 
*95°C 30” 55°C 1’ 72°C 2’+ x 1  
*95°C 20” 55°C 40” 70°C 1’20”+ x 2 *95°C 
20” 55°C 20”+ x 39 
*72°C 2’+ x 1 
12.5µl, 1.5% agarose, 150mAhrs 
Colony 
screening 
pGEMT 
0.42µM 2.9mM  1U *94°C 10’+ x 1 
*94°C 15” 54°C 15” 72°C 1’+ x 35 
*72°C 1’+ x 1 
10µl, 1.5% agarose, 100mAhrs 
Colony 
screening – 
pGL4.10 
0.42µM 2.9mM  1U *94°C 10’+ x 1 
*94°C 10” 61°C 10” 72°C 30”+ x 35 
*72°C 1’+ x 1 
10µl, 1.5% agarose, 100mAhrs 
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Appendix G.1  Microsatellite alleles and sizes 
Table G.3. The microsatellite alleles and sizes used in this study. 
Allele D6S1281 D6S105 D6S258 D6S265 D6S1019 
1 176bp 117bp 199bp 126bp 212bp 
2 188bp 133bp 197bp 122bp 214bp 
3 192bp 135bp 189bp 130bp 220bp 
4 196bp 131bp 201bp 134bp 222bp 
5 200bp 129bp 205bp 128bp 226bp 
6 204bp 127bp 193bp 132bp 228bp 
7 208bp 125bp 207bp 138bp 230bp 
8 212bp 123bp 203bp 124bp 232bp 
9 216bp 119bp 195bp 140bp 234bp 
10 172bp  -  187bp null 236bp 
11  -   -   -   -  224bp 
12  -  121bp  -   -  210bp 
 
Appendix G.2 Real time PCR  Allelic Discrimination conditions, Taqman 
assays 
Table G.4. The Taqman SNP assays used in this study.  
Gene SNP Total 
volume 
Cycle 
number 
Assay name 
TNFα rs1799964 5 40 C___7514871_10 
rs1799724 5 40 C__11918223_10 
rs1800629 5 40 C___7514879_10 
rs361525 5 40 C___2215707_10 
     
TMPRSS6 rs4820268 5 40 C___11885329_10 
     
Transferrin 
(TF) 
rs3811647 5 40 C__27492858_10 
rs1799852 5 50 C__12061602_10 
rs2280673 6 50 AH70MEZ 
     
CYBRD1 rs884409 5 40 C___2037060_10 
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Appendix G.3 Expression assays real time PCR 
Table G.5. The expression assays used in this study including threshold and background values 
used in the analysis.  
Gene Assay Total 
reaction vol 
1:10 cDNA 
(µl) 
Taqman 
master mix 
Threshold Back-
ground 
18S 
internal 
control 
4319413E      
HFE Hs00373474_m1 20µl 8µl 10µl 0.4705854 2-33 
HAMP Hs01057160_g1 20µl 8µl 10µl 0.6004843 3-30 
TFRC Hs00174609_m1 10µl 2µl 5µl 0.3295454 2-26 
TFR2 Hs01062113_m1 10µl 2µl 5µl 0.9777504 2-29 
TNFα Hs00174128_m1 10µl 2µl 5µl 0.3421385 2-22 
 
Appendix H. Restriction Digest conditions 
Appendix H.1 HFE C282Y (rs1800562) 
12 µl PCR product 
1.4 µl NEB Buffer 1 
0.5 µl ddH2O 
0.1U RsaI (NEB, cat# R0167L) 
Incubate 37°C overnight 
C – 250 bp + 146 bp 
Y – 250 bp + 119 bp + 29 bp 
 
 
Appendix H.2 HFE H63D (rs1799945) 
12 µl PCR product 
1.4µl NEB DpnII buffer 
0.5µl ddH2O 
0.1U DpnII (NEB, cat# R0543L) 
Incubate 37°C overnight 
H – 138bp + 70bp 
D – 208bp 
 
Appendix H.3 TNFα -863 (rs1800630) 
12 µl PCR product 
1.4 µl NEB buffer 1 
0.5 µl ddH2O 
0.1U HPYCH4IV (NEB, cat# R0619L) 
Incubate 37°C overnight 
C – 125 bp 
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A – 101 bp + 24 bp  
 
Appendix I.  Site-directed mutagenesis 
Appendix I.1 Primers 
Table I.1. Primers used for cloning and SDM. TNFpromF and TNFpromR were used to generate 
the insert for cloning for the samples that did not undergo SDM. The lower case letters 
indicate in blue indicate restriction sites introduced into the primer and the black lowercase is 
additional sequence.  
Primer name Sequence 
TNFpromF ccggggtaccGATAAGGGCTCAGAGAGC 
TNFpromR ggccctcgagCGGATCATGCTTTCAGTGC 
1031sdmF CTGAGAAGAtGAAGGAAAAGTC 
1031sdmR GACTTTTCCTTCaTCTTCTCAG 
238sdmF CCTCGGAATCgGAGCAGGGA 
238sdmR CTCCCTGCTCcGATTCCGAGG 
 
Appendix I.2 PCR conditions 
Table I.2. Amplification conditions and expected product sizes for the SDM primer pairs. All 
PCRs were carried out using the 5X HF buffer (NEB, supplied with enzyme), 0.25µM each 
primer, 2.5mM MgCl2 and 2U Phusion high fidelity polymerase (NEB, cat# F-530S). Genomic 
DNA was the template for PCRs i-iv with the gel-purified products from PCRs i-iv used as the 
template for amplifying the whole region with the mutation incorporated.  
PCR# Primer pair Template Cycling conditions Size 
i -238sdmF + TNFpromR  Genomic 
DNA 
*98°C 30”+ x 1 
*98°C 10” 61°C 10” 72°C 10”+ x 35 
[72°C 5’ 10°C hold+ x 1 
461 bp 
ii -238sdmR + TNFpromF Genomic 
DNA 
*98°C 30”+ x 1 
*98°C 10” 61°C 10” 72°C 40”+ x 35 
*72°C 5’ 10°C hold+ x 1 
938 bp 
iii -1031sdmF + TNFpromR Genomic 
DNA 
*98°C 30”+ x 1 
*98°C 10” 62°C 10” 72°C 40”+ x 35 
*72°C 5’ 10°C hold+ x 1 
1253 bp 
iv -1031sdmR + TNFpromF Genomic 
DNA 
*98°C 30”+ x 1 
*98°C 10” 65°C 10” 72°C 10”+ x 35 
*72°C 5’ 10°C hold+ x 1 
117 bp 
v TNFpromF + TNFpromR 1:1 of 
either (i+ii) 
or (iii+iv) 
*98°C 30”+ x 1 
*98°C 10” 62°C 10” 72°C 40”+ x 35 
*72°C 5’ 10°C hold+ x 1 
1348 bp 
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Appendix J. Non-significant associations of SNPs in TF and TMPRSS6 with 
SF levels 
Appendix J.1 TMPRSS6 – rs4820268 
 
Figure J.1. The average log10SF levels for all samples (A) and male C282Y homozygotes (B) 
based on their genotype at rs4820268 in TMPRSS6. 11 represents samples homozygous for the 
common allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. The number 
of samples in each group is indicated in parenthesis after the genotype. There were no 
significant differences in SF in either within the samples in (A), or within the asymptomatic or 
asymptomatic samples.  
 
Appendix J.2 Transferrin – rs2280673 
 
Figure J.2. The average log10SF levels for all samples (A) and male C282Y homozygotes (B) 
based on their genotype at rs2280673 in TF. 11 represents samples homozygous for the 
common allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. The number 
of samples in each group is indicated in parenthesis after the genotype. There were no 
significant differences in SF in either within the samples in (A), or within the asymptomatic or 
asymptomatic samples.  
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Appendix J.3 Transferrin – rs3811647 
 
Figure J.3. The average log10SF levels for all samples (A) and male C282Y homozygotes (B) 
based on their genotype at rs3811647 in TF. 11 represents samples homozygous for the 
common allele, 12 are heterozygotes and 22 are homozygotes for the rare allele. The number 
of samples in each group is indicated in parenthesis after the genotype. There were no 
significant differences in SF in either within the samples in (A), or within the asymptomatic or 
asymptomatic samples.  
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Appendix K. Expected TNFα haplotype frequencies based on SNP 
frequencies 
Table K.1. TNFα haplotype frequencies in the population compared to the expected 
frequencies. The YY homozygotes and the controls have been combined to give a total of 390 
individuals = 780 chromosomes. 
Haplotype 
Expected frequency 
(n=862) 
Observed frequency 
(n=862) 
11111 433.7 483 
11112 23.3 0 
11121 88.4 146 
11211 36.0 66 
12111 72.2 0 
12112 3.9 0 
12121 14.7 0 
12211 6.0 0 
12122 0.8 0 
12212 0.3 0 
12221 1.2 0 
12222 0.1 0 
11212 1.9 0 
11221 7.3 0 
11222 0.4 0 
11122 4.8 0 
21111 104.2 0 
21112 5.6 44 
21121 21.2 0 
21211 8.6 0 
22111 17.3 123 
22112 0.9 0 
22121 3.5 0 
22211 1.4 0 
22122 0.2 0 
22212 0.1 0 
22221 0.3 0 
22222 0.0 0 
21212 0.5 0 
21221 1.8 0 
21222 0.1 0 
21122 1.1 0 
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Appendix L. Luciferase results – HEK293H and HepG2 cells 
Appendix L.1 Luciferase results for HEK293H cells 
 
Figure L.1. Relative expression of the TNFα promoter constructs in the HEK293H cell line. 
Untreated cells are blue and those incubated with excess iron (5mM FAC) are purple. Error 
bars represent the SEM. 
 
Table L.1. The pairwise p values associated with haplotype expression levels in the HEK293H 
cell line. The blue values are those without iron treatment and the purple values are those 
with iron (5mM FAC) in the media. Values in bold and italicised remained significant (p<0.05) 
when a Bonferroni correction was applied.  
 
HEK293 11111 11121 11211 22111 21112 21111 11112 pGL4.10 
11111 - .450 .241 .156 .396 .411 .003 .000 
11121 .639 - .059 .032 .113 .961 .035 .000 
11211 .339 .154 - .829 .733 .048 .000 .000 
22111 .002 .000* .034 - .569 .025 .000 .000 
21112 .193 .077 .730 .075 - .095 .000 .000 
21111 .748 .430 .525 .006 .326 - .035 .000 
11112 .153 .338 .017 .000* .006 .080 - .000 
pGL4.10 .000 .000 .000 .000 .000 .000 .000 - 
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Appendix L.2 Luciferase results for HepG2 cells 
 
Figure L.2. Relative expression of the TNFα promoter constructs in the HepG2 cell line. 
Untreated cells are blue and those incubated with excess iron (5mM FAC) are purple. Error 
bars represent the SEM. 
 
Table L.2. The pairwise p values associated with haplotype expression levels in the HepG2 cell 
line. The blue values are those without iron treatment and the purple values are those with 
iron (5mM FAC) in the media. Values in bold and italicised remained significant (p<0.05) when 
a Bonferroni correction was applied.  
HepG2 11111 11121 11211 22111 21112 21111 11112 pGL4.10 
11111 - .007 .001 .089 .001 .002 .000 .000 
11121 .337 - .313 .284 .353 .587 .159 .000 
11211 .482 .781 - .054 .940 .611 .724 .001 
22111 .288 .939 .715 - .064 .113 .020 .000 
21112 .696 .175 .266 .139 - .668 .667 .000 
21111 .841 .439 .609 .380 .548 - .365 .000 
11112 .012 .001 .001 .000 .031 .006 - .002 
pGL4.10 .000 .000 .000 .000 .000 .000 .000 - 
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Appendix M. Table of predicted TFBS changes due to the SNPs -1031, -863, -857, -308 and -238 in the TNFα promoter 
Table M.1. The predicted TFBS that are altered as a consequence of one of the five TNFα promoter SNPs studied. A very brief functional description is given, 
previous associations of the transcription factor to the TNFα promoter, and whether a role for the transcription factor us likely based on the functional description. 
TFBS Program Generalised Function 
Evidence- 
TNFα? 
Likely- TNFα? 
AP-1 TESS Proliferation, inflammation, differentiation, apoptosis, cellular migration and wound healing Yes1 Yes 
AP-2α & AP-2β TESS Cell growth and differentiation N/A No 
BARX2 Genomatix Adhesion in central nervous system N/A No 
EVI1 Genomatix Haematopoiesis N/A No 
GABP TESS Cytokine regulation, cell cycle regulation, apoptosis, cellular respiration Intronic2 Maybe 
GATA-2 Consite Haematopoietic and endocrine development N/A No 
GATA-3 Consite, TESS T cell development, endothelial tissue biology N/A No 
GFI1 Genomatix Repressor in diverse development processes N/A No 
GKLF (KLF4) Genomatix Epithelial cell differentiation N/A Maybe 
HMX3 Genomatix Neuronal cell line differentiation N/A No 
HOXD3 Genomatix Morphogenesis + cell adhesion N/A No 
HSF1 Genomatix Heat shock response Yes3 Maybe 
LHX3 Genomatix Pituitary development, motor neuron specification N/A No 
MZF1 
Consite, 
TFSEARCH 
Myeloid development 
Not at -
3084 
No 
NFκB1 TESS Controls immune response, stress response Yes5 Maybe 
Oct-1 (POU2F1) TFSEARCH Housekeeping, Immune response Yes6 Maybe 
PHOX2 Genomatix Autonomic nervous system development N/A No 
POU4F3 (BRN3C) Genomatix Visual development N/A No 
PRDM5 Genomatix Tumour suppressor gene N/A No 
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TFBS Program Generalised Function 
Evidence- 
TNFα? 
Likely- TNFα? 
Sp1 (HiNF-C) 
Consite, TESS, 
TFSEARCH 
Immune response, apoptosis, angiogenesis, cell growth, differentiation Yes7 Maybe 
SPI-B Consite Dendritic cell development N/A No 
SRY TESS, TFSERACH Sex determination N/A No 
TFCP2 (LSF1) TESS Erythroid αγ cluster regulation, bone differentiation, sex determination, oncogenesis N/A No 
T3R- β (THRB) TESS Thyroid function N/A No 
TCF-1 (TCF7) TESS T cell differentiation N/A No 
VDR/RXR Genomatix Vitamin D/retinoic acid response pathway N/A No 
VMYB Genomatix Cancer N/A No 
ZIC2 Genomatix Repressor, dopamine receptor expression N/A No 
ZNF219 Genomatix Cell growth, differentiation, embryogenesis, tumorgenesis N/A No 
1 (Udalova and Kwiatkowski 2001); 2 (Tomaras, Foster et al. 1999); 3 (Singh, He et al. 2002); 4 (Baseggio, Bartholin et al. 2004); 5 (Falvo, Tsytsykova et al. 2010); 6 (van Heel, 
Udalova et al. 2002); 7 (Barthel, Tsytsykova et al. 2003). 
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Appendix N. Expression results from LCLs – HFE 
Appendix N.1 Expression of HFE under basal conditions 
 
 
Figure N.1. Basal expression of HFE in LCLs. Results by HFE genotype (A), TNFα haplotype (B), 
phenotype of C282Y homozygotes (C), TNFα haplotype in C282Y homozygotes (D), TNFα 
haplotype in heterozygotes (E), and TNFα haplotype in controls (F) and phenotype in YY 
homozygotes with the TNFα 21112 haplotype (G).  Error bars represent the SEM. There were 
no significant differences associated with any of the graphs.  
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Appendix N.2  The relative expression of HFE, 0.2mM FAC 
 
 
 
Figure N.2. Relative HFE expression results from LCLs treated with 0.2mM FAC. Results by 
TNFα haplotype in C282Y homozygotes (A), phenotype of C282Y homozygotes (B), and 
phenotype in YY homozygotes with the TNFα 21112 haplotype (C), TNFα haplotype in 
heterozygotes (E), and TNFα haplotype in controls (F). Error bars represent the SEM. There 
were no significant differences associated with any of the graphs.    
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Appendix N.3 The relative expression of HFE, 5mM FAC 
 
Figure N.3. Relative HFE expression results from LCLs treated with 5mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), TNFα haplotype in controls (E), and TNFα haplotype in C282Y 
heterozygotes (F) and phenotype in C282Y homozygotes with the TNFα 21112 haplotype (G).  
Error bars represent the SEM. There were no significant differences associated with any of the 
graphs.  
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Appendix O. Expression results from LCLs – TFRC  
Appendix O.1 Expression of TFRC under basal conditions 
  
  
  
Figure O.1. Basal expression of TFRC in LCLs. Results TNFα haplotype (A), phenotype of C282Y 
homozygotes (B), TNFα haplotype in C282Y homozygotes (C), TNFα haplotype in C282Y 
heterozygotes (D), TNFα haplotype in controls (E), and phenotype in YY homozygotes with the 
TNFα 21112 haplotype (F).  Error bars represent the SEM. There were no significant differences 
associated with any of the graphs. 
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Appendix O.2 The relative expression of TFRC, 0.2mM FAC 
   
  
Figure O.2. Relative TFRC expression results from LCLs treated with 0.2mM FAC. Results by 
TNFα haplotype (A), phenotype of C282Y homozygotes (B), TNFα haplotype in controls (C), and 
TNFα haplotype in C282Y heterozygotes (D).  Error bars represent the SEM. There were no 
significant differences associated with any of the graphs. 
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Appendix O.3 The relative expression of TFRC, 5mM FAC 
   
  
 
Figure O.3. Relative TFRC expression results from LCLs treated with 5mM FAC. Results by TNFα 
haplotype (A), TNFα haplotype in C282Y homozygotes (B), phenotype of C282Y homozygotes 
(C), TNFα haplotype in controls (D), and TNFα haplotype in C282Y heterozygotes (E).  Error bars 
represent the SEM. There were no significant differences associated with any of the graphs. 
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Appendix P.  Expression results from LCLs – HAMP  
Appendix P.1 HAMP expression under basal conditions 
  
  
 
Figure P.1. Basal expression of HAMP in LCLs. Results TNFα haplotype (A), TNFα haplotype in 
C282Y homozygotes (B), phenotype of C282Y homozygotes (C), TNFα haplotype in controls (D), 
and TNFα haplotype in C282Y heterozygotes (E). Error bars represent the SEM. There were no 
significant differences associated with any of the graphs. 
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Appendix P.2 The relative expression of HAMP, 0.2mM FAC 
  
  
 
Figure P.2. Relative HAMP expression results from LCLs treated with 0.2mM FAC. Results by 
TNFα haplotype in C282Y homozygotes (A), phenotype of C282Y homozygotes (B), TNFα 
haplotype in controls (C), TNFα haplotype in C282Y heterozygotes (D), and phenotype in C282Y 
homozygotes with the TNFα 21112 haplotype (E).  Error bars represent the SEM. There were 
no significant differences associated with any of the graphs. 
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Appendix P.3 The relative expression of HAMP, 5mM FAC 
  
  
  
 
Figure P.3. Relative HAMP expression results from LCLs treated with 5mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), TNFα haplotype in controls (E), and TNFα haplotype in C282Y 
heterozygotes (F) and phenotype in C282Y homozygotes with the TNFα 21112 haplotype (G).  
Error bars represent the SEM. There were no significant differences associated with any of the 
graphs.  
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Appendix Q.Expression results from LCLs – TFR2 
Appendix Q.1 Expression distribution pattern of TFR2 in LCLs 
 
 
Figure Q.1. The distribution of the ∆CTs for TFR2 expression in LCLs. Results are presented for 
all samples (A), controls that do not contain the C282Y mutation (B), C282Y heterozygotes (C); 
and C282Y homozygotes (D). The values for the x-axis in graphs B-D are identical to that in A 
which represents the ∆CT in 0.5 cycle groups. In all graphs the blue line represents the data 
generated from basal conditions, the purple line represents cells treated with 0.2mM FAC and 
the green line represents the results from cells treated with 5mM FAC. 
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Appendix Q.2 The expression of TFR2 under basal conditions 
  
  
  
 
Figure Q.2. Basal TFR2 expression results from LCLs. Results by HFE genotype (A), TNFα 
haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of C282Y homozygotes 
(D), phenotype in C282Y homozygotes with the TNFα 21112 haplotype (E),  TNFα haplotype in 
controls (F), and TNFα haplotype in C282Y heterozygotes (G).  Error bars represent the SEM. 
There were no significant differences associated with any of the graphs. 
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Appendix Q.3 The relative expression of TFR2, 0.2mM FAC 
  
  
  
 
Figure Q.3. Relative TFR2 expression results from LCLs treated with 0.2mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), phenotype in C282Y homozygotes with the TNFα 21112 haplotype (E),  
TNFα haplotype in controls (F), and TNFα haplotype in C282Y heterozygotes (G).  Error bars 
represent the SEM. There were no significant differences associated with any of the graphs. 
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Appendix Q.4 The relative expression of TFR2,  5mM FAC 
 
Figure Q.4. Relative TFR2 expression results from LCLs treated with 5mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), phenotype in C282Y homozygotes with the TNFα 21112 haplotype (E),  
TNFα haplotype in controls (F), and TNFα haplotype in C282Y heterozygotes (G).  Error bars 
represent the SEM. There were no significant differences associated with any of the graphs 
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Appendix R.  Expression results from LCLs – TNFα  
Appendix R.1 Expression distribution pattern of TNFα in LCLs 
 
Figure R.1. The distribution of the ∆CTs for TNFα expression in LCLs. Results are presented for 
all samples (A), controls that do not contain the C282Y mutation (B), C282Y heterozygotes (C); 
and C282Y homozygotes (D). The values for the x-axis in graphs B-D are identical to that in A 
which represents the ∆CT in 0.5 cycle groups. In all graphs the blue line represents the data 
generated from basal conditions, the red line is cells treated with 0.2mM FAC and the green 
line represents the results from cells treated with 5mM FAC.  
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Appendix R.2 The basal expression of TNFα 
 
Figure R.2. Basal TFR2 expression results from LCLs. Results by TNFα haplotype (A), TNFα 
haplotype in C282Y homozygotes (B), phenotype of C282Y homozygotes (C), phenotype in 
C282Y homozygotes with the TNFα 21112 haplotype (D),  TNFα haplotype in controls (E), and 
TNFα haplotype in C282Y heterozygotes (F).  Error bars represent the SEM. There were no 
significant differences associated with any of the graphs. 
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Appendix R.3 The relative expression of TNFα, 0.2mM FAC 
 
Figure R.3. Relative TNFα expression results from LCLs treated with 0.2mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), phenotype in C282Y homozygotes with the TNFα 21112 haplotype (E),  
TNFα haplotype in controls (F), and TNFα haplotype in C282Y heterozygotes (G).  Error bars 
represent the SEM. There were no significant differences associated with any of the graphs 
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Appendix R.4 The relative expression of TNFα, 5mM FAC 
 
Figure R.4. Relative TNFα expression results from LCLs treated with 5mM FAC. Results by HFE 
genotype (A), TNFα haplotype (B), TNFα haplotype in C282Y homozygotes (C), phenotype of 
C282Y homozygotes (D), phenotype in C282Y homozygotes with the TNFα 21112 haplotype (E),  
TNFα haplotype in controls (F), and TNFα haplotype in C282Y heterozygotes (G).  Error bars 
represent the SEM. There were no significant differences associated with any of the graphs. 
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